{"c220991f80fcbdec7ddee6d595962309950dde00": [["Objective 16Mortality by COVID-19 is lower in women than in men.", [["women", "ORGANISM", 46, 51], ["men", "ORGANISM", 60, 63], ["women", "SPECIES", 46, 51], ["men", "SPECIES", 60, 63], ["COVID", "TEST", 25, 30]]], ["1 Mortality pertains mostly to older ages, 17Objective 16where a protective effect of ovarian hormones is difficult to envision.", [["ovarian", "ANATOMY", 86, 93], ["ovarian", "ORGAN", 86, 93], ["ovarian hormones", "PROBLEM", 86, 102], ["ovarian", "ANATOMY", 86, 93]]], ["Yet speculation on a possible 18 protective effect of estrogens are being formulated.", [["estrogens", "CHEMICAL", 54, 63], ["estrogens", "CHEMICAL", 54, 63], ["estrogens", "SIMPLE_CHEMICAL", 54, 63], ["estrogens", "TREATMENT", 54, 63]]], ["So far, the epidemiological evidence has not 19 clarified whether mortality of infected individuals changes differently between sexes with age.", [["infected individuals changes", "PROBLEM", 79, 107], ["infected", "OBSERVATION", 79, 87]]], ["This 20 infection was obtained, stratified by age and sex, from the ISTAT database in the year 2018.", [["infection", "DISEASE", 8, 17], ["This 20 infection", "PROBLEM", 0, 17], ["infection", "OBSERVATION", 8, 17]]], ["This death rate was subtracted from 31 that observed in the cohort of COVID-19 infected individuals, to obtain the estimated excess death 32 rate due to COVID-19.", [["death", "DISEASE", 5, 10], ["death", "DISEASE", 132, 137], ["individuals", "ORGANISM", 88, 99], ["COVID-19", "DNA", 153, 161], ["This death rate", "TEST", 0, 15], ["COVID", "TEST", 70, 75], ["the estimated excess death", "PROBLEM", 111, 137], ["COVID", "TEST", 153, 158]]], ["Excess death rate was then stratified by sex and age in categories of 10 33 years.", [["death", "DISEASE", 7, 12], ["Excess death rate", "PROBLEM", 0, 17]]], ["In order to evaluate whether the difference of excess death rate (death/infected) due to 34 COVID-19 between men and women remained constant across age, for any age category, the ratio 35 of death rate of women/death rate of men was calculated and expressed as a percentage.", [["death", "DISEASE", 54, 59], ["death/infected", "DISEASE", 66, 80], ["death", "DISEASE", 191, 196], ["death", "DISEASE", 211, 216], ["men", "ORGANISM", 109, 112], ["women", "ORGANISM", 117, 122], ["women", "ORGANISM", 205, 210], ["men", "ORGANISM", 225, 228], ["men", "SPECIES", 109, 112], ["women", "SPECIES", 117, 122], ["women", "SPECIES", 205, 210], ["men", "SPECIES", 225, 228], ["excess death rate", "PROBLEM", 47, 64], ["COVID", "TEST", 92, 97]]], ["36 37Results 38In the ISS report there were 147706 affected individuals of whom 17520 died during the 2 months 39 (death rate of 11.8%).", [["death", "DISEASE", 115, 120], ["death rate", "TEST", 115, 125]]], ["Death rate of non-infected individuals for a similar period was 1.00%.", [["Death", "DISEASE", 0, 5], ["Death rate", "TEST", 0, 10], ["non-infected individuals", "PROBLEM", 14, 38]]], ["40Results 38Accordingly, excess death rate due to COVID-19 was estimated to be 10.8%.", [["death", "DISEASE", 32, 37], ["excess death rate", "PROBLEM", 25, 42], ["COVID", "TEST", 50, 55]]], ["Excess death rate 41 increased with age and was always lower in women than in men ( Figure 1A) .", [["death", "DISEASE", 7, 12], ["women", "ORGANISM", 64, 69], ["men", "ORGANISM", 78, 81], ["women", "SPECIES", 64, 69], ["men", "SPECIES", 78, 81], ["Excess death rate", "TEST", 0, 17], ["increased", "OBSERVATION_MODIFIER", 21, 30]]], ["In women, an excess 42 death rate by COVID-19 higher than 1% was observed after 50-59 years of age, while in men after 43 30-39 years of age ( Figure 1A) .", [["death", "DISEASE", 23, 28], ["women", "ORGANISM", 3, 8], ["men", "ORGANISM", 109, 112], ["women", "SPECIES", 3, 8], ["men", "SPECIES", 109, 112], ["death rate", "TEST", 23, 33], ["COVID", "TEST", 37, 42]]], ["The difference in excess death rate by COVID-19 between women 44 and men changed with age.", [["death", "DISEASE", 25, 30], ["women", "ORGANISM", 56, 61], ["men", "ORGANISM", 69, 72], ["women", "SPECIES", 56, 61], ["men", "SPECIES", 69, 72], ["excess death rate", "PROBLEM", 18, 35], ["COVID", "TEST", 39, 44], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["excess death", "OBSERVATION", 18, 30]]], ["By considering men's death rate equal to 100%, women's death rate 45 was 27.8% of this (-72.2%) in ages 20 to 59 years, and 50.6% of this (-49.4%) in ages 60 to 89 46 years ( Figure 1B) .", [["death", "DISEASE", 21, 26], ["death", "DISEASE", 55, 60], ["men", "ORGANISM", 15, 18], ["women", "ORGANISM", 47, 52], ["men", "SPECIES", 15, 18], ["women", "SPECIES", 47, 52], ["men's death rate", "TEST", 15, 31], ["women's death rate", "TEST", 47, 65]]], ["47 48Conclusion 49Excess death rate by COVID-19 is lower in women than in men.", [["death", "DISEASE", 25, 30], ["women", "ORGANISM", 60, 65], ["men", "ORGANISM", 74, 77], ["women", "SPECIES", 60, 65], ["men", "SPECIES", 74, 77], ["death rate", "TEST", 25, 35], ["COVID", "TEST", 39, 44], ["lower", "OBSERVATION_MODIFIER", 51, 56]]], ["Lifestyle, rate of smoking or other 50 risk factors may be different between men and women.", [["smoking", "CHEMICAL", 19, 26], ["men", "ORGANISM", 77, 80], ["women", "ORGANISM", 85, 90], ["men", "SPECIES", 77, 80], ["women", "SPECIES", 85, 90]]], ["Unfortunately, these data were not 51 available, and we could not control for them.", [["these data", "TEST", 15, 25]]], ["Genes are also different between 53 males and females.", [["different", "OBSERVATION_MODIFIER", 15, 24]]], ["All these factors may explain the different rate of COVID-19 related mortality 54 between sexes but are unlikely to explain the reason why the difference of death rate between sexes 55 changed abruptly and constantly after 50-59 years of age.", [["death", "DISEASE", 157, 162], ["COVID", "TEST", 52, 57], ["death rate", "TEST", 157, 167]]], ["The endocrine milieu is different between 56 men and women.", [["endocrine", "ANATOMY", 4, 13], ["men", "ORGANISM", 45, 48], ["women", "ORGANISM", 53, 58], ["men", "SPECIES", 45, 48], ["women", "SPECIES", 53, 58]]], ["In women, ovarian hormones influence inflammation, immunity and also the 57 expression of ACE2 converting enzyme 4 that seems to play a role in determining COVID-19 58 disease progression.", [["ovarian", "ANATOMY", 10, 17], ["inflammation", "DISEASE", 37, 49], ["women", "ORGANISM", 3, 8], ["ovarian", "ORGAN", 10, 17], ["ACE2 converting enzyme 4", "GENE_OR_GENE_PRODUCT", 90, 114], ["ACE2", "PROTEIN", 90, 94], ["enzyme 4", "PROTEIN", 106, 114], ["women", "SPECIES", 3, 8], ["ovarian hormones influence inflammation", "PROBLEM", 10, 49], ["ACE2 converting enzyme", "TREATMENT", 90, 112], ["disease progression", "PROBLEM", 168, 187], ["ovarian", "ANATOMY", 10, 17], ["inflammation", "OBSERVATION", 37, 49]]], ["1 These effects are lost after the menopause, that in Italian women occurs at 59 median age of 50 years (range 30-61 years).", [["women", "ORGANISM", 62, 67], ["women", "SPECIES", 62, 67]]], ["5 Unfortunately, we could not perform a more specific 60 calculation by dividing women before and after the menopause, but present results may prompt 61 further analyses on this issue.", [["women", "ORGANISM", 81, 86], ["women", "SPECIES", 81, 86]]]], "PMC7172877": [["IntroductionThe COVID-19 pandemic has evoked dramatic global disruption as health and governmental agencies struggle to manage this historic medical event.", [["dramatic global disruption", "PROBLEM", 45, 71], ["this historic medical event", "PROBLEM", 127, 154], ["dramatic", "OBSERVATION_MODIFIER", 45, 53], ["global", "OBSERVATION_MODIFIER", 54, 60], ["disruption", "OBSERVATION", 61, 71]]], ["As of April 4, 2020, over 200 countries and territories have been affected, with over 1,000,000 cases and 60,000 deaths worldwide [1].", [["deaths", "DISEASE", 113, 119]]], ["The United States currently is the country with the highest prevalence of COVID-19 cases, with New York City (NYC) serving as the epicenter of this pandemic [2].IntroductionEmergency medical services in NYC face unprecedented challenges in patient acuity, bed management, and hospital operations, while experiencing high levels of provider stress and fatigue.", [["COVID", "DISEASE", 74, 79], ["fatigue", "DISEASE", 351, 358], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 240, 247], ["bed management", "TREATMENT", 256, 270], ["hospital operations", "TREATMENT", 276, 295], ["fatigue", "PROBLEM", 351, 358]]], ["While robust literature on emergency medicine responses to natural disasters and pandemics exists [3], the unique challenges of the pandemic in NYC will likely be experienced by other emergency departments (EDs) across the country, as the disease continues its anticipated trajectory.", [["pandemics", "DISEASE", 81, 90], ["pandemics", "PROBLEM", 81, 90], ["the disease", "PROBLEM", 235, 246], ["disease", "OBSERVATION", 239, 246]]], ["Here, we report an overview of our experiences and response, as a NYC ED at the center of this pandemic.IntroductionThe volume and acuity of suspected COVID-19 cases in our ED accelerated rapidly over the course of four weeks.", [["suspected COVID", "TEST", 141, 156], ["volume", "OBSERVATION_MODIFIER", 120, 126]]], ["New York Presbyterian Hospital-Columbia encompasses an adult and pediatric academic quaternary medical center, in addition to community sites in upper Manhattan and Westchester, with a collective annual volume of approximately 250,000 visits.", [["upper", "ANATOMY_MODIFIER", 145, 150]]], ["For the month of March, we have seen approximately 850 cases of COVID-19 with the majority arriving from March-15th-30thz.", [["COVID", "TREATMENT", 64, 69]]], ["Faced with rapid acceleration of volume and acuity, broad challenges have included: optimization of physical space and staffing, the development of management strategies for high numbers of patients requiring respiratory support, minimizing transmission risk to other patients and healthcare staff, determining best strategies for redeployed non-emergency medicine physicians and staff, and finally, frontline staff fatigue and well-being.Taking a \u201ccomprehensive healthcare\u201d approach ::: Strategies and general approachesOur strategy included integration of ED, hospital, city, state, and national leadership to coordinate the delivery of efficient care during this pandemic.", [["fatigue", "DISEASE", 416, 423], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 268, 276], ["rapid acceleration of volume", "PROBLEM", 11, 39], ["management strategies", "TREATMENT", 148, 169], ["respiratory support", "TREATMENT", 209, 228], ["the delivery of efficient care", "TREATMENT", 623, 653], ["rapid", "OBSERVATION_MODIFIER", 11, 16], ["acceleration", "OBSERVATION_MODIFIER", 17, 29]]], ["With the support of institutional leadership we orchestrated a multi-departmental response to the crisis.", [["the crisis", "PROBLEM", 94, 104]]], ["Due to low pediatric volumes and cancellation of elective procedures/surgeries, we harnessed an influx of available critical care beds, physicians, and support staff.", [["low pediatric volumes", "PROBLEM", 7, 28], ["elective procedures", "TREATMENT", 49, 68], ["surgeries", "TREATMENT", 69, 78]]], ["In collaboration with the hospitalist service, transfers of care (e.g. \u201csign out\u201d) to admitting teams were done in the ED, with redeployed off-service clinicians managing admitted patients to allow emergency clinicians to treat new patients.", [["patients", "ORGANISM", 180, 188], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 232, 240]]], ["In collaboration with ambulatory care providers, \u201ccough and cold\u201d clinics were established outside of the ED to rapidly evaluate low acuity patients with viral symptoms, helping to reduce ED volumes.", [["cough", "DISEASE", 50, 55], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["cough", "PROBLEM", 50, 55], ["low acuity", "PROBLEM", 129, 139], ["viral symptoms", "PROBLEM", 154, 168]]], ["In addition, they performed a medical screening exam, facilitating transfer to specialty clinics for isolated low acuity complaints (e.g. orthopedics, gynecology).", [["low acuity complaints", "DISEASE", 110, 131], ["a medical screening exam", "TEST", 28, 52], ["isolated low acuity complaints", "PROBLEM", 101, 131]]], ["Finally, patient bedding was adjusted to reduce transmission risk, with suspected COVID-19 patients placed into isolation rooms and positive cases cohorted together.Coordinating care with other critical care services to optimize patient care and reduce provider risk ::: Strategies and general approachesThe volume of patients requiring high-risk aerosolizing procedures during COVID-19 has been significant.", [["COVID-19", "CHEMICAL", 378, 386], ["patient", "ORGANISM", 9, 16], ["patients", "ORGANISM", 91, 99], ["patient", "ORGANISM", 229, 236], ["patients", "ORGANISM", 318, 326], ["patient", "SPECIES", 9, 16], ["patients", "SPECIES", 91, 99], ["patient", "SPECIES", 229, 236], ["patients", "SPECIES", 318, 326], ["COVID", "TEST", 82, 87], ["high-risk aerosolizing procedures", "TREATMENT", 337, 370], ["COVID", "TEST", 378, 383], ["volume", "OBSERVATION_MODIFIER", 308, 314], ["significant", "OBSERVATION_MODIFIER", 396, 407]]], ["Recognizing the high volume of emergent airways, we developed protocols with the anesthesia service to assist with ED intubations that included the use of HEPA viral filters and appropriate PPE.", [["airways", "ANATOMY", 40, 47], ["airways", "MULTI-TISSUE_STRUCTURE", 40, 47], ["the anesthesia service", "TREATMENT", 77, 99], ["ED intubations", "TREATMENT", 115, 129], ["HEPA viral filters", "TREATMENT", 155, 173], ["appropriate PPE", "TREATMENT", 178, 193], ["high", "OBSERVATION_MODIFIER", 16, 20], ["volume", "OBSERVATION_MODIFIER", 21, 27], ["airways", "ANATOMY", 40, 47], ["viral filters", "OBSERVATION", 160, 173]]], ["Additionally, a COVID-19 \u201cSWAT\u201d team consisting of surgical chief residents and attendings was organized and available to perform procedures such as central lines and arterial lines.", [["central lines", "ANATOMY", 149, 162], ["arterial lines", "ANATOMY", 167, 181], ["central lines", "CELL", 149, 162], ["arterial lines", "CELL", 167, 181], ["central lines", "CELL_LINE", 149, 162], ["arterial lines", "CELL_LINE", 167, 181], ["procedures", "TREATMENT", 130, 140], ["central lines and arterial lines", "TREATMENT", 149, 181], ["central lines", "OBSERVATION", 149, 162], ["arterial lines", "OBSERVATION", 167, 181]]], ["Given the increased need for difficult goals of care conversations, we involved palliative care, social services, and ethics consultations early and often for critically ill patients, including pre-intubation.Consider remote/telemedicine opportunities for low acuity patients and follow-up care ::: Strategies and general approachesTelemedicine has played a critical role in our COVID response, providing another pathway for determining need for acute care, while also decreasing ED patient volume and potential viral exposure.", [["critically ill", "DISEASE", 159, 173], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 267, 275], ["patient", "ORGANISM", 483, 490], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 267, 275], ["patient", "SPECIES", 483, 490], ["pre-intubation", "TREATMENT", 194, 208], ["acute care", "TREATMENT", 446, 456], ["potential viral exposure", "PROBLEM", 502, 526], ["viral exposure", "OBSERVATION", 512, 526]]], ["Telemedicine has also allowed us to extend our footprint of care into the home, through a follow-up program involving video visits with oxygen concentrators and pulse oximeters distributed to patients during their index ED visit.Staff morale/health ::: Strategies and general approachesProtecting healthcare workforce is paramount in fighting COVID-19.", [["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["oxygen concentrators", "TREATMENT", 136, 156], ["pulse oximeters", "TREATMENT", 161, 176]]], ["The concern for illness, fatigue, low morale, and clinical error is high [4].", [["illness", "DISEASE", 16, 23], ["fatigue", "DISEASE", 25, 32], ["illness", "PROBLEM", 16, 23], ["fatigue", "PROBLEM", 25, 32], ["low morale", "PROBLEM", 34, 44], ["concern for", "UNCERTAINTY", 4, 15]]], ["It is important to allow for increased flexibility and surge staffing during this time period.", [["increased flexibility", "PROBLEM", 29, 50]]], ["We had a number of support resources available, including mental health experts, spiritual care, virtual wellness rounds, and frequent staff huddles.", [["spiritual care", "TREATMENT", 81, 95]]], ["Concerns about exposure risk were high amongst our providers, and an emphasis on PPE and supplies has been paramount.Staff morale/health ::: Strategies and general approachesThe COVID-19 pandemic has placed immense burdens on healthcare systems globally.", [["exposure risk", "PROBLEM", 15, 28], ["PPE", "TREATMENT", 81, 84], ["The COVID", "TREATMENT", 174, 183]]], ["We hope our early experiences in confronting the pandemic will provide valuable information for other EDs and health care systems around the country during this ongoing crisis.GrantNone.MeetingsNone.", [["GrantNone", "CHEMICAL", 176, 185], ["GrantNone", "SIMPLE_CHEMICAL", 176, 185], ["this ongoing crisis", "PROBLEM", 156, 175], ["GrantNone", "TREATMENT", 176, 185]]]], "PMC7235578": [["CommentaryCoronavirus disease 2019 (COVID-19) was declared a pandemic on 11th March 2020 by the World Health Organization (WHO).", [["Coronavirus disease", "DISEASE", 10, 29], ["CommentaryCoronavirus disease", "PROBLEM", 0, 29], ["COVID", "TEST", 36, 41], ["Coronavirus disease", "OBSERVATION", 10, 29]]], ["Since then, many societies, led by their respective governments, are fighting to reduce the number of infected cases \u2013 the actual famous motto \u201cflatten the curve\u201d.", [["many", "OBSERVATION_MODIFIER", 12, 16], ["societies", "OBSERVATION", 17, 26]]], ["The main purpose is avoiding the collapse of health systems and especially intensive care units by implementing social distancing policies, general population lockdowns and/or the reduction of non-essential activities.", [["the collapse of health systems", "PROBLEM", 29, 59], ["general population lockdowns", "TREATMENT", 140, 168], ["main", "OBSERVATION_MODIFIER", 4, 8], ["collapse", "OBSERVATION", 33, 41]]], ["While the economy of many countries remains at the stake due to the paralysis of their principal income activities, the SARS-CoV-2 virus keeps spreading worldwide.", [["paralysis", "DISEASE", 68, 77], ["SARS", "DISEASE", 120, 124], ["SARS-CoV-2 virus", "ORGANISM", 120, 136], ["CoV-2 virus", "SPECIES", 125, 136], ["SARS-CoV-2 virus", "SPECIES", 120, 136], ["the paralysis", "PROBLEM", 64, 77], ["the SARS", "TEST", 116, 124], ["CoV", "TEST", 125, 128], ["paralysis", "OBSERVATION", 68, 77]]], ["To date, on 6th May, approximately 3.74 million cases of COVID-19 have been reported in 212 countries and territories (Worldometers, 2020a).", [["COVID", "TEST", 57, 62]]], ["The impact of COVID-19 on the global economy remains a subject to debate as it will depend mostly on international government decisions and policymaking, however the climate for an economic recession is propitious and the International Monetary Fund (IMF) predicts its impact might be worse than the global financial crisis (IMF, 2020).CommentaryDemographically speaking, it is important to take into consideration that the collapse of the economy undoubtedly means a peak of unemployment rate and, consequently, a decline in birthrate.", [["COVID", "TREATMENT", 14, 19], ["an economic recession", "PROBLEM", 178, 199], ["a decline in birthrate", "PROBLEM", 513, 535], ["recession", "OBSERVATION", 190, 199], ["collapse", "OBSERVATION", 424, 432]]], ["Many couples cannot afford having children in that economic context due to the expenses of their nutrition, education and well-being.", [["children", "ORGANISM", 34, 42], ["children", "SPECIES", 34, 42]]], ["Southern-Europe societies were severely affected by the global financial crisis in 2008, importantly in Greece, Italy and Spain.", [["severely affected", "PROBLEM", 31, 48]]], ["Therefore, the crisis became both economic and sociodemographic, especially in the countries mentioned above, where gross domestic product (GDP) destined to household/family aid was already below the European mean.", [["the crisis", "PROBLEM", 11, 21]]], ["While the European Community invested on average 2.3% GDP in form of household/family aid, in 2017, Spain only invested a 1.2% (Eurostat, 2020).", [["GDP", "CHEMICAL", 54, 57], ["GDP", "CHEMICAL", 54, 57], ["GDP", "SIMPLE_CHEMICAL", 54, 57]]], ["Importantly, the Spanish fertility indicator is 1.32 children per women, also under the European mean 1.6, the second lowest fertility indicator in Europe after Malta (Eurostat, 2020).CommentaryDuring the 2008 global financial crisis, Spain experienced an unfavorable environment for the emancipation of young people, greatly hindering the possibility of creating family nuclei with descendants.", [["nuclei", "ANATOMY", 371, 377], ["children", "ORGANISM", 53, 61], ["women", "ORGANISM", 66, 71], ["people", "ORGANISM", 310, 316], ["nuclei", "CELLULAR_COMPONENT", 371, 377], ["children", "SPECIES", 53, 61], ["women", "SPECIES", 66, 71], ["people", "SPECIES", 310, 316], ["financial crisis", "OBSERVATION", 217, 233]]], ["The yearly growth rate of the Spanish population fell from 1.57% in 2007 to -0.33% in 2013, until it equaled the European population yearly growth rate of 1% in 2018 (Worldometers, 2020b).", [["growth rate", "TEST", 140, 151], ["growth", "OBSERVATION_MODIFIER", 11, 17]]], ["This list mainly had inscribed women or couples who could not reach a pregnancy, condition known as primary or secondary infertility - whether a previous pregnancy had been achieved or not.", [["infertility", "DISEASE", 121, 132], ["women", "ORGANISM", 31, 36], ["women", "SPECIES", 31, 36], ["secondary infertility", "PROBLEM", 111, 132], ["a previous pregnancy", "PROBLEM", 143, 163]]], ["However, an increasing number of additional categories were summing up: fertile women who wanted to have children but considered themselves too young to do so; the so-called normative infecundity and fertile women who wanted to conceive but postponed the latter as they did not meet the optimal conditions, either familiar and/or economic, to bear the costs implied.", [["women", "ORGANISM", 80, 85], ["children", "ORGANISM", 105, 113], ["women", "ORGANISM", 208, 213], ["women", "SPECIES", 80, 85], ["children", "SPECIES", 105, 113], ["women", "SPECIES", 208, 213], ["increasing", "OBSERVATION_MODIFIER", 12, 22], ["number", "OBSERVATION_MODIFIER", 23, 29]]], ["As the years of economic crisis went by, the list extended.CommentarySince female age is the most important independent variable of success at the time of conception, is it not absurd to assume that thousands of fertile couples were lost in the waiting list during the years that lasted the Spanish economic recession.", [["economic crisis", "PROBLEM", 16, 31]]], ["Plus, poor ovarian reserve due to ovarian aging is the main reason why patients seek aid in assisted reproductive medicine.", [["ovarian", "ANATOMY", 11, 18], ["ovarian", "ANATOMY", 34, 41], ["ovarian aging", "DISEASE", 34, 47], ["ovarian", "ORGAN", 11, 18], ["ovarian", "ORGAN", 34, 41], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["poor ovarian reserve", "PROBLEM", 6, 26], ["ovarian aging", "PROBLEM", 34, 47], ["assisted reproductive medicine", "TREATMENT", 92, 122], ["poor ovarian reserve", "OBSERVATION", 6, 26], ["ovarian", "ANATOMY", 34, 41], ["aging", "OBSERVATION", 42, 47]]], ["To date, In Spain, on July 2018, there were 1,414,000 women between 30 and 34 years old, of which, according to the Spanish Statistical Office, 52% were childless.", [["women", "ORGANISM", 54, 59], ["women", "SPECIES", 54, 59]]], ["Elective infecundity, or women choosing not to have children, represents up to 5% of Spanish women (Spanish Statistical Office, 2018), which leaves approximately 600,000-630,000 potentially fertile women who might be considering motherhood a future option.", [["women", "ORGANISM", 25, 30], ["children", "ORGANISM", 52, 60], ["women", "ORGANISM", 93, 98], ["women", "ORGANISM", 198, 203], ["women", "SPECIES", 25, 30], ["children", "SPECIES", 52, 60], ["women", "SPECIES", 93, 98], ["women", "SPECIES", 198, 203]]], ["Nevertheless, if another economic recession hits Spain, this population will be in an increased risk of subfertility.", [["subfertility", "DISEASE", 104, 116], ["another economic recession hits Spain", "PROBLEM", 17, 54], ["subfertility", "PROBLEM", 104, 116], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["subfertility", "OBSERVATION", 104, 116]]], ["Not to mention the approximately 480,000 childless Spanish women between 35 and 40 years old, which indeed will be close to reach biological infertility in that possible context.CommentaryDespite there is no evidence in the present relating SARS-CoV-2 infection and a hamper in reproductive potential either in men or women (Tesarik J., 2020), there might be a link to a short and mid-term increased global infertility.", [["infertility", "DISEASE", 141, 152], ["SARS", "DISEASE", 241, 245], ["infection", "DISEASE", 252, 261], ["infertility", "DISEASE", 407, 418], ["women", "ORGANISM", 59, 64], ["SARS-CoV-2", "ORGANISM", 241, 251], ["men", "ORGANISM", 311, 314], ["women", "ORGANISM", 318, 323], ["women", "SPECIES", 59, 64], ["men", "SPECIES", 311, 314], ["women", "SPECIES", 318, 323], ["SARS-CoV", "SPECIES", 241, 249], ["2 infection", "PROBLEM", 250, 261], ["a short and mid-term increased global infertility", "PROBLEM", 369, 418], ["no evidence in", "UNCERTAINTY", 205, 219], ["SARS", "OBSERVATION", 241, 245], ["infection", "OBSERVATION", 252, 261], ["increased", "OBSERVATION_MODIFIER", 390, 399], ["global", "OBSERVATION_MODIFIER", 400, 406], ["infertility", "OBSERVATION", 407, 418]]], ["This current pandemic menaces millions of lives worldwide and its economic hungover will shackle Human Rights while imperiling the demography of countries internationally as it will hinder short and midterm birthrates.CommentaryWhile the WHO already recognized infertility as a Global Health Issue (WHO, 2019), the context of an imminent economic recession threatens reproductive rights per se too, as they \u201crest on the recognition of the basic right of all couples and individuals to decide freely and responsibly the number, spacing and timing of their children and to have the information and means to do so, and the right to attain the highest standard of reproductive health\u201d (WHO, 2009).", [["infertility", "DISEASE", 261, 272], ["Human", "ORGANISM", 97, 102], ["children", "ORGANISM", 555, 563], ["Human", "SPECIES", 97, 102], ["children", "SPECIES", 555, 563], ["short and midterm birthrates", "PROBLEM", 189, 217], ["an imminent economic recession", "PROBLEM", 326, 356], ["economic", "OBSERVATION_MODIFIER", 338, 346], ["recession", "OBSERVATION", 347, 356], ["right", "ANATOMY_MODIFIER", 445, 450], ["right", "ANATOMY_MODIFIER", 620, 625]]], ["Therefore, it is not overstated to predict that the economic impact that will follow the pandemic will coerce the desired family planning of couples and single women, postponing the ideal time of conception.", [["women", "ORGANISM", 160, 165], ["women", "SPECIES", 160, 165]]], ["Up to 66% of European countries have adopted policies that include baby bonuses, flexible work schedules, parental leave and tax incentives (UN, 2015).", [["flexible work schedules", "TREATMENT", 81, 104]]], ["Supporting aids and subsidies directed towards family benefits, such as financial support for families and children, or other social areas such as health and housing might be actions to be considered by policymakers in order to palliate demographic decline (UN, 2015).", [["children", "SPECIES", 107, 115]]], ["However, assisted reproductive techniques (ART) may also contribute to alleviate the impact that the economic recession might have on fertility.", [["the economic recession", "PROBLEM", 97, 119], ["economic", "OBSERVATION_MODIFIER", 101, 109], ["recession", "OBSERVATION", 110, 119]]], ["For example, elective fertility preservation may be considered as a plausible option when attempting to maintain Reproductive Rights of individuals and overcome the age burden that threats ovarian reserve and oocyte quality (ASRM, 2018).", [["ovarian", "ANATOMY", 189, 196], ["oocyte", "ANATOMY", 209, 215], ["ovarian", "ORGAN", 189, 196], ["oocyte", "DEVELOPING_ANATOMICAL_STRUCTURE", 209, 215], ["elective fertility preservation", "TREATMENT", 13, 44]]], ["Similarly, embryo cryopreservation can also be a candidate option in order to postpone childbearing.", [["embryo", "ANATOMY", 11, 17], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 11, 17], ["embryo cryopreservation", "TREATMENT", 11, 34], ["embryo cryopreservation", "OBSERVATION", 11, 34]]], ["Therefore, we suggest that governments should study easing the access to these techniques to couples or women who desire so, especially considering that approximately 8.5% of births that occurred in Spain during 2017 were conceived via ART, according to the Spanish Fertility Society Registry.", [["women", "ORGANISM", 104, 109], ["women", "SPECIES", 104, 109]]], ["As a final remark, Reproductive Rights are Human Rights and, as mentioned before, they are all about the \u201cwhen\u201d and \u201chow\u201d.Uncited References:(Spanish Statistical Office, United Nations 2018)", [["Human", "ORGANISM", 43, 48], ["Human", "SPECIES", 43, 48]]]], "e642816c09dd07b7bdf515088670a72ee8698bd8": [["ResultsOne year post discharge, mild to moderate pulmonary dysfunction was observed in the majority of patients.", [["pulmonary", "ANATOMY", 49, 58], ["pulmonary dysfunction", "DISEASE", 49, 70], ["pulmonary", "ORGAN", 49, 58], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["mild to moderate pulmonary dysfunction", "PROBLEM", 32, 70], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["moderate", "OBSERVATION_MODIFIER", 40, 48], ["pulmonary", "ANATOMY", 49, 58], ["dysfunction", "OBSERVATION", 59, 70]]], ["Further, 54.2% of patients had signs of severe abnormal pulmonary function, including diffusion disorder (33.3%) and small airway dysfunction (33.3%).", [["pulmonary", "ANATOMY", 56, 65], ["airway", "ANATOMY", 123, 129], ["abnormal pulmonary function", "DISEASE", 47, 74], ["diffusion disorder", "DISEASE", 86, 104], ["airway dysfunction", "DISEASE", 123, 141], ["patients", "ORGANISM", 18, 26], ["pulmonary", "ORGAN", 56, 65], ["airway", "MULTI-TISSUE_STRUCTURE", 123, 129], ["patients", "SPECIES", 18, 26], ["severe abnormal pulmonary function", "PROBLEM", 40, 74], ["diffusion disorder", "PROBLEM", 86, 104], ["small airway dysfunction", "PROBLEM", 117, 141], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["abnormal", "OBSERVATION_MODIFIER", 47, 55], ["pulmonary function", "OBSERVATION", 56, 74], ["small", "OBSERVATION_MODIFIER", 117, 122], ["airway", "ANATOMY", 123, 129], ["dysfunction", "OBSERVATION", 130, 141]]], ["Fourteen patients presented with respiratory tract infection symptoms; 12 with abnormal pulmonary function and two with normal pulmonary function.", [["respiratory tract", "ANATOMY", 33, 50], ["pulmonary", "ANATOMY", 88, 97], ["pulmonary", "ANATOMY", 127, 136], ["respiratory tract infection", "DISEASE", 33, 60], ["abnormal pulmonary function", "DISEASE", 79, 106], ["patients", "ORGANISM", 9, 17], ["tract", "ORGANISM_SUBDIVISION", 45, 50], ["pulmonary", "ORGAN", 88, 97], ["pulmonary", "ORGAN", 127, 136], ["patients", "SPECIES", 9, 17], ["respiratory tract infection symptoms", "PROBLEM", 33, 69], ["abnormal pulmonary function", "PROBLEM", 79, 106], ["respiratory tract", "ANATOMY", 33, 50], ["infection", "OBSERVATION", 51, 60], ["pulmonary", "ANATOMY", 88, 97], ["normal", "OBSERVATION", 120, 126], ["pulmonary", "ANATOMY", 127, 136], ["function", "OBSERVATION", 137, 145]]], ["Our results indicated that the change in pulmonary function at one year post discharge was not significantly correlated with the severity of H1N1 influenza.ConclusionSigns and symptoms of abnormal pulmonary function accompanied by respiratory tract infection symptoms remain for some patients after one year following discharge from the hospital for mild influenza A virus subtype H1N1 infection.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 197, 206], ["respiratory tract", "ANATOMY", 231, 248], ["influenza", "DISEASE", 146, 155], ["abnormal pulmonary function", "DISEASE", 188, 215], ["respiratory tract infection", "DISEASE", 231, 258], ["influenza A virus subtype H1N1 infection", "DISEASE", 355, 395], ["pulmonary", "ORGAN", 41, 50], ["pulmonary", "ORGAN", 197, 206], ["respiratory tract", "ORGANISM_SUBDIVISION", 231, 248], ["patients", "ORGANISM", 284, 292], ["influenza A virus subtype H1N1", "ORGANISM", 355, 385], ["patients", "SPECIES", 284, 292], ["influenza A virus subtype H1N1", "SPECIES", 355, 385], ["the change in pulmonary function", "PROBLEM", 27, 59], ["H1N1 influenza", "PROBLEM", 141, 155], ["ConclusionSigns", "PROBLEM", 156, 171], ["symptoms", "PROBLEM", 176, 184], ["abnormal pulmonary function", "PROBLEM", 188, 215], ["respiratory tract infection symptoms", "PROBLEM", 231, 267], ["mild influenza A virus subtype H1N1 infection", "PROBLEM", 350, 395], ["change", "OBSERVATION_MODIFIER", 31, 37], ["pulmonary", "ANATOMY", 41, 50], ["H1N1", "OBSERVATION", 141, 145], ["abnormal", "OBSERVATION_MODIFIER", 188, 196], ["pulmonary", "ANATOMY", 197, 206], ["respiratory tract", "ANATOMY", 231, 248], ["infection", "OBSERVATION", 249, 258], ["mild", "OBSERVATION_MODIFIER", 350, 354], ["influenza", "OBSERVATION", 355, 364], ["infection", "OBSERVATION", 386, 395]]], ["These patients should continue Introduction Influenza A virus subtype H1N1, a pandemic 2009 strain, caused widespread outbreaks of influenza in humans.", [["Influenza A virus subtype H1N1", "DISEASE", 44, 74], ["influenza", "DISEASE", 131, 140], ["patients", "ORGANISM", 6, 14], ["Influenza A virus subtype H1N1", "ORGANISM", 44, 74], ["humans", "ORGANISM", 144, 150], ["patients", "SPECIES", 6, 14], ["Influenza A virus subtype H1N1", "SPECIES", 44, 74], ["humans", "SPECIES", 144, 150], ["Influenza A virus subtype H1N1", "SPECIES", 44, 74], ["humans", "SPECIES", 144, 150], ["Introduction Influenza A virus subtype H1N1", "PROBLEM", 31, 74], ["influenza in humans", "PROBLEM", 131, 150], ["widespread", "OBSERVATION_MODIFIER", 107, 117], ["outbreaks", "OBSERVATION_MODIFIER", 118, 127], ["influenza", "OBSERVATION", 131, 140]]], ["As of 17 June 2010, more than 214 countries had reported confirmed cases of infection with pandemic 2009 influenza A (H1N1) virus [1] .", [["infection", "DISEASE", 76, 85], ["influenza A (H1N1) virus", "DISEASE", 105, 129], ["2009 influenza A (H1N1) virus", "ORGANISM", 100, 129], ["influenza A (H1N1) virus", "SPECIES", 105, 129], ["pandemic 2009 influenza A (H1N1) virus", "SPECIES", 91, 129], ["infection", "PROBLEM", 76, 85], ["pandemic 2009 influenza A (H1N1) virus", "PROBLEM", 91, 129], ["infection", "OBSERVATION", 76, 85]]], ["Patients typically presented with severe pneumonia and acute respiratory distress syndrome (ARDS), which led to severe lung damage and in some cases death.", [["respiratory", "ANATOMY", 61, 72], ["lung", "ANATOMY", 119, 123], ["pneumonia", "DISEASE", 41, 50], ["acute respiratory distress syndrome", "DISEASE", 55, 90], ["ARDS", "DISEASE", 92, 96], ["lung damage", "DISEASE", 119, 130], ["death", "DISEASE", 149, 154], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 119, 123], ["Patients", "SPECIES", 0, 8], ["severe pneumonia", "PROBLEM", 34, 50], ["acute respiratory distress syndrome", "PROBLEM", 55, 90], ["ARDS", "PROBLEM", 92, 96], ["severe lung damage", "PROBLEM", 112, 130], ["some cases death", "PROBLEM", 138, 154], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["pneumonia", "OBSERVATION", 41, 50], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["respiratory distress", "OBSERVATION", 61, 81], ["syndrome", "OBSERVATION", 82, 90], ["ARDS", "OBSERVATION", 92, 96], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["lung", "ANATOMY", 119, 123], ["damage", "OBSERVATION", 124, 130]]], ["After recovery from severe pneumonia and ARDS, various degrees of lung lesions occur, having an impact on patients' respiratory function and in turn his or her quality of life.", [["lung lesions", "ANATOMY", 66, 78], ["respiratory", "ANATOMY", 116, 127], ["pneumonia", "DISEASE", 27, 36], ["ARDS", "DISEASE", 41, 45], ["lung lesions", "DISEASE", 66, 78], ["lung lesions", "PATHOLOGICAL_FORMATION", 66, 78], ["patients", "ORGANISM", 106, 114], ["respiratory", "ORGAN", 116, 127], ["patients", "SPECIES", 106, 114], ["severe pneumonia", "PROBLEM", 20, 36], ["ARDS", "PROBLEM", 41, 45], ["lung lesions", "PROBLEM", 66, 78], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["pneumonia", "OBSERVATION", 27, 36], ["ARDS", "OBSERVATION", 41, 45], ["various degrees", "OBSERVATION_MODIFIER", 47, 62], ["lung", "ANATOMY", 66, 70], ["lesions", "OBSERVATION", 71, 78], ["respiratory function", "OBSERVATION", 116, 136]]], ["In this study, we examined the pulmonary function of patients infected with influenza A virus subtype H1N1 one year after hospitalization for the infection.", [["pulmonary", "ANATOMY", 31, 40], ["influenza A virus", "DISEASE", 76, 93], ["infection", "DISEASE", 146, 155], ["pulmonary", "ORGAN", 31, 40], ["patients", "ORGANISM", 53, 61], ["influenza A virus subtype H1N1", "ORGANISM", 76, 106], ["patients", "SPECIES", 53, 61], ["influenza A virus subtype H1N1", "SPECIES", 76, 106], ["influenza A virus subtype H1N1", "SPECIES", 76, 106], ["this study", "TEST", 3, 13], ["influenza A virus subtype H1N1", "PROBLEM", 76, 106], ["the infection", "PROBLEM", 142, 155], ["pulmonary", "ANATOMY", 31, 40], ["infection", "OBSERVATION", 146, 155]]], ["These results provide valuable information for future diagnosis and rehabilitation treatment of H1N1 and other pandemic or severe influenza strain infections.", [["H1N1", "DISEASE", 96, 100], ["pandemic", "DISEASE", 111, 119], ["influenza strain infections", "DISEASE", 130, 157], ["rehabilitation treatment", "TREATMENT", 68, 92], ["H1N1", "PROBLEM", 96, 100], ["severe influenza strain infections", "PROBLEM", 123, 157], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["influenza", "OBSERVATION", 130, 139]]], ["To ensure patients were not examined during or shortly after airway infections, all participants answered a questionnaire detailing any complaints of dyspnea, tiredness, cough, expectoration, medical treatment and smoking habits.", [["airway", "ANATOMY", 61, 67], ["airway infections", "DISEASE", 61, 78], ["dyspnea", "DISEASE", 150, 157], ["tiredness", "DISEASE", 159, 168], ["cough", "DISEASE", 170, 175], ["expectoration", "DISEASE", 177, 190], ["patients", "ORGANISM", 10, 18], ["airway", "MULTI-TISSUE_STRUCTURE", 61, 67], ["patients", "SPECIES", 10, 18], ["participants", "SPECIES", 84, 96], ["airway infections", "PROBLEM", 61, 78], ["dyspnea", "PROBLEM", 150, 157], ["tiredness", "PROBLEM", 159, 168], ["cough", "PROBLEM", 170, 175], ["expectoration", "PROBLEM", 177, 190], ["medical treatment", "TREATMENT", 192, 209], ["airway", "ANATOMY", 61, 67], ["infections", "OBSERVATION", 68, 78]]], ["The Modified Medical Research Council Dyspnea Scale was used to evaluate dyspnea of patients with abnormal pulmonary function (a score of 4 points, 2 cases; 3 points, 4 cases; 2 points, 14 cases;1 point, 4 cases; and 0 points, 2 cases) and with normal pulmonary function (a score of 4 points, 2 cases; 3 points, 2 cases; 2 points, 8 cases;1 point, 10 cases; and 0 points, 2 cases).", [["pulmonary", "ANATOMY", 107, 116], ["pulmonary", "ANATOMY", 252, 261], ["Dyspnea", "DISEASE", 38, 45], ["dyspnea", "DISEASE", 73, 80], ["abnormal pulmonary function", "DISEASE", 98, 125], ["patients", "ORGANISM", 84, 92], ["pulmonary", "ORGAN", 107, 116], ["pulmonary", "ORGAN", 252, 261], ["patients", "SPECIES", 84, 92], ["dyspnea", "PROBLEM", 73, 80], ["abnormal pulmonary function", "PROBLEM", 98, 125], ["cases", "TEST", 189, 194], ["cases", "TEST", 351, 356], ["pulmonary", "ANATOMY", 107, 116], ["normal", "OBSERVATION", 245, 251], ["pulmonary", "ANATOMY", 252, 261]]], ["Of these 48 patients, 38 were diagnosed by members of the Department of Respiratory Medicine and ten were diagnosed by members of the Department of Infection.", [["Infection", "DISEASE", 148, 157], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["Respiratory Medicine", "TREATMENT", 72, 92], ["Infection", "PROBLEM", 148, 157], ["Infection", "OBSERVATION", 148, 157]]], ["The study included 26 male and 22 female patients with an average age of 29.5 years (range 27-39.5).", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["The study", "TEST", 0, 9]]], ["Of the original 102 patients, eight (7.8%) had died: one from pneumonia and seven from disorders that could not be attributed to pulmonary disease.", [["pulmonary", "ANATOMY", 129, 138], ["pneumonia", "DISEASE", 62, 71], ["pulmonary disease", "DISEASE", 129, 146], ["patients", "ORGANISM", 20, 28], ["pulmonary", "ORGAN", 129, 138], ["patients", "SPECIES", 20, 28], ["pneumonia", "PROBLEM", 62, 71], ["disorders", "PROBLEM", 87, 96], ["pulmonary disease", "PROBLEM", 129, 146], ["pneumonia", "OBSERVATION", 62, 71], ["could not be attributed to", "UNCERTAINTY", 102, 128], ["pulmonary", "ANATOMY", 129, 138], ["disease", "OBSERVATION", 139, 146]]], ["Fortysix (45.1%) patients were not re-examined due to practical problems.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["Fortysix", "TEST", 0, 8], ["practical problems", "PROBLEM", 54, 72]]], ["However, based on the data from 2009, these 46 patients did not differ from the 48 re-examined patients with respect to age, sex, disease duration, or degree of pulmonary function.", [["pulmonary", "ANATOMY", 161, 170], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 95, 103], ["pulmonary", "ORGAN", 161, 170], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 95, 103], ["disease duration", "PROBLEM", 130, 146], ["degree of pulmonary function", "PROBLEM", 151, 179], ["pulmonary", "ANATOMY", 161, 170]]], ["Patients with chronic respiratory system disease (i.e. chronic obstructive pulmonary disease, asthma, pulmonary fibrosis, silicosis), chronic heart disease, or nervous and mental diseases were excluded.", [["respiratory system", "ANATOMY", 22, 40], ["pulmonary", "ANATOMY", 75, 84], ["pulmonary", "ANATOMY", 102, 111], ["heart", "ANATOMY", 142, 147], ["nervous", "ANATOMY", 160, 167], ["chronic respiratory system disease", "DISEASE", 14, 48], ["chronic obstructive pulmonary disease", "DISEASE", 55, 92], ["asthma", "DISEASE", 94, 100], ["pulmonary fibrosis", "DISEASE", 102, 120], ["silicosis", "DISEASE", 122, 131], ["chronic heart disease, or nervous and mental diseases", "DISEASE", 134, 187], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 75, 84], ["pulmonary", "ORGAN", 102, 111], ["heart", "ORGAN", 142, 147], ["nervous", "ANATOMICAL_SYSTEM", 160, 167], ["Patients", "SPECIES", 0, 8], ["chronic respiratory system disease", "PROBLEM", 14, 48], ["chronic obstructive pulmonary disease", "PROBLEM", 55, 92], ["asthma", "PROBLEM", 94, 100], ["pulmonary fibrosis", "PROBLEM", 102, 120], ["silicosis", "PROBLEM", 122, 131], ["chronic heart disease", "PROBLEM", 134, 155], ["nervous and mental diseases", "PROBLEM", 160, 187], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["respiratory system disease", "OBSERVATION", 22, 48], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["obstructive", "OBSERVATION_MODIFIER", 63, 74], ["pulmonary", "ANATOMY", 75, 84], ["disease", "OBSERVATION", 85, 92], ["asthma", "OBSERVATION", 94, 100], ["pulmonary", "ANATOMY", 102, 111], ["fibrosis", "OBSERVATION", 112, 120], ["silicosis", "OBSERVATION", 122, 131], ["chronic", "OBSERVATION_MODIFIER", 134, 141], ["heart", "ANATOMY", 142, 147], ["disease", "OBSERVATION", 148, 155], ["mental diseases", "OBSERVATION", 172, 187]]], ["Written informed consent was obtained from each subject.Ethics statementThe experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Jilin University, China.", [["Human", "ORGANISM", 203, 208], ["Human", "SPECIES", 203, 208], ["The experimental protocol", "TREATMENT", 72, 97]]], ["Written informed consent was obtained from individual participants.Pulmonary function testsApproximately one year (\u00b11 months) after recovery from influenza and discharge from the hospital, each patient included in the study was assessed for pulmonary function using the Mas-terScreen PFT system (Jaeger, Germany).", [["Pulmonary", "ANATOMY", 67, 76], ["pulmonary", "ANATOMY", 241, 250], ["influenza", "DISEASE", 146, 155], ["Pulmonary", "ORGAN", 67, 76], ["patient", "ORGANISM", 194, 201], ["pulmonary", "ORGAN", 241, 250], ["participants", "SPECIES", 54, 66], ["patient", "SPECIES", 194, 201], ["influenza", "PROBLEM", 146, 155], ["the study", "TEST", 214, 223], ["pulmonary function", "TEST", 241, 259], ["influenza", "OBSERVATION", 146, 155], ["pulmonary", "ANATOMY", 241, 250]]], ["The indices for pulmonary function as part of this test include: Tidal volume (VT), vital capacity (VC), flow-volume loop, forced expiratory volume at 1 second (FEV1), maximal mid-expiratory flow (MMEF), forced expiratory flow at 50% and 75% (FEF50, FEF75) and maximum voluntary ventilation (MVV).", [["pulmonary", "ANATOMY", 16, 25], ["pulmonary", "ORGAN", 16, 25], ["The indices", "TEST", 0, 11], ["pulmonary function", "TEST", 16, 34], ["this test", "TEST", 46, 55], ["Tidal volume", "TEST", 65, 77], ["VT", "TEST", 79, 81], ["vital capacity", "TEST", 84, 98], ["flow-volume loop", "TEST", 105, 121], ["forced expiratory volume", "TEST", 123, 147], ["FEV1", "TEST", 161, 165], ["maximal mid-expiratory flow", "TEST", 168, 195], ["forced expiratory flow", "TEST", 204, 226], ["FEF50", "TEST", 243, 248], ["FEF75", "TEST", 250, 255], ["maximum voluntary ventilation", "TREATMENT", 261, 290], ["pulmonary", "ANATOMY", 16, 25], ["volume loop", "OBSERVATION", 110, 121], ["expiratory volume", "OBSERVATION", 130, 147]]], ["The indices for pulmonary diffusion function include diffusing capacity of the lungs for carbon monoxide (DLCO) and diffusion rate.", [["pulmonary", "ANATOMY", 16, 25], ["lungs", "ANATOMY", 79, 84], ["carbon monoxide", "CHEMICAL", 89, 104], ["carbon monoxide", "CHEMICAL", 89, 104], ["pulmonary", "ORGAN", 16, 25], ["lungs", "ORGAN", 79, 84], ["carbon monoxide", "SIMPLE_CHEMICAL", 89, 104], ["The indices", "TEST", 0, 11], ["pulmonary diffusion function", "TEST", 16, 44], ["diffusing capacity of the lungs", "PROBLEM", 53, 84], ["carbon monoxide", "TEST", 89, 104], ["diffusion rate", "TEST", 116, 130], ["pulmonary", "ANATOMY", 16, 25], ["diffusing capacity", "OBSERVATION", 53, 71], ["lungs", "ANATOMY", 79, 84]]], ["Patients rested for 30 minutes before testing, and tests were performed in duplicate for each patient with the higher of the two values being included in the study.Clinical evaluationRespiratory tract infection symptoms (e.g. cough, expectoration or gasping), vital signs and pulse oxygen saturation (SpO2) were evaluated for each patient.", [["evaluationRespiratory tract infection", "DISEASE", 173, 210], ["cough", "DISEASE", 226, 231], ["expectoration", "DISEASE", 233, 246], ["oxygen", "CHEMICAL", 282, 288], ["oxygen", "CHEMICAL", 282, 288], ["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 94, 101], ["tract", "ORGANISM_SUBDIVISION", 195, 200], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["patient", "ORGANISM", 331, 338], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 331, 338], ["testing", "TEST", 38, 45], ["tests", "TEST", 51, 56], ["the study", "TEST", 154, 163], ["Clinical evaluationRespiratory tract infection symptoms", "PROBLEM", 164, 219], ["cough", "PROBLEM", 226, 231], ["expectoration", "PROBLEM", 233, 246], ["gasping", "PROBLEM", 250, 257], ["vital signs", "TEST", 260, 271], ["pulse oxygen saturation", "TEST", 276, 299], ["SpO2", "TEST", 301, 305]]], ["Retrospective evaluation: Clinical data including respiratory tract infection symptoms and vital signs [3, 4] , chest CT, blood gas analysis, mechanical ventilation, and the presence of secondary infection was also retrospectively analyzed at one year post hospital discharge.", [["respiratory tract", "ANATOMY", 50, 67], ["chest", "ANATOMY", 112, 117], ["blood", "ANATOMY", 122, 127], ["respiratory tract infection", "DISEASE", 50, 77], ["infection", "DISEASE", 196, 205], ["tract", "ORGANISM_SUBDIVISION", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["Retrospective evaluation", "TEST", 0, 24], ["Clinical data", "TEST", 26, 39], ["respiratory tract infection symptoms", "PROBLEM", 50, 86], ["vital signs", "TEST", 91, 102], ["chest CT", "TEST", 112, 120], ["blood gas analysis", "TEST", 122, 140], ["mechanical ventilation", "TREATMENT", 142, 164], ["secondary infection", "PROBLEM", 186, 205], ["respiratory tract", "ANATOMY", 50, 67], ["chest", "ANATOMY", 112, 117], ["mechanical ventilation", "OBSERVATION", 142, 164], ["secondary", "OBSERVATION_MODIFIER", 186, 195], ["infection", "OBSERVATION", 196, 205]]], ["Results from the current clinical testing and from the retrospective analysis were correlated with the severity of H1N1 influenza infection.", [["influenza infection", "DISEASE", 120, 139], ["the current clinical testing", "TEST", 13, 41], ["the retrospective analysis", "TEST", 51, 77], ["H1N1 influenza infection", "PROBLEM", 115, 139], ["H1N1", "OBSERVATION", 115, 119], ["infection", "OBSERVATION", 130, 139]]], ["When subjects' na\u00efve pulmonary function tests were normal by routine blood test and physical examination at the one-year follow-up test, chest X-rays showed no significant change.Statistical analysisStatistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).", [["pulmonary", "ANATOMY", 21, 30], ["blood", "ANATOMY", 69, 74], ["pulmonary", "ORGAN", 21, 30], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["' na\u00efve pulmonary function tests", "TEST", 13, 45], ["routine blood test", "TEST", 61, 79], ["physical examination", "TEST", 84, 104], ["chest X-rays", "TEST", 137, 149], ["significant change", "PROBLEM", 160, 178], ["Statistical analysisStatistical analysis", "TEST", 179, 219], ["SPSS", "TEST", 240, 244], ["SPSS Inc.", "TEST", 251, 260], ["pulmonary", "ANATOMY", 21, 30], ["chest", "ANATOMY", 137, 142], ["no", "UNCERTAINTY", 157, 159], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["change", "OBSERVATION", 172, 178]]], ["Numeration data were expressed as the incidence rate, a chi-square test was used, data were expressed as mean \u00b1 standard deviation, and parametric statistics was used.ResultsIn order to assess the potential long term effects of mild H1N1 influenza infection patients were first assessed at approximately one year following recovery and hospital discharge.", [["influenza infection", "DISEASE", 238, 257], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["a chi-square test", "TEST", 54, 71], ["parametric statistics", "TEST", 136, 157], ["mild H1N1 influenza infection", "PROBLEM", 228, 257], ["long term", "OBSERVATION_MODIFIER", 207, 216], ["mild", "OBSERVATION_MODIFIER", 228, 232], ["H1N1", "OBSERVATION", 233, 237]]], ["At this time, 29.2% (14/48) were observed to have obvious respiratory tract infection symptoms and 41.7% (20/48) had difficulties in performing physical activities.", [["respiratory tract", "ANATOMY", 58, 75], ["respiratory tract infection", "DISEASE", 58, 85], ["respiratory tract", "ORGANISM_SUBDIVISION", 58, 75], ["obvious respiratory tract infection symptoms", "PROBLEM", 50, 94], ["difficulties in performing physical activities", "PROBLEM", 117, 163], ["respiratory tract", "ANATOMY", 58, 75], ["infection", "OBSERVATION", 76, 85]]], ["Pulse oxygen saturation was greater than 95% in all patients and no abnormal vital signs.", [["oxygen", "CHEMICAL", 6, 12], ["oxygen", "CHEMICAL", 6, 12], ["oxygen", "SIMPLE_CHEMICAL", 6, 12], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Pulse oxygen saturation", "TEST", 0, 23], ["abnormal vital signs", "PROBLEM", 68, 88], ["no", "UNCERTAINTY", 65, 67], ["abnormal", "OBSERVATION_MODIFIER", 68, 76]]], ["We then tested each patient for pulmonary function and found 45.8% (22/48) had normal pulmonary function while 54.2% (26/48) had abnormal pulmonary function, all presenting with changes of mild to moderate H1N1 influenza.", [["pulmonary", "ANATOMY", 32, 41], ["pulmonary", "ANATOMY", 86, 95], ["pulmonary", "ANATOMY", 138, 147], ["abnormal pulmonary function", "DISEASE", 129, 156], ["influenza", "DISEASE", 211, 220], ["patient", "ORGANISM", 20, 27], ["pulmonary", "ORGAN", 32, 41], ["pulmonary", "ORGAN", 86, 95], ["pulmonary", "ORGAN", 138, 147], ["patient", "SPECIES", 20, 27], ["pulmonary function", "TEST", 32, 50], ["abnormal pulmonary function", "PROBLEM", 129, 156], ["mild to moderate H1N1 influenza", "PROBLEM", 189, 220], ["pulmonary", "ANATOMY", 32, 41], ["pulmonary", "ANATOMY", 86, 95], ["pulmonary", "ANATOMY", 138, 147], ["mild", "OBSERVATION_MODIFIER", 189, 193], ["moderate", "OBSERVATION_MODIFIER", 197, 205], ["H1N1 influenza", "OBSERVATION", 206, 220]]], ["Several changes caused by abnormal pulmonary function were found, including diffusion disorder, small airway function disorder, and weakened storing function (Table 1) .ResultsOf the 22 patients having normal pulmonary function, each had respiratory tract infection symptoms while six were observed to have a decreased ability to perform general physical activities.", [["pulmonary", "ANATOMY", 35, 44], ["airway", "ANATOMY", 102, 108], ["pulmonary", "ANATOMY", 209, 218], ["respiratory tract", "ANATOMY", 238, 255], ["abnormal pulmonary function", "DISEASE", 26, 53], ["diffusion disorder", "DISEASE", 76, 94], ["airway function disorder", "DISEASE", 102, 126], ["respiratory tract infection", "DISEASE", 238, 265], ["pulmonary", "ORGAN", 35, 44], ["airway", "MULTI-TISSUE_STRUCTURE", 102, 108], ["patients", "ORGANISM", 186, 194], ["pulmonary", "ORGAN", 209, 218], ["tract", "ORGANISM_SUBDIVISION", 250, 255], ["patients", "SPECIES", 186, 194], ["Several changes", "PROBLEM", 0, 15], ["abnormal pulmonary function", "PROBLEM", 26, 53], ["diffusion disorder", "PROBLEM", 76, 94], ["small airway function disorder", "PROBLEM", 96, 126], ["weakened storing function", "PROBLEM", 132, 157], ["respiratory tract infection symptoms", "PROBLEM", 238, 274], ["a decreased ability", "PROBLEM", 307, 326], ["abnormal", "OBSERVATION_MODIFIER", 26, 34], ["pulmonary function", "OBSERVATION", 35, 53], ["small", "OBSERVATION_MODIFIER", 96, 101], ["airway function disorder", "OBSERVATION", 102, 126], ["weakened", "OBSERVATION_MODIFIER", 132, 140], ["pulmonary", "ANATOMY", 209, 218], ["respiratory tract", "ANATOMY", 238, 255], ["infection", "OBSERVATION", 256, 265]]], ["Of the 26 patients tested to have abnormal pulmonary function, 12 had respiratory tract infection systems and 14 had decreased ability to perform general physical activities.", [["pulmonary", "ANATOMY", 43, 52], ["respiratory tract", "ANATOMY", 70, 87], ["abnormal pulmonary function", "DISEASE", 34, 61], ["respiratory tract infection", "DISEASE", 70, 97], ["patients", "ORGANISM", 10, 18], ["pulmonary", "ORGAN", 43, 52], ["tract", "ORGANISM_SUBDIVISION", 82, 87], ["patients", "SPECIES", 10, 18], ["abnormal pulmonary function", "PROBLEM", 34, 61], ["respiratory tract infection systems", "PROBLEM", 70, 105], ["pulmonary", "ANATOMY", 43, 52], ["respiratory tract", "ANATOMY", 70, 87]]], ["There was a clear correlation between respiratory tract infection symptoms and pulmonary function.", [["respiratory tract", "ANATOMY", 38, 55], ["pulmonary", "ANATOMY", 79, 88], ["respiratory tract infection", "DISEASE", 38, 65], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["pulmonary", "ORGAN", 79, 88], ["respiratory tract infection symptoms", "PROBLEM", 38, 74], ["pulmonary function", "TEST", 79, 97], ["respiratory tract", "ANATOMY", 38, 55], ["infection", "OBSERVATION", 56, 65], ["pulmonary", "ANATOMY", 79, 88]]], ["Patients that tested for abnormal pulmonary function had a higher percentage respiratory tract infection symptoms when compared with the group of patients with normal pulmonary function (P = 0.047).", [["pulmonary", "ANATOMY", 34, 43], ["respiratory tract", "ANATOMY", 77, 94], ["pulmonary", "ANATOMY", 167, 176], ["abnormal pulmonary function", "DISEASE", 25, 52], ["respiratory tract infection", "DISEASE", 77, 104], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 34, 43], ["respiratory tract", "ORGANISM_SUBDIVISION", 77, 94], ["patients", "ORGANISM", 146, 154], ["pulmonary", "ORGAN", 167, 176], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 146, 154], ["abnormal pulmonary function", "PROBLEM", 25, 52], ["a higher percentage respiratory tract infection symptoms", "PROBLEM", 57, 113], ["pulmonary", "ANATOMY", 34, 43], ["respiratory tract", "ANATOMY", 77, 94], ["infection", "OBSERVATION", 95, 104], ["pulmonary", "ANATOMY", 167, 176]]], ["Furthermore, patients with abnormal pulmonary function had a slightly, but not significant, greater influence on daily activities than normal pulmonary function (P = 0.188) ( Table 2) .", [["pulmonary", "ANATOMY", 36, 45], ["pulmonary", "ANATOMY", 142, 151], ["patients", "ORGANISM", 13, 21], ["pulmonary", "ORGAN", 36, 45], ["pulmonary", "ORGAN", 142, 151], ["patients", "SPECIES", 13, 21], ["abnormal pulmonary function", "PROBLEM", 27, 54], ["P", "TEST", 162, 163], ["pulmonary", "ANATOMY", 36, 45], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["greater", "OBSERVATION_MODIFIER", 92, 99], ["pulmonary", "ANATOMY", 142, 151]]], ["Finally, ten patients were observed to have greater than three abnormal pulmonary function indices, manifesting as respiratory tract infection symptoms and resulting in decreased general physical activates.ResultsUsing the Modified Medical Research Council Dyspnea Scale, scores of four (two cases), three (four cases), two (14 cases), one (four cases) and zero (two cases) were observed for patients with abnormal pulmonary function.", [["pulmonary", "ANATOMY", 72, 81], ["respiratory tract", "ANATOMY", 115, 132], ["pulmonary", "ANATOMY", 415, 424], ["respiratory tract infection", "DISEASE", 115, 142], ["Dyspnea", "DISEASE", 257, 264], ["abnormal pulmonary function", "DISEASE", 406, 433], ["patients", "ORGANISM", 13, 21], ["pulmonary", "ORGAN", 72, 81], ["tract", "ORGANISM_SUBDIVISION", 127, 132], ["patients", "ORGANISM", 392, 400], ["pulmonary", "ORGAN", 415, 424], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 392, 400], ["three abnormal pulmonary function indices", "PROBLEM", 57, 98], ["respiratory tract infection symptoms", "PROBLEM", 115, 151], ["decreased general physical activates", "PROBLEM", 169, 205], ["abnormal pulmonary function", "PROBLEM", 406, 433], ["abnormal", "OBSERVATION_MODIFIER", 63, 71], ["pulmonary", "ANATOMY", 72, 81], ["function indices", "OBSERVATION", 82, 98], ["respiratory tract", "ANATOMY", 115, 132], ["infection", "OBSERVATION", 133, 142], ["decreased", "OBSERVATION_MODIFIER", 169, 178], ["pulmonary", "ANATOMY", 415, 424]]], ["Similarly, for patients with normal pulmonary function, scores of four (two cases), three (two cases), two (eight cases), one (ten cases) and zero (two cases) were observed.", [["pulmonary", "ANATOMY", 36, 45], ["patients", "ORGANISM", 15, 23], ["pulmonary", "ORGAN", 36, 45], ["patients", "SPECIES", 15, 23], ["pulmonary", "ANATOMY", 36, 45]]], ["There were no significant differences in pulmonary function and ARDS scores between patients with abnormal pulmonary function and patients with normal pulmonary function.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 107, 116], ["pulmonary", "ANATOMY", 151, 160], ["ARDS", "DISEASE", 64, 68], ["abnormal pulmonary function", "DISEASE", 98, 125], ["pulmonary", "ORGAN", 41, 50], ["patients", "ORGANISM", 84, 92], ["pulmonary", "ORGAN", 107, 116], ["patients", "ORGANISM", 130, 138], ["pulmonary", "ORGAN", 151, 160], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 130, 138], ["significant differences in pulmonary function", "PROBLEM", 14, 59], ["ARDS scores", "PROBLEM", 64, 75], ["abnormal pulmonary function", "PROBLEM", 98, 125], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["pulmonary", "ANATOMY", 41, 50], ["function", "OBSERVATION", 51, 59], ["ARDS", "OBSERVATION", 64, 68], ["pulmonary", "ANATOMY", 107, 116], ["pulmonary", "ANATOMY", 151, 160]]], ["In addition, there were no significant differences in total hospital days and poorest oxygenation index between patients with normal pulmonary function and patients with abnormal pulmonary function.", [["pulmonary", "ANATOMY", 133, 142], ["pulmonary", "ANATOMY", 179, 188], ["abnormal pulmonary function", "DISEASE", 170, 197], ["patients", "ORGANISM", 112, 120], ["pulmonary", "ORGAN", 133, 142], ["patients", "ORGANISM", 156, 164], ["pulmonary", "ORGAN", 179, 188], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 156, 164], ["poorest oxygenation index", "TEST", 78, 103], ["abnormal pulmonary function", "PROBLEM", 170, 197], ["no", "UNCERTAINTY", 24, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["differences", "OBSERVATION_MODIFIER", 39, 50], ["pulmonary", "ANATOMY", 133, 142], ["pulmonary", "ANATOMY", 179, 188]]], ["Taken together, these result do not represent a correlation between pulmonary function at one year after discharge and the severity of the initial influenza infection (Table 3 ).DiscussionA common severe clinical manifestation of patients infected with influenza A virus subtype H1N1 is severe ARDS [5] .", [["pulmonary", "ANATOMY", 68, 77], ["influenza infection", "DISEASE", 147, 166], ["influenza A virus", "DISEASE", 253, 270], ["H1N1", "DISEASE", 279, 283], ["ARDS", "DISEASE", 294, 298], ["pulmonary", "ORGAN", 68, 77], ["patients", "ORGANISM", 230, 238], ["influenza A virus subtype H1N1", "ORGANISM", 253, 283], ["patients", "SPECIES", 230, 238], ["influenza A virus subtype H1N1", "SPECIES", 253, 283], ["the initial influenza infection", "PROBLEM", 135, 166], ["influenza A virus subtype H1N1", "PROBLEM", 253, 283], ["severe ARDS", "PROBLEM", 287, 298], ["pulmonary", "ANATOMY", 68, 77], ["influenza", "OBSERVATION", 147, 156], ["severe", "OBSERVATION_MODIFIER", 287, 293], ["ARDS", "OBSERVATION", 294, 298]]], ["During recovery, pulmonary fibrosis is the major pathological change observed during recovery [4] .", [["pulmonary", "ANATOMY", 17, 26], ["fibrosis", "DISEASE", 27, 35], ["pulmonary", "ORGAN", 17, 26], ["pulmonary fibrosis", "PROBLEM", 17, 35], ["pulmonary", "ANATOMY", 17, 26], ["fibrosis", "OBSERVATION", 27, 35]]], ["In addition, abnormal pulmonary function is manifested as decreased diffusion function and restrictive ventilatory disorder [6] .", [["pulmonary", "ANATOMY", 22, 31], ["ventilatory disorder", "DISEASE", 103, 123], ["pulmonary", "ORGAN", 22, 31], ["abnormal pulmonary function", "PROBLEM", 13, 40], ["decreased diffusion function", "PROBLEM", 58, 86], ["restrictive ventilatory disorder", "PROBLEM", 91, 123], ["abnormal", "OBSERVATION_MODIFIER", 13, 21], ["pulmonary function", "OBSERVATION", 22, 40], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["diffusion function", "OBSERVATION", 68, 86], ["restrictive", "OBSERVATION_MODIFIER", 91, 102], ["ventilatory disorder", "OBSERVATION", 103, 123]]], ["There is precedence for long term negative effects from pulmonary infection, as viral pneumonia-caused ARDS is a typical manifestation of severe acute respiratory syndrome (SARS) infections.", [["pulmonary", "ANATOMY", 56, 65], ["pulmonary infection", "DISEASE", 56, 75], ["viral pneumonia", "DISEASE", 80, 95], ["ARDS", "DISEASE", 103, 107], ["acute respiratory syndrome (SARS) infections", "DISEASE", 145, 189], ["pulmonary", "ORGAN", 56, 65], ["long term negative effects", "PROBLEM", 24, 50], ["pulmonary infection", "PROBLEM", 56, 75], ["viral pneumonia", "PROBLEM", 80, 95], ["ARDS", "PROBLEM", 103, 107], ["severe acute respiratory syndrome", "PROBLEM", 138, 171], ["SARS) infections", "PROBLEM", 173, 189], ["precedence for", "UNCERTAINTY", 9, 23], ["long term", "OBSERVATION_MODIFIER", 24, 33], ["pulmonary", "ANATOMY", 56, 65], ["infection", "OBSERVATION", 66, 75], ["viral", "OBSERVATION_MODIFIER", 80, 85], ["pneumonia", "OBSERVATION", 86, 95], ["ARDS", "OBSERVATION", 103, 107], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory syndrome", "OBSERVATION", 151, 171]]], ["Specifically, SARS patients presented with decreased pulmonary diffusion function during recovery [7] [8] [9] [10] .", [["pulmonary", "ANATOMY", 53, 62], ["SARS", "DISEASE", 14, 18], ["patients", "ORGANISM", 19, 27], ["pulmonary", "ORGAN", 53, 62], ["patients", "SPECIES", 19, 27], ["decreased pulmonary diffusion function", "PROBLEM", 43, 81], ["pulmonary", "ANATOMY", 53, 62]]], ["Furthermore, a study by Neff et al [11] revealed that among 16 survivors of severe ARDS, 9 had abnormal pulmonary function, while four presented with obstructive ventilatory disorder and four with restrictive ventilatory disorder.", [["pulmonary", "ANATOMY", 104, 113], ["ARDS", "DISEASE", 83, 87], ["abnormal pulmonary function", "DISEASE", 95, 122], ["obstructive ventilatory disorder", "DISEASE", 150, 182], ["ventilatory disorder", "DISEASE", 209, 229], ["pulmonary", "ORGAN", 104, 113], ["a study", "TEST", 13, 20], ["severe ARDS", "PROBLEM", 76, 87], ["abnormal pulmonary function", "PROBLEM", 95, 122], ["obstructive ventilatory disorder", "PROBLEM", 150, 182], ["restrictive ventilatory disorder", "PROBLEM", 197, 229], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["ARDS", "OBSERVATION", 83, 87], ["pulmonary", "ANATOMY", 104, 113], ["obstructive", "OBSERVATION_MODIFIER", 150, 161], ["ventilatory disorder", "OBSERVATION", 162, 182], ["restrictive", "OBSERVATION_MODIFIER", 197, 208], ["ventilatory disorder", "OBSERVATION", 209, 229]]], ["In addition, a study by Li et al [12] found the incidence of obstructive ventilatory disorder and restrictive ventilatory disorder was approximately 30% following infection.", [["obstructive ventilatory disorder", "DISEASE", 61, 93], ["ventilatory disorder", "DISEASE", 110, 130], ["infection", "DISEASE", 163, 172], ["a study", "TEST", 13, 20], ["obstructive ventilatory disorder", "PROBLEM", 61, 93], ["restrictive ventilatory disorder", "PROBLEM", 98, 130], ["infection", "PROBLEM", 163, 172], ["obstructive", "OBSERVATION_MODIFIER", 61, 72], ["ventilatory disorder", "OBSERVATION", 73, 93], ["restrictive", "OBSERVATION_MODIFIER", 98, 109], ["ventilatory disorder", "OBSERVATION", 110, 130], ["infection", "OBSERVATION", 163, 172]]], ["Interestingly small airway dysfunction was also reported in a small number of SARS patients during recovery [8] .", [["airway", "ANATOMY", 20, 26], ["airway dysfunction", "DISEASE", 20, 38], ["SARS", "DISEASE", 78, 82], ["airway", "MULTI-TISSUE_STRUCTURE", 20, 26], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Interestingly small airway dysfunction", "PROBLEM", 0, 38], ["small", "OBSERVATION_MODIFIER", 14, 19], ["airway dysfunction", "OBSERVATION", 20, 38], ["small", "OBSERVATION_MODIFIER", 62, 67]]], ["This is the first study to assess the long term effects of mild influenza A virus subtype H1N1.", [["mild influenza A virus subtype H1N1", "ORGANISM", 59, 94], ["influenza A virus subtype H1N1", "SPECIES", 64, 94], ["influenza A virus", "SPECIES", 64, 81], ["the first study", "TEST", 8, 23], ["mild influenza A virus subtype H1N1", "PROBLEM", 59, 94], ["long term", "OBSERVATION_MODIFIER", 38, 47], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["influenza", "OBSERVATION", 64, 73]]], ["Pulmonary diffusion disorder during H1N1 influenza infection recovery is similar to ARDS, however, a large proportion of patients recovering from influenza infection also show signs of small airway obstruction.", [["Pulmonary", "ANATOMY", 0, 9], ["airway", "ANATOMY", 191, 197], ["Pulmonary diffusion disorder", "DISEASE", 0, 28], ["influenza infection", "DISEASE", 41, 60], ["ARDS", "DISEASE", 84, 88], ["influenza infection", "DISEASE", 146, 165], ["airway obstruction", "DISEASE", 191, 209], ["Pulmonary", "ORGAN", 0, 9], ["patients", "ORGANISM", 121, 129], ["airway obstruction", "PATHOLOGICAL_FORMATION", 191, 209], ["patients", "SPECIES", 121, 129], ["Pulmonary diffusion disorder", "PROBLEM", 0, 28], ["H1N1 influenza infection", "PROBLEM", 36, 60], ["ARDS", "PROBLEM", 84, 88], ["influenza infection", "PROBLEM", 146, 165], ["small airway obstruction", "PROBLEM", 185, 209], ["diffusion disorder", "OBSERVATION", 10, 28], ["ARDS", "OBSERVATION", 84, 88], ["large", "OBSERVATION_MODIFIER", 101, 106], ["influenza infection", "OBSERVATION", 146, 165], ["small", "OBSERVATION_MODIFIER", 185, 190], ["airway", "ANATOMY", 191, 197], ["obstruction", "OBSERVATION", 198, 209]]], ["In addition, this study reveals that approximately half of patients recovering from H1N1 influenza had abnormal pulmonary function, one third had diffusion dysfunction, a third had small airway obstruction, and another third presented with decreased ventilation function.", [["pulmonary", "ANATOMY", 112, 121], ["airway", "ANATOMY", 187, 193], ["influenza", "DISEASE", 89, 98], ["abnormal pulmonary function", "DISEASE", 103, 130], ["diffusion dysfunction", "DISEASE", 146, 167], ["airway obstruction", "DISEASE", 187, 205], ["patients", "ORGANISM", 59, 67], ["pulmonary", "ORGAN", 112, 121], ["airway obstruction", "PATHOLOGICAL_FORMATION", 187, 205], ["patients", "SPECIES", 59, 67], ["H1N1 influenza", "SPECIES", 84, 98], ["this study", "TEST", 13, 23], ["H1N1 influenza", "PROBLEM", 84, 98], ["abnormal pulmonary function", "PROBLEM", 103, 130], ["diffusion dysfunction", "PROBLEM", 146, 167], ["small airway obstruction", "PROBLEM", 181, 205], ["decreased ventilation function", "PROBLEM", 240, 270], ["H1N1", "OBSERVATION", 84, 88], ["pulmonary", "ANATOMY", 112, 121], ["small", "OBSERVATION_MODIFIER", 181, 186], ["airway", "ANATOMY", 187, 193], ["obstruction", "OBSERVATION", 194, 205], ["decreased", "OBSERVATION_MODIFIER", 240, 249], ["ventilation function", "OBSERVATION", 250, 270]]], ["The pathological changes following H1N1 influenza-induced severe pneumonia include three types: diffuse alveolar lesion, necrotizing bronchiolitis and widespread pulmonary hemorrhage [13] .", [["alveolar lesion", "ANATOMY", 104, 119], ["pulmonary", "ANATOMY", 162, 171], ["influenza", "DISEASE", 40, 49], ["pneumonia", "DISEASE", 65, 74], ["alveolar lesion", "DISEASE", 104, 119], ["bronchiolitis", "DISEASE", 133, 146], ["pulmonary hemorrhage", "DISEASE", 162, 182], ["alveolar lesion", "PATHOLOGICAL_FORMATION", 104, 119], ["pulmonary", "ORGAN", 162, 171], ["H1N1 influenza", "SPECIES", 35, 49], ["The pathological changes", "PROBLEM", 0, 24], ["H1N1 influenza", "PROBLEM", 35, 49], ["severe pneumonia", "PROBLEM", 58, 74], ["diffuse alveolar lesion", "PROBLEM", 96, 119], ["necrotizing bronchiolitis", "PROBLEM", 121, 146], ["widespread pulmonary hemorrhage", "PROBLEM", 151, 182], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["pneumonia", "OBSERVATION", 65, 74], ["diffuse", "OBSERVATION_MODIFIER", 96, 103], ["alveolar", "ANATOMY_MODIFIER", 104, 112], ["lesion", "OBSERVATION", 113, 119], ["necrotizing", "OBSERVATION_MODIFIER", 121, 132], ["bronchiolitis", "OBSERVATION", 133, 146], ["widespread", "OBSERVATION_MODIFIER", 151, 161], ["pulmonary", "ANATOMY", 162, 171], ["hemorrhage", "OBSERVATION", 172, 182]]], ["This suggests that necrotizing bronchiolitis is likely to be the pathological basis of small airway obstruction.", [["airway", "ANATOMY", 93, 99], ["bronchiolitis", "DISEASE", 31, 44], ["airway obstruction", "DISEASE", 93, 111], ["airway obstruction", "PATHOLOGICAL_FORMATION", 93, 111], ["necrotizing bronchiolitis", "PROBLEM", 19, 44], ["small airway obstruction", "PROBLEM", 87, 111], ["necrotizing", "OBSERVATION_MODIFIER", 19, 30], ["bronchiolitis", "OBSERVATION", 31, 44], ["likely to be", "UNCERTAINTY", 48, 60], ["small", "OBSERVATION_MODIFIER", 87, 92], ["airway", "ANATOMY", 93, 99], ["obstruction", "OBSERVATION", 100, 111]]], ["Here, we found 25% of patients had respiratory tract infection symptoms including cough, expectoration, or gasping, while 41.7% of patients had difficulties in performing general physical activities.", [["respiratory tract", "ANATOMY", 35, 52], ["respiratory tract infection", "DISEASE", 35, 62], ["cough", "DISEASE", 82, 87], ["expectoration", "DISEASE", 89, 102], ["patients", "ORGANISM", 22, 30], ["tract", "ORGANISM_SUBDIVISION", 47, 52], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 131, 139], ["respiratory tract infection symptoms", "PROBLEM", 35, 71], ["cough", "PROBLEM", 82, 87], ["expectoration", "PROBLEM", 89, 102], ["gasping", "PROBLEM", 107, 114], ["respiratory tract", "ANATOMY", 35, 52], ["infection", "OBSERVATION", 53, 62]]], ["Interestingly, the observed clinical symptoms correlated with patients having greater than three abnormal pulmonary function indices.", [["pulmonary", "ANATOMY", 106, 115], ["patients", "ORGANISM", 62, 70], ["pulmonary", "ORGAN", 106, 115], ["patients", "SPECIES", 62, 70], ["the observed clinical symptoms", "PROBLEM", 15, 45], ["three abnormal pulmonary function indices", "PROBLEM", 91, 132], ["pulmonary", "ANATOMY", 106, 115], ["function indices", "OBSERVATION", 116, 132]]], ["In this study, we did not identify a relationship between abnormal pulmonary function of patients with H1N1 influenza and the severity of pulmonary function impairment during hospitalization, possibly because mild H1N1 influenza patients and a small number of H1N1 influenza patients were involved.", [["pulmonary", "ANATOMY", 67, 76], ["pulmonary", "ANATOMY", 138, 147], ["abnormal pulmonary function", "DISEASE", 58, 85], ["influenza", "DISEASE", 108, 117], ["pulmonary function impairment", "DISEASE", 138, 167], ["influenza", "DISEASE", 219, 228], ["influenza", "DISEASE", 265, 274], ["pulmonary", "ORGAN", 67, 76], ["patients", "ORGANISM", 89, 97], ["pulmonary", "ORGAN", 138, 147], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 89, 97], ["H1N1 influenza", "SPECIES", 214, 228], ["patients", "SPECIES", 229, 237], ["H1N1 influenza", "SPECIES", 260, 274], ["patients", "SPECIES", 275, 283], ["this study", "TEST", 3, 13], ["abnormal pulmonary function", "PROBLEM", 58, 85], ["H1N1 influenza", "PROBLEM", 103, 117], ["pulmonary function impairment", "PROBLEM", 138, 167], ["mild H1N1 influenza patients", "PROBLEM", 209, 237], ["H1N1 influenza patients", "PROBLEM", 260, 283], ["abnormal", "OBSERVATION_MODIFIER", 58, 66], ["pulmonary", "ANATOMY", 67, 76], ["pulmonary", "ANATOMY", 138, 147], ["mild", "OBSERVATION_MODIFIER", 209, 213], ["H1N1", "OBSERVATION", 214, 218], ["small", "OBSERVATION_MODIFIER", 244, 249]]], ["This is consistent with previous studies investigating the effects of ARDS on pulmonary function [14, 15] .", [["pulmonary", "ANATOMY", 78, 87], ["ARDS", "DISEASE", 70, 74], ["pulmonary", "ORGAN", 78, 87], ["previous studies", "TEST", 24, 40], ["ARDS", "PROBLEM", 70, 74], ["pulmonary function", "TEST", 78, 96], ["consistent with", "UNCERTAINTY", 8, 23], ["ARDS", "OBSERVATION", 70, 74], ["pulmonary", "ANATOMY", 78, 87]]], ["Several variables were not included in this study that may have also had an effect on the recovery of pulmonary function following influenza infection, including age, obesity, gender, recovery time, heart function, and the amount of physical rehabilitation exercise.DiscussionWhile some patients still have respiratory tract infection symptoms and limited physical activity one year after recovering from H1N1 infection.", [["pulmonary", "ANATOMY", 102, 111], ["heart", "ANATOMY", 199, 204], ["respiratory tract", "ANATOMY", 307, 324], ["influenza infection", "DISEASE", 131, 150], ["obesity", "DISEASE", 167, 174], ["respiratory tract infection", "DISEASE", 307, 334], ["H1N1 infection", "DISEASE", 405, 419], ["pulmonary", "ORGAN", 102, 111], ["heart", "ORGAN", 199, 204], ["patients", "ORGANISM", 287, 295], ["tract", "ORGANISM_SUBDIVISION", 319, 324], ["patients", "SPECIES", 287, 295], ["this study", "TEST", 39, 49], ["influenza infection", "PROBLEM", 131, 150], ["obesity", "PROBLEM", 167, 174], ["heart function", "TEST", 199, 213], ["physical rehabilitation exercise", "TREATMENT", 233, 265], ["respiratory tract infection symptoms", "PROBLEM", 307, 343], ["H1N1 infection", "PROBLEM", 405, 419], ["pulmonary", "ANATOMY", 102, 111], ["heart", "ANATOMY", 199, 204], ["respiratory tract", "ANATOMY", 307, 324], ["infection", "OBSERVATION", 325, 334], ["H1N1", "OBSERVATION_MODIFIER", 405, 409], ["infection", "OBSERVATION", 410, 419]]], ["While no correlations were drawn between severity of infection and these symptoms, care should be paid to these patients, including follow-up pulmonary function tests to guide patients to the proper rehabilitation treatment, with the ultimate goal of improving patients' quality of life.", [["pulmonary", "ANATOMY", 142, 151], ["infection", "DISEASE", 53, 62], ["patients", "ORGANISM", 112, 120], ["pulmonary", "ORGAN", 142, 151], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 261, 269], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 261, 269], ["infection", "PROBLEM", 53, 62], ["these symptoms", "PROBLEM", 67, 81], ["pulmonary function tests", "TEST", 142, 166], ["the proper rehabilitation treatment", "TREATMENT", 188, 223], ["infection", "OBSERVATION", 53, 62], ["pulmonary", "ANATOMY", 142, 151]]]], "PMC7185771": [], "52612c74e0017bd50d980a7d4b3b09836277decc": [["Traditionally, examining the phenotypic correlation or coexistence of other factors is a useful 135 way to investigate the heterogeneity of asthma.", [["asthma", "DISEASE", 140, 146], ["asthma", "PROBLEM", 140, 146], ["asthma", "OBSERVATION", 140, 146]]], ["However, this approach may have residual 136 confounding and provide insufficient biological insight as to which underlying mechanism(s) 137 drive the association.", [["residual 136 confounding", "PROBLEM", 32, 56]]], ["A major advantage going from phenotypic correlations to genetic 138 correlations is to improve understanding of the mechanism(s)-shared genetic components can 139 be identified at different levels, from whole genome to individual variants, providing insights 140 into the reasons why asthma and coexistent diseases or traits are correlated.", [["asthma", "DISEASE", 284, 290], ["asthma", "PROBLEM", 284, 290], ["coexistent diseases", "PROBLEM", 295, 314]]], ["A purely environmental confounding factor (e.g., air pollution) would not lead to 145 genetic correlation because it is not associated with any genetic variant (Figure 2a and 2b) .", [["A purely environmental confounding factor", "PROBLEM", 0, 41]]], ["Population stratification is 149 arguably the only confounding factor in GWAS but it can be effectively controlled using 150 principal components from genome-wide genetic markers.", [["Population stratification", "TEST", 0, 25]]], ["25 Once the genetic effect on diseases 151 and traits are robustly established, the genetic correlation between diseases and traits can be 152 reliably estimated and replicated.", [["diseases", "PROBLEM", 30, 38]]], ["[26] [27] [28] [29] In the following sections, we will discuss a range of 153 detailed analyses that compile a comprehensive investigation between asthma and other 154 coexistent diseases or traits.Genome-wide cross-trait analysis study designapplicable to asthma and many other diseases/traits.", [["asthma", "DISEASE", 147, 153], ["asthma", "DISEASE", 257, 263], ["[26] [27] [28] [29", "SIMPLE_CHEMICAL", 0, 18], ["asthma", "PROBLEM", 147, 153], ["other 154 coexistent diseases", "PROBLEM", 158, 187], ["wide cross-trait analysis study", "TEST", 205, 236], ["asthma", "PROBLEM", 257, 263], ["many other diseases/traits", "PROBLEM", 268, 294], ["asthma", "OBSERVATION", 257, 263]]], ["The design has been successfully applied to 170 the UK Biobank and GWAS consortia datasets, and determined the shared genetic architecture 171 between asthma and allergic diseases, 22 obesity, 12 and mental health disorders, 21 which were 172 reproducible in other studies.", [["asthma", "DISEASE", 151, 157], ["allergic diseases", "DISEASE", 162, 179], ["obesity", "DISEASE", 184, 191], ["GWAS consortia datasets", "TEST", 67, 90], ["asthma", "PROBLEM", 151, 157], ["allergic diseases", "PROBLEM", 162, 179], ["22 obesity", "PROBLEM", 181, 191], ["mental health disorders", "PROBLEM", 200, 223], ["other studies", "TEST", 259, 272], ["asthma", "OBSERVATION", 151, 157], ["allergic diseases", "OBSERVATION", 162, 179]]], ["26-29 A genome-wide cross-trait analysis features several analyses: 173 genetic correlation, cross-trait meta-analysis, Mendelian randomization, polygenic risk score, 174 and GWAS functional analysis.", [["genetic correlation", "TEST", 72, 91], ["cross-trait meta-analysis", "TEST", 93, 118], ["Mendelian randomization", "TEST", 120, 143], ["polygenic risk score", "TEST", 145, 165], ["GWAS functional analysis", "TEST", 175, 199]]], ["Each component is discussed in more detail in subsequent 175 sections and depicted in Figure 3 .", [["sections", "ANATOMY", 61, 69]]], ["A summary of genome-wide cross-trait analysis methods may be found in 177 suggests obesity-to-asthma effects, reduction of body mass index (BMI) in patients with obesity 195 might counteract the genetic effect, thereby potentially preventing the development of asthma.196Therefore, distinguishing horizontal pleiotropy from vertical pleiotropy where both contribute to 197 genetic correlations are important and can be challenging.", [["body", "ANATOMY", 123, 127], ["obesity", "DISEASE", 83, 90], ["asthma", "DISEASE", 94, 100], ["obesity", "DISEASE", 162, 169], ["asthma", "DISEASE", 261, 267], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["obesity", "PROBLEM", 83, 90], ["asthma effects", "PROBLEM", 94, 108], ["body mass index", "PROBLEM", 123, 138], ["obesity", "PROBLEM", 162, 169], ["asthma", "PROBLEM", 261, 267], ["horizontal pleiotropy from vertical pleiotropy", "PROBLEM", 297, 343], ["obesity", "OBSERVATION", 83, 90], ["body", "OBSERVATION_MODIFIER", 123, 127], ["mass", "OBSERVATION", 128, 132], ["obesity", "OBSERVATION", 162, 169], ["asthma", "OBSERVATION", 261, 267], ["horizontal pleiotropy", "OBSERVATION", 297, 318], ["vertical pleiotropy", "OBSERVATION", 324, 343]]], ["We discuss methods for these analyses 198 in the sections below on cross-trait meta-analysis and Mendelian randomization.", [["sections", "ANATOMY", 49, 57], ["these analyses", "TEST", 23, 37], ["Mendelian randomization", "TREATMENT", 97, 120]]], ["The sensitivity analyses showed that the Rg estimate from LDSC is unbiased to overlapping and asthma, 21 the use of ASSET identified 7 loci that are jointly associated with ADHD and 260 asthma, one locus with anxiety disorder and asthma, 10 loci with major depressive disorder and asthma.", [["asthma", "DISEASE", 94, 100], ["ADHD", "DISEASE", 173, 177], ["asthma", "DISEASE", 186, 192], ["anxiety disorder", "DISEASE", 209, 225], ["asthma", "DISEASE", 230, 236], ["depressive disorder", "DISEASE", 257, 276], ["asthma", "DISEASE", 281, 287], ["ASSET", "DNA", 116, 121], ["The sensitivity analyses", "TEST", 0, 24], ["LDSC", "PROBLEM", 58, 62], ["asthma", "PROBLEM", 94, 100], ["ADHD", "PROBLEM", 173, 177], ["asthma", "PROBLEM", 186, 192], ["anxiety disorder", "PROBLEM", 209, 225], ["asthma", "PROBLEM", 230, 236], ["major depressive disorder", "PROBLEM", 251, 276], ["asthma", "PROBLEM", 281, 287], ["asthma", "OBSERVATION", 94, 100], ["asthma", "OBSERVATION", 230, 236], ["asthma", "OBSERVATION", 281, 287]]], ["Of note, the human leukocyte antigen (HLA) region (chr6: 25-34Mb) was found to be 262 shared in the cross-trait meta-analysis of allergic disease and asthma as well as that between 263 major depressive disorder and asthma.", [["allergic disease", "DISEASE", 129, 145], ["asthma", "DISEASE", 150, 156], ["depressive disorder", "DISEASE", 191, 210], ["asthma", "DISEASE", 215, 221], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 13, 36], ["HLA", "GENE_OR_GENE_PRODUCT", 38, 41], ["human leukocyte antigen (HLA) region", "DNA", 13, 49], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["the human leukocyte antigen", "TEST", 9, 36], ["chr6", "TEST", 51, 55], ["Mb", "TEST", 62, 64], ["allergic disease", "PROBLEM", 129, 145], ["asthma", "PROBLEM", 150, 156], ["major depressive disorder", "PROBLEM", 185, 210], ["asthma", "PROBLEM", 215, 221], ["allergic disease", "OBSERVATION", 129, 145], ["asthma", "OBSERVATION", 150, 156], ["asthma", "OBSERVATION", 215, 221]]], ["The HLA region was commonly reported to haveTerminologyDefinition Cross-trait meta-analysis A meta-analysis that tests the null hypothesis that none of the traits being examined is associated with the genetic variant.", [["HLA region", "DNA", 4, 14], ["A meta-analysis", "TEST", 92, 107], ["the null hypothesis", "PROBLEM", 119, 138], ["genetic variant", "OBSERVATION", 201, 216]]], ["One genetic variant is tested at a time.", [["variant", "OBSERVATION", 12, 19]]], ["Expression quantitative trait loci (eQTLs) Genetic variants that are associated with the gene expression levels.Genetic correlationAssuming all genetic variants have some effect on a trait and their effect size follow a Gaussian distribution (called the infinitesimal model), the genetic correlation between two traits (A and B) measures the Pearson's correlation between the genetic variant effect on traits A and B. Genome-wide association study (GWAS) An analytical method that tests the association between each genetic variant and a specific phenotype (a disease status or a quantitative trait).", [["eQTLs", "DNA", 36, 41], ["Expression quantitative trait loci (eQTLs) Genetic variants", "PROBLEM", 0, 59], ["the gene expression levels", "PROBLEM", 85, 111], ["An analytical method", "TEST", 455, 475], ["a specific phenotype (a disease status", "PROBLEM", 536, 574]]], ["One genetic variant is tested at a time.", [["variant", "OBSERVATION", 12, 19]]], ["Human leukocyte antigen (HLA)/ major histocompatibility complex (MHC) region A genomic region of approximately 3.6 Mb genome sequence located on the chromosome 6p21, which is mainly known for its pervasive pleiotropic effect and immune-related function.", [["chromosome 6p21", "ANATOMY", 149, 164], ["Human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 0, 23], ["HLA)/ major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 25, 63], ["chromosome 6p21", "CELLULAR_COMPONENT", 149, 164], ["Human leukocyte antigen (HLA)/ major histocompatibility complex (MHC) region", "DNA", 0, 76], ["3.6 Mb genome sequence", "DNA", 111, 133], ["chromosome 6p21", "DNA", 149, 164], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human leukocyte antigen", "TEST", 0, 23], ["HLA", "TEST", 25, 28], ["major histocompatibility complex (MHC) region A genomic region", "PROBLEM", 31, 93], ["Mb genome sequence", "TEST", 115, 133], ["its pervasive pleiotropic effect", "PROBLEM", 192, 224]]], ["The extended MHC region is at 25-34 Mb on chromosome 6.", [["chromosome 6", "ANATOMY", 42, 54], ["chromosome 6", "CELLULAR_COMPONENT", 42, 54], ["MHC region", "DNA", 13, 23], ["chromosome 6", "DNA", 42, 54]]], ["Horizontal pleiotropy A genetic variant or gene having independent effects on multiple traits, which do not have causal effect on each other.Instrumental variablesVariables that are associated with the modifiable exposure or risk factor of interest and affect the outcome only through the exposure or risk factor.", [["Horizontal pleiotropy A genetic variant", "PROBLEM", 0, 39], ["Instrumental variables", "PROBLEM", 141, 163], ["risk factor", "PROBLEM", 301, 312], ["genetic variant", "OBSERVATION", 24, 39]]], ["Mendelian randomization An analytic approach that examines the causality of an observed association of a modifiable exposure or risk factor with an outcome of interest using one or more genetic instrumental variables.", [["Mendelian randomization", "TREATMENT", 0, 23], ["An analytic approach", "TEST", 24, 44], ["risk factor", "PROBLEM", 128, 139]]], ["Polygenic risk score A score based on a set of disease/trait-associated genetic variants, commonly defined as weighted sum of their genotypes.", [["Polygenic risk score A score", "PROBLEM", 0, 28], ["disease/trait", "PROBLEM", 47, 60], ["genetic variants", "PROBLEM", 72, 88], ["disease", "OBSERVATION", 47, 54], ["genetic variants", "OBSERVATION", 72, 88]]], ["Weights are chosen by their association effect on the disease/trait, directly from GWAS or further modified based on suitable statistical model incorporating all genetic variants on the genome.", [["Weights", "TEST", 0, 7], ["the disease/trait", "PROBLEM", 50, 67]]], ["Vertical pleiotropy (genetic causality) A genetic variant or gene having an effect on a trait, which has causal effect on another trait.SoftwareAdvantages Disadvantages Examples of application in asthma or complex traits/PMID", [["asthma", "DISEASE", 196, 202], ["Vertical pleiotropy (genetic causality", "PROBLEM", 0, 38], ["asthma", "PROBLEM", 196, 202], ["genetic variant", "OBSERVATION", 42, 57]]]], "PMC7459353": [["IntroductionEbola virus (EBOV), a member of the family Filoviridae, is an enveloped, single-stranded RNA virus that can cause Ebola virus disease (EVD), a highly lethal illness with up to 90% mortality1.", [["Ebola virus disease", "DISEASE", 126, 145], ["EVD", "DISEASE", 147, 150], ["illness", "DISEASE", 169, 176], ["IntroductionEbola virus", "ORGANISM", 0, 23], ["EBOV", "ORGANISM", 25, 29], ["Filoviridae", "GENE_OR_GENE_PRODUCT", 55, 66], ["Ebola virus", "ORGANISM", 126, 137], ["Ebola virus", "SPECIES", 126, 137], ["IntroductionEbola virus", "SPECIES", 0, 23], ["EBOV", "SPECIES", 25, 29], ["Ebola virus", "SPECIES", 126, 137], ["IntroductionEbola virus", "PROBLEM", 0, 23], ["the family Filoviridae", "TREATMENT", 44, 66], ["single-stranded RNA virus", "PROBLEM", 85, 110], ["Ebola virus disease", "PROBLEM", 126, 145], ["a highly lethal illness", "PROBLEM", 153, 176], ["Ebola virus", "OBSERVATION", 126, 137], ["highly", "OBSERVATION_MODIFIER", 155, 161], ["lethal", "OBSERVATION_MODIFIER", 162, 168]]], ["Since its discovery in 1976, EBOV has caused sporadic outbreaks across Central Africa and was responsible for the 2013\u20132016 EVD epidemic in West Africa2, which was the largest EBOV outbreak on record and resulted in more than 28,600 cases and over 11,300 deaths3.", [["EBOV", "DISEASE", 29, 33], ["deaths", "DISEASE", 255, 261], ["EBOV", "ORGANISM", 29, 33], ["EBOV", "ORGANISM", 176, 180], ["EBOV", "SPECIES", 29, 33], ["EBOV", "SPECIES", 176, 180], ["sporadic outbreaks", "PROBLEM", 45, 63], ["Central Africa", "PROBLEM", 71, 85], ["sporadic", "OBSERVATION_MODIFIER", 45, 53], ["outbreaks", "OBSERVATION", 54, 63], ["Central Africa", "OBSERVATION", 71, 85], ["largest", "OBSERVATION_MODIFIER", 168, 175], ["EBOV", "OBSERVATION", 176, 180]]], ["This outbreak constituted a public health emergency of international concern and highlighted the urgent need for vaccines and therapeutics against EBOV.IntroductionThe EBOV RNA genome is approximately 19 kb in length and encodes seven main proteins.", [["EBOV", "DISEASE", 147, 151], ["EBOV", "ORGANISM", 147, 151], ["EBOV", "ORGANISM", 168, 172], ["EBOV RNA genome", "DNA", 168, 183], ["EBOV", "SPECIES", 147, 151], ["EBOV", "SPECIES", 168, 172], ["vaccines", "TREATMENT", 113, 121], ["therapeutics", "TREATMENT", 126, 138], ["EBOV", "PROBLEM", 147, 151], ["EBOV", "OBSERVATION", 168, 172], ["RNA genome", "OBSERVATION", 173, 183]]], ["The envelope glycoprotein (GP) of EBOV forms homotrimeric spikes that project from the surface of the viral particles4.", [["surface", "ANATOMY", 87, 94], ["GP", "GENE_OR_GENE_PRODUCT", 27, 29], ["EBOV", "ORGANISM", 34, 38], ["surface", "CELLULAR_COMPONENT", 87, 94], ["envelope glycoprotein", "PROTEIN", 4, 25], ["GP", "PROTEIN", 27, 29], ["EBOV", "SPECIES", 34, 38], ["The envelope glycoprotein (GP)", "TREATMENT", 0, 30], ["EBOV forms homotrimeric spikes", "PROBLEM", 34, 64], ["envelope", "OBSERVATION_MODIFIER", 4, 12], ["glycoprotein", "OBSERVATION_MODIFIER", 13, 25], ["viral particles4", "OBSERVATION", 102, 118]]], ["Surface GP is critical for host cell attachment and fusion5,6 and is a target for neutralising antibodies7.", [["cell", "ANATOMY", 32, 36], ["host cell", "CELL", 27, 36], ["fusion5,6", "GENE_OR_GENE_PRODUCT", 52, 61], ["GP", "PROTEIN", 8, 10], ["fusion5,6", "PROTEIN", 52, 61], ["neutralising antibodies7", "PROTEIN", 82, 106], ["host cell attachment", "PROBLEM", 27, 47], ["fusion5", "TEST", 52, 59], ["neutralising antibodies7", "PROBLEM", 82, 106], ["host cell attachment", "OBSERVATION", 27, 47]]], ["Survivors of EVD are thought to protected against subsequent EBOV infection and neutralising antibodies to the viral surface GP are possible correlates of protection8,9.", [["surface", "ANATOMY", 117, 124], ["EVD", "DISEASE", 13, 16], ["EBOV infection", "DISEASE", 61, 75], ["EBOV", "ORGANISM", 61, 65], ["neutralising antibodies", "PROTEIN", 80, 103], ["viral surface GP", "PROTEIN", 111, 127], ["EBOV", "SPECIES", 61, 65], ["EVD", "TREATMENT", 13, 16], ["subsequent EBOV infection", "PROBLEM", 50, 75], ["neutralising antibodies", "TREATMENT", 80, 103], ["EBOV", "OBSERVATION_MODIFIER", 61, 65], ["infection", "OBSERVATION", 66, 75]]], ["Serological assays, such as the plaque reduction neutralisation test (PRNT), are central to evaluate neutralising antibodies against EBOV GP.", [["plaque", "ANATOMY", 32, 38], ["EBOV GP", "ORGANISM", 133, 140], ["neutralising antibodies", "PROTEIN", 101, 124], ["EBOV GP", "PROTEIN", 133, 140], ["EBOV", "SPECIES", 133, 137], ["Serological assays", "TEST", 0, 18], ["the plaque reduction neutralisation test", "TEST", 28, 68], ["neutralising antibodies", "TEST", 101, 124]]], ["However, because of its severe pathogenicity, potential transmission from person-to-person and lack of approved vaccines or antiviral treatments, handling of EBOV is restricted to containment level (CL) 4 laboratories.", [["EBOV", "DISEASE", 158, 162], ["EBOV", "ORGANISM", 158, 162], ["person", "SPECIES", 74, 80], ["person", "SPECIES", 84, 90], ["EBOV", "SPECIES", 158, 162], ["its severe pathogenicity", "PROBLEM", 20, 44], ["approved vaccines", "TREATMENT", 103, 120], ["antiviral treatments", "TREATMENT", 124, 144], ["handling of EBOV", "TREATMENT", 146, 162], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["pathogenicity", "OBSERVATION", 31, 44]]], ["Furthermore, the assay format and time required for plaque development, which can take approximately nine days, makes it time-consuming and restricts high-throughput sample processing.", [["plaque", "ANATOMY", 52, 58], ["the assay format", "TEST", 13, 29], ["plaque development", "PROBLEM", 52, 70], ["plaque", "OBSERVATION", 52, 58]]], ["Development of novel serological assays that utilise genetically modified recombinant or chimeric viruses with attenuated pathogenicity have enabled more widespread investigation of neutralising antibodies against highly pathogenic viruses including EBOV10,11.IntroductionPseudotyped viruses are replication-defective chimeric virions that comprise the structural and enzymatic core of one virus, bearing the envelope protein or glycoprotein of another, and encode a quantifiable reporter gene.", [["chimeric viruses", "ORGANISM", 89, 105], ["EBOV10,11", "ORGANISM", 250, 259], ["Pseudotyped viruses", "ORGANISM", 272, 291], ["neutralising antibodies", "PROTEIN", 182, 205], ["envelope protein", "PROTEIN", 409, 425], ["glycoprotein", "PROTEIN", 429, 441], ["reporter gene", "DNA", 480, 493], ["novel serological assays", "PROBLEM", 15, 39], ["chimeric viruses", "PROBLEM", 89, 105], ["attenuated pathogenicity", "PROBLEM", 111, 135], ["neutralising antibodies", "TEST", 182, 205], ["highly pathogenic viruses", "PROBLEM", 214, 239], ["IntroductionPseudotyped viruses", "PROBLEM", 260, 291], ["defective chimeric virions", "PROBLEM", 308, 334], ["one virus", "PROBLEM", 386, 395], ["Pseudotyped viruses", "OBSERVATION", 272, 291], ["defective", "OBSERVATION_MODIFIER", 308, 317], ["chimeric virions", "OBSERVATION", 318, 334]]], ["Retroviruses, including lentiviruses and gammaretroviruses such as human immunodeficiency virus (HIV) and murine leukaemia virus (MLV), respectively, and rhabdoviruses, such as vesicular stomatitis virus (VSV), have been used extensively as cores for pseudotyped viruses12,13, including for EBOV14,15.", [["human immunodeficiency virus (HIV) and murine leukaemia virus", "DISEASE", 67, 128], ["vesicular stomatitis", "DISEASE", 177, 197], ["Retroviruses", "ORGANISM", 0, 12], ["lentiviruses", "ORGANISM", 24, 36], ["gammaretroviruses", "GENE_OR_GENE_PRODUCT", 41, 58], ["human immunodeficiency virus", "ORGANISM", 67, 95], ["HIV", "ORGANISM", 97, 100], ["murine leukaemia virus", "ORGANISM", 106, 128], ["MLV", "ORGANISM", 130, 133], ["rhabdoviruses", "GENE_OR_GENE_PRODUCT", 154, 167], ["vesicular stomatitis virus", "ORGANISM", 177, 203], ["VSV", "ORGANISM", 205, 208], ["pseudotyped viruses", "ORGANISM", 251, 270], ["human immunodeficiency virus (HIV", "SPECIES", 67, 100], ["murine", "SPECIES", 106, 112], ["leukaemia virus", "SPECIES", 113, 128], ["vesicular stomatitis virus", "SPECIES", 177, 203], ["human immunodeficiency virus", "SPECIES", 67, 95], ["HIV", "SPECIES", 97, 100], ["murine leukaemia virus", "SPECIES", 106, 128], ["MLV", "SPECIES", 130, 133], ["vesicular stomatitis virus", "SPECIES", 177, 203], ["VSV", "SPECIES", 205, 208], ["Retroviruses", "TREATMENT", 0, 12], ["lentiviruses", "PROBLEM", 24, 36], ["gammaretroviruses", "PROBLEM", 41, 58], ["human immunodeficiency virus", "PROBLEM", 67, 95], ["HIV", "PROBLEM", 97, 100], ["murine leukaemia virus", "PROBLEM", 106, 128], ["rhabdoviruses", "PROBLEM", 154, 167], ["vesicular stomatitis virus (VSV", "PROBLEM", 177, 208], ["pseudotyped viruses", "PROBLEM", 251, 270], ["lentiviruses", "OBSERVATION", 24, 36], ["leukaemia virus", "OBSERVATION", 113, 128], ["vesicular stomatitis", "OBSERVATION", 177, 197]]], ["A number of EBOV GP pseudotyped virus neutralisation assays have been developed to investigate immune responses to EBOV infection and vaccination16\u201318, as well as for evaluation of monoclonal antibody (mAb) therapies19\u201321.IntroductionThere are many factors that need to be considered when developing and optimising pseudotyped virus neutralisation assays, to assess experimental parameters that can affect assay performance and to ensure accuracy and reproducibility.", [["EBOV infection", "DISEASE", 115, 129], ["EBOV GP pseudotyped virus", "ORGANISM", 12, 37], ["EBOV", "ORGANISM", 115, 119], ["pseudotyped virus", "ORGANISM", 315, 332], ["monoclonal antibody (mAb) therapies19\u201321", "PROTEIN", 181, 221], ["EBOV", "SPECIES", 12, 16], ["EBOV", "SPECIES", 115, 119], ["EBOV GP pseudotyped virus neutralisation assays", "TEST", 12, 59], ["immune responses", "PROBLEM", 95, 111], ["EBOV infection", "PROBLEM", 115, 129], ["vaccination", "TEST", 134, 145], ["evaluation", "TEST", 167, 177], ["monoclonal antibody (mAb", "TREATMENT", 181, 205], ["pseudotyped virus neutralisation assays", "TEST", 315, 354], ["experimental parameters", "TEST", 366, 389], ["assay performance", "TEST", 406, 423], ["accuracy", "TEST", 438, 446]]], ["These include, choice of core virus and reporter gene, determination of target cell line and amount of pseudotyped virus input, as well as correlation with live virus neutralisation22.", [["cell line", "ANATOMY", 79, 88], ["cell line", "CELL", 79, 88], ["pseudotyped virus", "ORGANISM", 103, 120], ["reporter gene", "DNA", 40, 53], ["target cell line", "CELL_LINE", 72, 88], ["core virus", "TREATMENT", 25, 35], ["target cell line", "TREATMENT", 72, 88], ["pseudotyped virus input", "PROBLEM", 103, 126], ["cell line", "OBSERVATION", 79, 88], ["pseudotyped virus", "OBSERVATION", 103, 120]]], ["The aim of this study was to assess the suitability of EBOV GP pseudotyped HIV-1 and VSV systems to measure neutralisation by EVD survivor plasma, in comparison with results from a live EBOV neutralisation assay.Cell tropism of EBOV GP pseudotyped viruses ::: ResultsPseudotyped HIV-1 and VSV bearing the envelope GP from EBOV (Mayinga) were generated and quantified by measuring luminescence in a range of target cell lines, in order to determine the optimum cell line to use in neutralisation assays.", [["plasma", "ANATOMY", 139, 145], ["Cell", "ANATOMY", 212, 216], ["cell lines", "ANATOMY", 414, 424], ["cell line", "ANATOMY", 460, 469], ["EBOV", "ORGANISM", 55, 59], ["GP pseudotyped HIV-1", "ORGANISM", 60, 80], ["VSV", "ORGANISM", 85, 88], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["EBOV", "ORGANISM", 186, 190], ["Cell", "CELL", 212, 216], ["EBOV GP pseudotyped viruses", "ORGANISM", 228, 255], ["ResultsPseudotyped", "ORGANISM", 260, 278], ["HIV-1", "ORGANISM", 279, 284], ["VSV", "ORGANISM", 289, 292], ["envelope GP", "ORGANISM", 305, 316], ["EBOV", "ORGANISM", 322, 326], ["cell lines", "CELL", 414, 424], ["cell line", "CELL", 460, 469], ["envelope GP", "PROTEIN", 305, 316], ["target cell lines", "CELL_LINE", 407, 424], ["optimum cell line", "CELL_LINE", 452, 469], ["HIV-1", "SPECIES", 75, 80], ["HIV-1", "SPECIES", 279, 284], ["VSV", "SPECIES", 289, 292], ["EBOV", "SPECIES", 55, 59], ["HIV-1", "SPECIES", 75, 80], ["VSV", "SPECIES", 85, 88], ["EBOV", "SPECIES", 186, 190], ["EBOV GP pseudotyped viruses", "SPECIES", 228, 255], ["HIV-1", "SPECIES", 279, 284], ["VSV", "SPECIES", 289, 292], ["EBOV", "SPECIES", 322, 326], ["this study", "TEST", 11, 21], ["VSV systems", "TEST", 85, 96], ["a live EBOV neutralisation assay", "TEST", 179, 211], ["Cell tropism", "TEST", 212, 224], ["ResultsPseudotyped HIV", "TEST", 260, 282], ["target cell lines", "TREATMENT", 407, 424], ["the optimum cell line", "TREATMENT", 448, 469], ["neutralisation assays", "TEST", 480, 501], ["EBOV", "OBSERVATION_MODIFIER", 228, 232], ["pseudotyped viruses", "OBSERVATION", 236, 255], ["cell lines", "OBSERVATION", 414, 424], ["cell line", "OBSERVATION", 460, 469]]], ["Cells only controls were used to determine background levels of luminescence (Supplementary Fig. S1).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["S1", "GENE_OR_GENE_PRODUCT", 97, 99], ["S1", "PROTEIN", 97, 99], ["Supplementary Fig", "TREATMENT", 78, 95]]], ["Reporter activity was detected in all cell lines infected with EBOV GP pseudotyped HIV-1 and VSV, demonstrating the broad tissue range conferred by EBOV GP, although differences in luminescence were observed (Fig. 1a,b).", [["cell lines", "ANATOMY", 38, 48], ["tissue", "ANATOMY", 122, 128], ["cell lines", "CELL", 38, 48], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 63, 88], ["VSV", "ORGANISM", 93, 96], ["tissue", "TISSUE", 122, 128], ["EBOV", "ORGANISM", 148, 152], ["cell lines", "CELL_LINE", 38, 48], ["EBOV GP", "PROTEIN", 148, 155], ["HIV-1", "SPECIES", 83, 88], ["EBOV", "SPECIES", 63, 67], ["HIV-1", "SPECIES", 83, 88], ["VSV", "SPECIES", 93, 96], ["EBOV", "SPECIES", 148, 152], ["EBOV GP pseudotyped HIV", "TEST", 63, 86], ["VSV", "PROBLEM", 93, 96], ["cell lines", "OBSERVATION", 38, 48], ["broad tissue", "ANATOMY", 116, 128], ["EBOV", "OBSERVATION", 148, 152]]], ["For EBOV GP pseudotyped HIV-1, highest TCID50/ml values were observed in 293T/17 cells, followed by Huh-7 cells (Fig. 1c).", [["293T/17 cells", "ANATOMY", 73, 86], ["Huh-7 cells", "ANATOMY", 100, 111], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 4, 29], ["293T/17 cells", "CELL", 73, 86], ["Huh-7 cells", "CELL", 100, 111], ["Fig. 1c", "CELL", 113, 120], ["293T/17 cells", "CELL_LINE", 73, 86], ["Huh-7 cells", "CELL_LINE", 100, 111], ["HIV-1", "SPECIES", 24, 29], ["EBOV", "SPECIES", 4, 8], ["HIV-1", "SPECIES", 24, 29], ["EBOV GP pseudotyped HIV", "TEST", 4, 27], ["highest TCID50/ml values", "TEST", 31, 55], ["Huh", "TEST", 100, 103]]], ["Titres generated by infection of 293T/17 cells were approximately 3, 33 and 73 times greater than those produced by infection of Huh-7, HeLa and Vero E6 cells, respectively.", [["293T/17 cells", "ANATOMY", 33, 46], ["Huh-7", "ANATOMY", 129, 134], ["HeLa", "ANATOMY", 136, 140], ["Vero E6 cells", "ANATOMY", 145, 158], ["infection", "DISEASE", 20, 29], ["infection", "DISEASE", 116, 125], ["293T/17 cells", "CELL", 33, 46], ["Huh-7", "CELL", 129, 134], ["HeLa", "CELL", 136, 140], ["Vero E6 cells", "CELL", 145, 158], ["293T/17 cells", "CELL_LINE", 33, 46], ["Huh-7", "CELL_LINE", 129, 134], ["HeLa", "CELL_LINE", 136, 140], ["Vero E6 cells", "CELL_LINE", 145, 158], ["Huh-7", "SPECIES", 129, 134], ["Vero E6", "SPECIES", 145, 152], ["Huh", "TEST", 129, 132], ["infection", "OBSERVATION", 20, 29], ["infection", "OBSERVATION", 116, 125], ["E6 cells", "OBSERVATION", 150, 158]]], ["For EBOV GP pseudotyped VSV, highest titres were obtained in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 61, 74], ["EBOV GP pseudotyped VSV", "ORGANISM", 4, 27], ["Vero E6 cells", "CELL", 61, 74], ["Vero E6 cells", "CELL_LINE", 61, 74], ["pseudotyped", "SPECIES", 12, 23], ["EBOV", "SPECIES", 4, 8], ["VSV", "SPECIES", 24, 27], ["Vero E6", "SPECIES", 61, 68], ["EBOV GP pseudotyped VSV", "PROBLEM", 4, 27], ["highest titres", "TEST", 29, 43]]], ["The TCID50/ml values generated by infection of Vero E6 cells were approximately 1.5, 22 and 30 times greater than those produced by infection of 293T/17, Huh-7 and HeLa cells, respectively (Fig. 1d).", [["Vero E6 cells", "ANATOMY", 47, 60], ["293T/17", "ANATOMY", 145, 152], ["Huh-7", "ANATOMY", 154, 159], ["HeLa cells", "ANATOMY", 164, 174], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 132, 141], ["Vero E6 cells", "CELL", 47, 60], ["293T/17", "CELL", 145, 152], ["Huh-7", "CELL", 154, 159], ["HeLa cells", "CELL", 164, 174], ["Vero E6 cells", "CELL_LINE", 47, 60], ["Huh-7", "CELL_LINE", 154, 159], ["HeLa cells", "CELL_LINE", 164, 174], ["Vero E6", "SPECIES", 47, 54], ["The TCID50/ml values", "TEST", 0, 20], ["infection", "PROBLEM", 34, 43], ["Vero E6 cells", "TEST", 47, 60], ["infection", "TEST", 132, 141], ["Huh", "TEST", 154, 157], ["HeLa cells", "TEST", 164, 174], ["infection", "OBSERVATION", 132, 141], ["HeLa cells", "ANATOMY", 164, 174]]], ["Based on these results, the 293T/17 and Vero E6 target cell lines were selected for use in all subsequent neutralisation assays using EBOV GP pseudotyped HIV-1 and VSV, respectively.Neutralisation of EBOV GP pseudotyped viruses by anti-EBOV GP mAb ::: ResultsDuring the initial stages of assay development, it is important to evaluate neutralisation of pseudotyped viruses using well characterised antibodies in order to demonstrate the validity and accuracy of the assay.", [["cell lines", "ANATOMY", 55, 65], ["293T/17", "ORGANISM", 28, 35], ["Vero E6", "ORGANISM", 40, 47], ["cell lines", "CELL", 55, 65], ["EBOV", "ORGANISM", 134, 138], ["GP pseudotyped HIV-1", "ORGANISM", 139, 159], ["VSV", "ORGANISM", 164, 167], ["EBOV GP pseudotyped viruses", "ORGANISM", 200, 227], ["pseudotyped", "ORGANISM", 353, 364], ["Vero E6 target cell lines", "CELL_LINE", 40, 65], ["anti-EBOV GP mAb", "PROTEIN", 231, 247], ["antibodies", "PROTEIN", 398, 408], ["HIV-1", "SPECIES", 154, 159], ["Vero E6", "SPECIES", 40, 47], ["EBOV", "SPECIES", 134, 138], ["HIV-1", "SPECIES", 154, 159], ["VSV", "SPECIES", 164, 167], ["EBOV GP pseudotyped viruses", "SPECIES", 200, 227], ["anti-EBOV", "SPECIES", 231, 240], ["Vero E6 target cell lines", "TREATMENT", 40, 65], ["all subsequent neutralisation assays", "TEST", 91, 127], ["EBOV GP pseudotyped HIV", "TEST", 134, 157], ["pseudotyped viruses", "PROBLEM", 353, 372], ["the assay", "TEST", 462, 471], ["cell lines", "OBSERVATION", 55, 65]]], ["The EBOV GP pseudotyped viruses were assessed for neutralisation by the human anti-EBOV GP mAb, KZ52.", [["EBOV GP pseudotyped viruses", "ORGANISM", 4, 31], ["human", "ORGANISM", 72, 77], ["KZ52", "SIMPLE_CHEMICAL", 96, 100], ["human anti-EBOV GP mAb", "PROTEIN", 72, 94], ["KZ52", "PROTEIN", 96, 100], ["human", "SPECIES", 72, 77], ["EBOV GP pseudotyped viruses", "SPECIES", 4, 31], ["human", "SPECIES", 72, 77], ["The EBOV GP pseudotyped viruses", "PROBLEM", 0, 31], ["KZ52", "TREATMENT", 96, 100], ["pseudotyped viruses", "OBSERVATION", 12, 31]]], ["KZ52 is an antibody isolated from a human survivor of the 1995 outbreak in Kikwit that neutralises EBOV in vitro and recognises a conformational epitope at the base of the GP23\u201325.", [["KZ52", "CHEMICAL", 0, 4], ["Kikwit", "CHEMICAL", 75, 81], ["KZ52", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 36, 41], ["EBOV", "ORGANISM", 99, 103], ["KZ52", "PROTEIN", 0, 4], ["GP23\u201325", "DNA", 172, 179], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["EBOV", "SPECIES", 99, 103], ["an antibody", "TEST", 8, 19]]], ["Human anti-EBOV GP mAb, KZ52 was unable to neutralise the EBOV GP pseudotyped HIV-1 (Fig. 2a) within the range tested, however it was able to neutralise the EBOV GP pseudotyped VSV (Fig. 2b), suggesting that VSV-based pseudotyped viruses are more sensitive to neutralisation then lentiviral-based, possibly the density of EBOV GP on the pseudotyped HIV-1 may differ from that on the pseudotyped VSV or live EBOV.Assessment of EBOV GP pseudotyped virus input for neutralisation ::: ResultsTo determine the optimal pseudotyped virus input to use in the HIV- and VSV-based assays, neutralisation of different amounts of the EBOV GP pseudotyped viruses by plasma from a Guinean EVD survivor donor or human anti-EBOV GP mAb KZ52 was assessed.", [["plasma", "ANATOMY", 652, 658], ["Human", "ORGANISM", 0, 5], ["anti-EBOV GP mAb", "GENE_OR_GENE_PRODUCT", 6, 22], ["KZ52", "GENE_OR_GENE_PRODUCT", 24, 28], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 58, 83], ["Fig. 2a", "ORGANISM", 85, 92], ["EBOV GP pseudotyped VSV", "ORGANISM", 157, 180], ["Fig. 2b", "ORGANISM", 182, 189], ["VSV", "ORGANISM", 208, 211], ["pseudotyped viruses", "ORGANISM", 218, 237], ["lentiviral", "ORGANISM", 280, 290], ["EBOV GP", "ORGANISM", 322, 329], ["pseudotyped HIV-1", "ORGANISM", 337, 354], ["pseudotyped VSV", "ORGANISM", 383, 398], ["live EBOV", "ORGANISM", 402, 411], ["EBOV", "ORGANISM", 426, 430], ["GP pseudotyped virus", "ORGANISM", 431, 451], ["pseudotyped", "ORGANISM", 513, 524], ["VSV", "ORGANISM", 560, 563], ["EBOV", "ORGANISM", 621, 625], ["GP pseudotyped viruses", "ORGANISM", 626, 648], ["plasma", "ORGANISM_SUBSTANCE", 652, 658], ["human", "ORGANISM", 696, 701], ["Human anti-EBOV GP mAb", "PROTEIN", 0, 22], ["KZ52", "PROTEIN", 24, 28], ["EBOV GP", "PROTEIN", 322, 329], ["human anti-EBOV GP mAb KZ52", "PROTEIN", 696, 723], ["Human", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 78, 83], ["pseudotyped", "SPECIES", 165, 176], ["HIV-1", "SPECIES", 349, 354], ["VSV", "SPECIES", 395, 398], ["HIV", "SPECIES", 551, 554], ["human", "SPECIES", 696, 701], ["Human", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 78, 83], ["EBOV GP pseudotyped VSV", "SPECIES", 157, 180], ["VSV", "SPECIES", 208, 211], ["EBOV", "SPECIES", 322, 326], ["HIV-1", "SPECIES", 349, 354], ["VSV", "SPECIES", 395, 398], ["EBOV", "SPECIES", 407, 411], ["EBOV GP pseudotyped virus", "SPECIES", 426, 451], ["HIV", "SPECIES", 551, 554], ["VSV", "SPECIES", 560, 563], ["EBOV", "SPECIES", 621, 625], ["human", "SPECIES", 696, 701], ["the EBOV GP pseudotyped HIV", "TEST", 54, 81], ["VSV-based pseudotyped viruses", "PROBLEM", 208, 237], ["EBOV GP", "PROBLEM", 322, 329], ["the pseudotyped HIV", "PROBLEM", 333, 352], ["the pseudotyped VSV", "TREATMENT", 379, 398], ["the optimal pseudotyped virus input", "TREATMENT", 501, 536], ["the HIV", "TEST", 547, 554], ["VSV", "TREATMENT", 560, 563], ["the EBOV GP pseudotyped viruses", "PROBLEM", 617, 648], ["a Guinean EVD survivor donor", "TREATMENT", 664, 692], ["human anti-EBOV GP mAb KZ52", "TREATMENT", 696, 723], ["pseudotyped viruses", "OBSERVATION", 218, 237]]], ["KZ52 was selected as it is commercially available and there is accompanying information regarding its neutralisation activity against EBOV GP pseudotyped VSV expressing luciferase.", [["KZ52", "CHEMICAL", 0, 4], ["KZ52", "SIMPLE_CHEMICAL", 0, 4], ["EBOV GP pseudotyped VSV", "ORGANISM", 134, 157], ["luciferase", "GENE_OR_GENE_PRODUCT", 169, 179], ["luciferase", "PROTEIN", 169, 179], ["VSV", "SPECIES", 154, 157], ["EBOV GP pseudotyped VSV", "SPECIES", 134, 157]]], ["However, as the EBOV GP pseudotyped HIV-1 was not neutralised by KZ52 (Fig. 2a) in the range tested, plasma from an EVD survivor was used to assess the effect of pseudotyped HIV-1 input on neutralisation instead.", [["plasma", "ANATOMY", 101, 107], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 16, 41], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["pseudotyped HIV-1", "ORGANISM", 162, 179], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 174, 179], ["EBOV", "SPECIES", 16, 20], ["HIV-1", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 174, 179], ["the EBOV GP pseudotyped HIV", "TEST", 12, 39], ["an EVD survivor", "TREATMENT", 113, 128], ["pseudotyped HIV", "PROBLEM", 162, 177], ["neutralisation", "TREATMENT", 189, 203]]], ["Survivor plasma sample CS001 was chosen as it displayed strong neutralising ability against live EBOV neutralisation, with a geometric mean titre (GMT) of 1,218.", [["plasma sample", "ANATOMY", 9, 22], ["CS001", "CHEMICAL", 23, 28], ["plasma", "ORGANISM_SUBSTANCE", 9, 15], ["EBOV", "ORGANISM", 97, 101], ["EBOV", "SPECIES", 97, 101], ["Survivor plasma sample CS001", "TEST", 0, 28], ["a geometric mean titre", "TEST", 123, 145]]], ["Percentage infectivity was determined relative to infectivity of cells by the EBOV GP pseudotyped viruses alone (Fig. 3a,b) and 50% inhibitory concentration (IC50) of pseudotyped virus neutralisation were estimated by model of nonlinear regression dose\u2013response curves (Fig. 3c,d).", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["EBOV", "ORGANISM", 78, 82], ["GP pseudotyped viruses", "ORGANISM", 83, 105], ["pseudotyped", "ORGANISM", 167, 178], ["EBOV GP pseudotyped viruses", "SPECIES", 78, 105], ["Percentage infectivity", "PROBLEM", 0, 22], ["infectivity of cells", "PROBLEM", 50, 70], ["the EBOV GP pseudotyped viruses", "PROBLEM", 74, 105], ["pseudotyped virus neutralisation", "TREATMENT", 167, 199]]], ["Plasma from EVD survivor CS001 displayed neutralising activity against all amounts of EBOV GP pseudotyped HIV-1 tested (Fig. 3a).", [["CS001", "CHEMICAL", 25, 30], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 86, 111], ["HIV-1", "SPECIES", 106, 111], ["EBOV", "SPECIES", 86, 90], ["HIV-1", "SPECIES", 106, 111], ["Plasma from EVD survivor CS001", "TEST", 0, 30], ["neutralising activity", "PROBLEM", 41, 62], ["EBOV GP pseudotyped HIV", "PROBLEM", 86, 109]]], ["Lower pseudotyped virus input resulted in larger variability and less curve fitting.", [["pseudotyped virus", "ORGANISM", 6, 23], ["Lower pseudotyped virus input", "PROBLEM", 0, 29], ["larger variability", "PROBLEM", 42, 60], ["pseudotyped virus", "OBSERVATION", 6, 23], ["larger", "OBSERVATION_MODIFIER", 42, 48], ["variability", "OBSERVATION_MODIFIER", 49, 60], ["less curve", "OBSERVATION_MODIFIER", 65, 75]]], ["Therefore, an EBOV GP pseudotyped HIV-1 input of at least 8.6 \u00d7 104 RLU/well, with a target input of 2.0 \u00d7 105 RLU/well, was used in subsequent neutralisation assays.", [["EBOV GP pseudotyped", "ORGANISM", 14, 33], ["HIV-1", "ORGANISM", 34, 39], ["HIV-1", "SPECIES", 34, 39], ["EBOV", "SPECIES", 14, 18], ["HIV-1", "SPECIES", 34, 39], ["an EBOV GP pseudotyped HIV", "TEST", 11, 37], ["a target input", "TEST", 83, 97], ["subsequent neutralisation assays", "TEST", 133, 165]]], ["KZ52 neutralised all dilutions of EBOV GP pseudotyped VSV tested (Fig. 3b) and IC50 values decreased with decreasing amounts of pseudotyped virus input (Fig. 3d, Supplementary Table S1).", [["KZ52", "CHEMICAL", 0, 4], ["KZ52", "SIMPLE_CHEMICAL", 0, 4], ["EBOV", "ORGANISM", 34, 38], ["GP pseudotyped VSV", "ORGANISM", 39, 57], ["EBOV", "SPECIES", 34, 38], ["VSV", "SPECIES", 54, 57], ["KZ52", "TREATMENT", 0, 4], ["EBOV GP pseudotyped VSV", "TREATMENT", 34, 57], ["IC50 values", "TEST", 79, 90], ["pseudotyped virus input", "TREATMENT", 128, 151]]], ["When using 3.9 \u00d7 104 RLU/well of EBOV GP pseudotyped VSV, IC50 of virus neutralisation (0.07 \u00b5g/ml) was similar to that expected according to the manufacturer\u2019s product data sheet (0.06 \u00b5g/ml).", [["EBOV", "ORGANISM", 33, 37], ["GP pseudotyped VSV", "ORGANISM", 38, 56], ["EBOV", "SPECIES", 33, 37], ["VSV", "SPECIES", 53, 56], ["EBOV GP pseudotyped VSV", "TREATMENT", 33, 56], ["virus neutralisation", "TREATMENT", 66, 86]]], ["Therefore, a target input of approximately 3.7 \u00d7 104 RLU/well was used in subsequent EBOV GP pseudotyped VSV neutralisation assays.Neutralisation of EBOV GP pseudotyped viruses by EVD survivor plasma ::: ResultsIn order to compare the specificity and sensitivity of EBOV GP pseudotyped HIV-1 and VSV-based assays, we evaluated neutralisation of the EBOV GP pseudotyped HIV-1 and VSV using plasma samples collected from 30 EVD survivors of the 2013\u20132016 EBOV outbreak and 10 negative control donors from Guinea.", [["plasma", "ANATOMY", 193, 199], ["plasma samples", "ANATOMY", 389, 403], ["EBOV", "ORGANISM", 85, 89], ["pseudotyped", "ORGANISM", 93, 104], ["VSV", "ORGANISM", 105, 108], ["EBOV GP pseudotyped viruses", "ORGANISM", 149, 176], ["plasma", "ORGANISM_SUBSTANCE", 193, 199], ["EBOV", "ORGANISM", 266, 270], ["GP pseudotyped HIV-1", "ORGANISM", 271, 291], ["VSV", "ORGANISM", 296, 299], ["EBOV", "ORGANISM", 349, 353], ["GP pseudotyped HIV-1", "ORGANISM", 354, 374], ["VSV", "ORGANISM", 379, 382], ["plasma samples", "ORGANISM_SUBSTANCE", 389, 403], ["EBOV", "ORGANISM", 453, 457], ["donors", "ORGANISM", 491, 497], ["HIV-1", "SPECIES", 286, 291], ["pseudotyped", "SPECIES", 357, 368], ["HIV-1", "SPECIES", 369, 374], ["EBOV", "SPECIES", 85, 89], ["VSV", "SPECIES", 105, 108], ["EBOV", "SPECIES", 266, 270], ["HIV-1", "SPECIES", 286, 291], ["VSV", "SPECIES", 296, 299], ["EBOV", "SPECIES", 349, 353], ["HIV-1", "SPECIES", 369, 374], ["VSV", "SPECIES", 379, 382], ["2013\u20132016 EBOV", "SPECIES", 443, 457], ["EBOV GP pseudotyped viruses", "PROBLEM", 149, 176], ["EBOV GP pseudotyped HIV", "TEST", 266, 289], ["VSV", "TEST", 296, 299], ["the EBOV GP pseudotyped HIV", "TEST", 345, 372], ["plasma samples", "TEST", 389, 403]]], ["The IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear regression dose\u2013response curves (Supplementary Table S2).", [["pseudotyped", "ORGANISM", 12, 23], ["pseudotyped virus neutralisation", "TREATMENT", 12, 44], ["pseudotyped virus", "OBSERVATION", 12, 29]]], ["Neutralisation of EBOV GP pseudotyped HIV-1 and VSV by positive (EVD survivor) and negative (UK donor) control plasma was assessed in several independent assays (Supplementary Fig. S2).", [["plasma", "ANATOMY", 111, 117], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 18, 43], ["VSV", "ORGANISM", 48, 51], ["plasma", "ORGANISM_SUBSTANCE", 111, 117], ["S2", "PROTEIN", 181, 183], ["pseudotyped", "SPECIES", 26, 37], ["HIV-1", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 38, 43], ["VSV", "SPECIES", 48, 51], ["EBOV GP pseudotyped HIV", "TEST", 18, 41], ["VSV", "TEST", 48, 51], ["EVD survivor", "TEST", 65, 77], ["Supplementary Fig", "TREATMENT", 162, 179]]], ["The background level of neutralisation was determined using plasma from a UK negative control donor.", [["plasma", "ANATOMY", 60, 66], ["plasma", "ORGANISM_SUBSTANCE", 60, 66], ["UK", "GENE_OR_GENE_PRODUCT", 74, 76]]], ["For the HIV-1-based assay this was calculated as IC50 6.28 reciprocal dilution.", [["HIV-1", "ORGANISM", 8, 13], ["HIV-1", "SPECIES", 8, 13], ["HIV-1", "SPECIES", 8, 13], ["the HIV", "TEST", 4, 11], ["based assay", "TEST", 14, 25], ["IC50", "TEST", 49, 53], ["reciprocal dilution", "TREATMENT", 59, 78]]], ["The negative control plasma displayed no neutralising activity against EBOV GP pseudotyped VSV, and therefore the background level of neutralisation was assigned the lowest dilution of sample tested in the assay (1/20).", [["plasma", "ANATOMY", 21, 27], ["sample", "ANATOMY", 185, 191], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["EBOV", "ORGANISM", 71, 75], ["GP pseudotyped VSV", "ORGANISM", 76, 94], ["pseudotyped", "SPECIES", 79, 90], ["EBOV GP pseudotyped VSV", "SPECIES", 71, 94], ["neutralising activity", "PROBLEM", 41, 62], ["EBOV GP pseudotyped VSV", "PROBLEM", 71, 94]]], ["In the HIV-1-based assay, dose\u2013response curves were unable to be fitted for three of the 30 EVD survivor samples and six of the samples were deemed below the background level of neutralisation.", [["samples", "ANATOMY", 105, 112], ["samples", "ANATOMY", 128, 135], ["HIV-1", "ORGANISM", 7, 12], ["HIV-1", "SPECIES", 7, 12], ["HIV-1", "SPECIES", 7, 12], ["dose\u2013response curves", "TEST", 26, 46], ["the samples", "TEST", 124, 135], ["neutralisation", "OBSERVATION", 178, 192]]], ["In contrast, a dose\u2013response curve was unable to be fitted for only one of the EVD survivor samples tested in the VSV-based neutralisation assay.", [["samples", "ANATOMY", 92, 99], ["VSV", "ORGANISM", 114, 117], ["VSV", "SPECIES", 114, 117], ["a dose\u2013response curve", "TEST", 13, 34], ["the EVD survivor samples", "TEST", 75, 99], ["the VSV", "TEST", 110, 117]]], ["In the HIV-1-based assay, three of the 10 negative plasma samples tested were above the background level of neutralisation, whereas only one of the negative samples tested was above the background level of neutralisation in the VSV-based assay.", [["plasma samples", "ANATOMY", 51, 65], ["samples", "ANATOMY", 157, 164], ["HIV-1", "ORGANISM", 7, 12], ["plasma samples", "ORGANISM_SUBSTANCE", 51, 65], ["VSV", "ORGANISM", 228, 231], ["HIV-1", "SPECIES", 7, 12], ["HIV-1", "SPECIES", 7, 12], ["VSV", "SPECIES", 228, 231], ["plasma samples", "TEST", 51, 65], ["neutralisation", "OBSERVATION", 108, 122], ["neutralisation", "OBSERVATION", 206, 220]]], ["Although some differences in the discriminatory power of positive and negative samples between the assays were observed, a statistically significant difference in neutralisation titres was detected between the EVD survivors and negative plasma samples in the HIV-1-based assay (Mann\u2013Whitney, p = 0.0054) (Fig. 4a) and in the VSV-based assay (Mann\u2013Whitney, p < 0.0001) (Fig. 4b, Supplementary Table S3).", [["plasma samples", "ANATOMY", 237, 251], ["plasma samples", "ORGANISM_SUBSTANCE", 237, 251], ["HIV-1", "ORGANISM", 259, 264], ["VSV", "ORGANISM", 325, 328], ["HIV-1", "SPECIES", 259, 264], ["HIV-1", "SPECIES", 259, 264], ["VSV", "SPECIES", 325, 328], ["the assays", "TEST", 95, 105], ["a statistically significant difference in neutralisation titres", "PROBLEM", 121, 184], ["the EVD survivors", "TEST", 206, 223], ["plasma samples", "TEST", 237, 251], ["the HIV", "TEST", 255, 262], ["the VSV", "TEST", 321, 328], ["significant", "OBSERVATION_MODIFIER", 137, 148], ["difference", "OBSERVATION_MODIFIER", 149, 159], ["neutralisation titres", "OBSERVATION", 163, 184]]], ["Remarkably, this difference was more significant and the separation of the positive and negative plasma was better in the VSV-based assay (Fig. 4b).", [["plasma", "ANATOMY", 97, 103], ["plasma", "ORGANISM_SUBSTANCE", 97, 103], ["VSV", "ORGANISM", 122, 125], ["VSV", "SPECIES", 122, 125], ["the VSV", "TEST", 118, 125], ["positive", "OBSERVATION", 75, 83]]], ["The sum of these results clearly show that the VSV-based EBOV GP neutralisation assay displayed better reliability, specificity and sensitivity compared to the HIV-1-based assay.Correlation with live EBOV neutralisation ::: ResultsThe neutralising capacity of the individual plasma samples against authentic EBOV was assessed by a live virus neutralisation assay (Supplementary Table S3, Supplementary Fig. S3).", [["plasma samples", "ANATOMY", 275, 289], ["VSV", "ORGANISM", 47, 50], ["EBOV", "ORGANISM", 57, 61], ["GP", "ORGANISM", 62, 64], ["EBOV", "ORGANISM", 200, 204], ["plasma samples", "ORGANISM_SUBSTANCE", 275, 289], ["EBOV", "ORGANISM", 308, 312], ["VSV", "SPECIES", 47, 50], ["EBOV", "SPECIES", 57, 61], ["HIV-1", "SPECIES", 160, 165], ["EBOV", "SPECIES", 200, 204], ["EBOV", "SPECIES", 308, 312], ["the VSV", "TEST", 43, 50], ["EBOV GP neutralisation assay", "TEST", 57, 85], ["sensitivity", "TEST", 132, 143], ["the HIV", "TEST", 156, 163], ["the individual plasma samples", "TEST", 260, 289], ["authentic EBOV", "PROBLEM", 298, 312], ["a live virus neutralisation assay", "TEST", 329, 362], ["Supplementary Fig", "TREATMENT", 388, 405], ["EBOV", "OBSERVATION", 308, 312]]], ["When IC50 values of EBOV GP pseudotyped HIV-1 neutralisation of the 30 EVD survivor and 10 negative plasma samples were compared with GMT values for the live EBOV neutralisation assay, a positive correlation (rs = 0.54) was determined using the nonparametric Spearman correlation coefficient (Fig. 5a) and this was statistically significant (p = 0.0004).", [["plasma samples", "ANATOMY", 100, 114], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 20, 45], ["plasma samples", "ORGANISM_SUBSTANCE", 100, 114], ["EBOV", "ORGANISM", 158, 162], ["GMT", "PROTEIN", 134, 137], ["HIV-1", "SPECIES", 40, 45], ["EBOV", "SPECIES", 20, 24], ["HIV-1", "SPECIES", 40, 45], ["EBOV", "SPECIES", 158, 162], ["IC50 values", "TEST", 5, 16], ["EBOV GP pseudotyped HIV", "TEST", 20, 43], ["plasma samples", "TEST", 100, 114], ["GMT values", "TEST", 134, 144], ["the live EBOV neutralisation assay", "TEST", 149, 183]]], ["Remarkably, a stronger statistically significant (p < 0.0001) positive correlation (rs = 0.86) was observed when IC50 values of EBOV GP pseudotyped VSV neutralisation were compared with GMT values for the live EBOV neutralisation assay (Fig. 5b).", [["EBOV", "ORGANISM", 128, 132], ["pseudotyped", "ORGANISM", 136, 147], ["VSV", "ORGANISM", 148, 151], ["EBOV", "ORGANISM", 210, 214], ["GMT", "PROTEIN", 186, 189], ["EBOV", "SPECIES", 128, 132], ["VSV", "SPECIES", 148, 151], ["EBOV", "SPECIES", 210, 214], ["rs", "TEST", 84, 86], ["IC50 values", "TEST", 113, 124], ["EBOV GP pseudotyped VSV neutralisation", "TREATMENT", 128, 166], ["GMT values", "TEST", 186, 196]]], ["The correlation coefficients for EBOV GP HIV-1 and VSV IC50 compared with live EBOV GMT without the negative controls were 0.38 (p = 0.0375) and 0.69 (p < 0.0001), respectively.", [["EBOV GP HIV-1", "ORGANISM", 33, 46], ["VSV", "ORGANISM", 51, 54], ["EBOV", "ORGANISM", 79, 83], ["HIV-1", "SPECIES", 41, 46], ["EBOV", "SPECIES", 33, 37], ["HIV-1", "SPECIES", 41, 46], ["VSV", "SPECIES", 51, 54], ["EBOV", "SPECIES", 79, 83], ["The correlation coefficients", "TEST", 0, 28], ["EBOV GP HIV", "TEST", 33, 44], ["VSV IC50", "TEST", 51, 59], ["live EBOV GMT", "TEST", 74, 87]]], ["Therefore, the VSV-based EBOV GP pseudotyped virus neutralisation assay correlated better with live EBOV neutralisation than the HIV-1-based neutralisation assay.DiscussionPseudotyped viruses can be used as alternatives to infectious virus in serological assays to measure neutralising antibodies to viral envelope glycoproteins11.", [["VSV", "ORGANISM", 15, 18], ["EBOV", "ORGANISM", 25, 29], ["GP pseudotyped virus", "ORGANISM", 30, 50], ["EBOV", "ORGANISM", 100, 104], ["HIV-1", "ORGANISM", 129, 134], ["neutralising antibodies", "PROTEIN", 273, 296], ["viral envelope glycoproteins11", "PROTEIN", 300, 330], ["HIV-1", "SPECIES", 129, 134], ["VSV", "SPECIES", 15, 18], ["EBOV GP pseudotyped virus", "SPECIES", 25, 50], ["EBOV", "SPECIES", 100, 104], ["HIV-1", "SPECIES", 129, 134], ["the VSV", "TEST", 11, 18], ["EBOV GP pseudotyped virus neutralisation assay", "TEST", 25, 71], ["the HIV", "TEST", 125, 132], ["based neutralisation assay", "TEST", 135, 161], ["Pseudotyped viruses", "PROBLEM", 172, 191], ["infectious virus", "PROBLEM", 223, 239], ["serological assays", "TEST", 243, 261], ["neutralising antibodies", "TEST", 273, 296], ["viral envelope glycoproteins", "TREATMENT", 300, 328]]], ["Pseudotyped virus assays used to profile neutralising antibody responses against severe acute respiratory syndrome-associated coronavirus (SARS-CoV)26, influenza (H5N1 and H7N9)27\u201329, rabies30,31 and chikungunya virus32, for example, found that results correlated well with those from replication-competent or live virus assays.", [["acute respiratory syndrome-associated coronavirus", "DISEASE", 88, 137], ["SARS-CoV)", "DISEASE", 139, 148], ["influenza", "DISEASE", 152, 161], ["rabies", "DISEASE", 184, 190], ["chikungunya", "DISEASE", 200, 211], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 81, 137], ["SARS-CoV)26", "ORGANISM", 139, 150], ["influenza (H5N1 and H7N9)27\u201329", "ORGANISM", 152, 182], ["rabies30,31", "ORGANISM", 184, 195], ["chikungunya virus32", "ORGANISM", 200, 219], ["neutralising antibody", "PROTEIN", 41, 62], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 81, 137], ["SARS-CoV", "SPECIES", 139, 147], ["H7N9", "SPECIES", 172, 176], ["Pseudotyped virus assays", "PROBLEM", 0, 24], ["profile neutralising antibody responses", "TEST", 33, 72], ["severe acute respiratory syndrome", "PROBLEM", 81, 114], ["associated coronavirus (SARS-CoV)", "PROBLEM", 115, 148], ["influenza", "PROBLEM", 152, 161], ["H5N1", "PROBLEM", 163, 167], ["H7N9", "PROBLEM", 172, 176], ["rabies", "TEST", 184, 190], ["chikungunya virus32", "PROBLEM", 200, 219], ["live virus assays", "PROBLEM", 310, 327], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114], ["coronavirus", "OBSERVATION", 126, 137]]], ["A high degree of correlation has been demonstrated between EBOV CL4 PRNT and an EBOV pseudotyped VSV CL2 fluorescence reduction neutralisation test (FRNT)33.", [["EBOV", "ORGANISM", 59, 63], ["CL4", "GENE_OR_GENE_PRODUCT", 64, 67], ["VSV", "ORGANISM", 97, 100], ["EBOV CL4 PRNT", "PROTEIN", 59, 72], ["EBOV", "SPECIES", 59, 63], ["EBOV", "SPECIES", 80, 84], ["VSV", "SPECIES", 97, 100], ["EBOV CL4 PRNT", "TREATMENT", 59, 72], ["an EBOV pseudotyped VSV CL2 fluorescence reduction", "TREATMENT", 77, 127], ["neutralisation test", "TEST", 128, 147], ["high degree", "OBSERVATION_MODIFIER", 2, 13]]], ["However, pseudotyped virus assays may not always accurately determine neutralisation34,35.", [["pseudotyped virus", "ORGANISM", 9, 26], ["pseudotyped virus", "SPECIES", 9, 26], ["pseudotyped virus assays", "TEST", 9, 33], ["pseudotyped virus", "OBSERVATION", 9, 26]]], ["Live EBOV and EBOV GP pseudotyped neutralisation assays have previously been shown to yield variable results8,36, which could be due to differing experimental conditions and viral systems.", [["EBOV", "ORGANISM", 5, 9], ["EBOV GP pseudotyped", "ORGANISM", 14, 33], ["EBOV", "SPECIES", 5, 9], ["EBOV", "SPECIES", 14, 18], ["EBOV GP pseudotyped neutralisation assays", "TEST", 14, 55], ["differing experimental conditions", "PROBLEM", 136, 169], ["viral systems", "PROBLEM", 174, 187]]], ["It is therefore important to optimise pseudotyped virus neutralisation assays in context of the particular viral GP being studied in order to obtain reliable specificity and sensitivity.", [["pseudotyped virus", "ORGANISM", 38, 55], ["pseudotyped virus neutralisation assays", "PROBLEM", 38, 77], ["the particular viral GP", "PROBLEM", 92, 115]]], ["The aim of this study was to assess the suitability of EBOV GP pseudotyped HIV-1 and VSV systems to measure the neutralising ability of plasma from EVD survivors, when compared to live EBOV neutralisation.DiscussionReporter activity was detected in all cell lines (293T/17, Huh-7, HeLa and Vero E6) infected with EBOV GP (Mayinga) pseudotyped HIV-1 and VSV, demonstrating the broad tissue range conferred by EBOV GP, although differences in luminescence were observed.", [["plasma", "ANATOMY", 136, 142], ["cell lines", "ANATOMY", 253, 263], ["293T/17", "ANATOMY", 265, 272], ["Huh-7", "ANATOMY", 274, 279], ["HeLa", "ANATOMY", 281, 285], ["tissue", "ANATOMY", 382, 388], ["EBOV", "ORGANISM", 55, 59], ["GP pseudotyped HIV-1", "ORGANISM", 60, 80], ["VSV", "ORGANISM", 85, 88], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["EBOV", "ORGANISM", 185, 189], ["cell lines", "CELL", 253, 263], ["293T/17", "CELL", 265, 272], ["Huh-7", "CELL", 274, 279], ["HeLa", "CELL", 281, 285], ["Vero E6", "ORGANISM", 290, 297], ["EBOV GP", "ORGANISM", 313, 320], ["Mayinga) pseudotyped HIV-1", "ORGANISM", 322, 348], ["VSV", "ORGANISM", 353, 356], ["tissue", "TISSUE", 382, 388], ["EBOV", "ORGANISM", 408, 412], ["cell lines", "CELL_LINE", 253, 263], ["293T/17", "CELL_LINE", 265, 272], ["Huh-7", "CELL_LINE", 274, 279], ["HeLa", "CELL_LINE", 281, 285], ["Vero E6", "CELL_LINE", 290, 297], ["EBOV GP", "PROTEIN", 408, 415], ["HIV-1", "SPECIES", 75, 80], ["pseudotyped", "SPECIES", 331, 342], ["HIV-1", "SPECIES", 343, 348], ["EBOV", "SPECIES", 55, 59], ["HIV-1", "SPECIES", 75, 80], ["VSV", "SPECIES", 85, 88], ["EBOV", "SPECIES", 185, 189], ["Vero E6", "SPECIES", 290, 297], ["EBOV", "SPECIES", 313, 317], ["HIV-1", "SPECIES", 343, 348], ["VSV", "SPECIES", 353, 356], ["EBOV", "SPECIES", 408, 412], ["this study", "TEST", 11, 21], ["VSV systems", "TEST", 85, 96], ["EVD survivors", "TREATMENT", 148, 161], ["Huh", "TEST", 274, 277], ["HeLa", "TEST", 281, 285], ["pseudotyped HIV", "TEST", 331, 346], ["VSV", "PROBLEM", 353, 356], ["cell lines", "OBSERVATION", 253, 263], ["broad tissue", "OBSERVATION_MODIFIER", 376, 388], ["EBOV", "OBSERVATION", 408, 412]]], ["This may reflect general defects in viral entry in different cells.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["general defects", "PROBLEM", 17, 32], ["viral entry in different cells", "PROBLEM", 36, 66], ["may reflect", "UNCERTAINTY", 5, 16], ["general", "OBSERVATION_MODIFIER", 17, 24], ["defects", "OBSERVATION", 25, 32], ["viral entry", "OBSERVATION", 36, 47], ["different cells", "OBSERVATION", 51, 66]]], ["A relatively lower level of EBOV GP pseudotyped HIV-1 transduction was exhibited by Vero E6 cells, which might be due to an intrinsic restriction factor, TRIM5\u03b1, which restricts retroviral infection by specifically recognising the HIV-1 capsid and promoting its rapid, premature disassembly37.", [["Vero E6 cells", "ANATOMY", 84, 97], ["retroviral infection", "DISEASE", 178, 198], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 28, 53], ["Vero E6 cells", "CELL", 84, 97], ["TRIM5\u03b1", "GENE_OR_GENE_PRODUCT", 154, 160], ["retroviral", "ORGANISM", 178, 188], ["HIV-1", "ORGANISM", 231, 236], ["Vero E6 cells", "CELL_LINE", 84, 97], ["intrinsic restriction factor", "PROTEIN", 124, 152], ["TRIM5\u03b1", "PROTEIN", 154, 160], ["HIV-1 capsid", "PROTEIN", 231, 243], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 231, 236], ["HIV-1", "SPECIES", 48, 53], ["Vero E6", "SPECIES", 84, 91], ["retroviral", "SPECIES", 178, 188], ["HIV-1", "SPECIES", 231, 236], ["A relatively lower level of EBOV GP pseudotyped HIV", "PROBLEM", 0, 51], ["Vero E6 cells", "PROBLEM", 84, 97], ["an intrinsic restriction factor", "PROBLEM", 121, 152], ["TRIM5\u03b1", "TREATMENT", 154, 160], ["retroviral infection", "PROBLEM", 178, 198], ["premature disassembly37", "PROBLEM", 269, 292], ["lower", "OBSERVATION_MODIFIER", 13, 18], ["E6 cells", "OBSERVATION", 89, 97], ["retroviral infection", "OBSERVATION", 178, 198], ["rapid", "OBSERVATION_MODIFIER", 262, 267]]], ["Highest TCID50 values were obtained following EBOV GP pseudotyped HIV-1 and VSV infection of 293T/17 and Vero E6 cells, respectively.", [["293T/17", "ANATOMY", 93, 100], ["Vero E6 cells", "ANATOMY", 105, 118], ["infection", "DISEASE", 80, 89], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 46, 71], ["VSV", "ORGANISM", 76, 79], ["293T/17", "CELL", 93, 100], ["Vero E6 cells", "CELL", 105, 118], ["Vero E6 cells", "CELL_LINE", 105, 118], ["HIV-1", "SPECIES", 66, 71], ["EBOV", "SPECIES", 46, 50], ["HIV-1", "SPECIES", 66, 71], ["VSV", "SPECIES", 76, 79], ["Vero E6", "SPECIES", 105, 112], ["Highest TCID50 values", "TEST", 0, 21], ["EBOV GP pseudotyped HIV", "TEST", 46, 69], ["VSV infection", "TEST", 76, 89], ["Vero E6 cells", "TEST", 105, 118], ["E6 cells", "OBSERVATION", 110, 118]]], ["There seemed to be large variability of the luminescent measurement for the VSV-based platform, which may be caused by the sensitive nature of the luciferase signal detection.", [["VSV", "ORGANISM", 76, 79], ["luciferase", "GENE_OR_GENE_PRODUCT", 147, 157], ["luciferase", "PROTEIN", 147, 157], ["the luminescent measurement", "TEST", 40, 67], ["the luciferase signal detection", "TEST", 143, 174], ["seemed to be", "UNCERTAINTY", 6, 18], ["large", "OBSERVATION_MODIFIER", 19, 24], ["variability", "OBSERVATION_MODIFIER", 25, 36], ["may be caused", "UNCERTAINTY", 102, 115]]], ["This highlights the importance of titrating each pseudotyped virus batch before use in neutralisation assays, and the inclusion of multiple replicates.DiscussionThe EBOV GP pseudotyped viruses were used to assess the neutralising activity of a human anti-EBOV GP mAb, KZ52.", [["KZ52", "CHEMICAL", 268, 272], ["pseudotyped", "ORGANISM", 49, 60], ["EBOV", "ORGANISM", 165, 169], ["GP pseudotyped viruses", "ORGANISM", 170, 192], ["human", "ORGANISM", 244, 249], ["KZ52", "SIMPLE_CHEMICAL", 268, 272], ["human anti-EBOV GP mAb", "PROTEIN", 244, 266], ["KZ52", "PROTEIN", 268, 272], ["human", "SPECIES", 244, 249], ["EBOV GP pseudotyped viruses", "SPECIES", 165, 192], ["human", "SPECIES", 244, 249], ["titrating each pseudotyped virus batch", "TREATMENT", 34, 72], ["neutralisation assays", "TEST", 87, 108], ["The EBOV GP pseudotyped viruses", "TREATMENT", 161, 192], ["a human anti-EBOV GP mAb", "TREATMENT", 242, 266], ["KZ52", "TREATMENT", 268, 272]]], ["KZ52 has been shown previously to neutralise EBOV pseudotyped viruses17,19,38.", [["KZ52", "CHEMICAL", 0, 4], ["KZ52", "GENE_OR_GENE_PRODUCT", 0, 4], ["EBOV pseudotyped viruse", "ORGANISM", 45, 68], ["KZ52", "PROTEIN", 0, 4]]], ["However, within the range tested here, KZ52 did not display neutralisation against EBOV GP pseudotyped HIV-1, suggesting that the EBOV GP on the pseudotyped HIV-1 might be at higher levels, thereby reducing assay sensitivity, and neutralisation may be observed using a higher concentration of KZ52.", [["KZ52", "CHEMICAL", 39, 43], ["KZ52", "CHEMICAL", 293, 297], ["KZ52", "CHEMICAL", 39, 43], ["KZ52", "CHEMICAL", 293, 297], ["KZ52", "SIMPLE_CHEMICAL", 39, 43], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 83, 108], ["EBOV GP", "ORGANISM", 130, 137], ["pseudotyped HIV-1", "ORGANISM", 145, 162], ["KZ52", "SIMPLE_CHEMICAL", 293, 297], ["EBOV GP", "PROTEIN", 130, 137], ["HIV-1", "SPECIES", 103, 108], ["HIV-1", "SPECIES", 157, 162], ["EBOV", "SPECIES", 83, 87], ["HIV-1", "SPECIES", 103, 108], ["EBOV", "SPECIES", 130, 134], ["HIV-1", "SPECIES", 157, 162], ["KZ52", "TEST", 39, 43], ["neutralisation", "PROBLEM", 60, 74], ["EBOV GP pseudotyped HIV", "PROBLEM", 83, 106], ["the EBOV GP", "PROBLEM", 126, 137], ["the pseudotyped HIV", "TEST", 141, 160], ["assay sensitivity", "TEST", 207, 224], ["a higher concentration of KZ52", "TREATMENT", 267, 297]]], ["In contrast, KZ52 was able to neutralise the EBOV GP pseudotyped VSV.DiscussionTo assess the effects of differing amounts of pseudotyped virus input on neutralisation, plasma from an EVD survivor of the 2013\u20132016 EBOV outbreak and KZ52 were screened against different amounts of the EBOV GP pseudotyped HIV-1 and VSV, respectively.", [["plasma", "ANATOMY", 168, 174], ["KZ52", "CHEMICAL", 13, 17], ["KZ52", "SIMPLE_CHEMICAL", 13, 17], ["EBOV", "ORGANISM", 45, 49], ["GP pseudotyped VSV", "ORGANISM", 50, 68], ["pseudotyped", "ORGANISM", 125, 136], ["plasma", "ORGANISM_SUBSTANCE", 168, 174], ["EBOV", "ORGANISM", 213, 217], ["EBOV", "ORGANISM", 283, 287], ["GP pseudotyped HIV-1", "ORGANISM", 288, 308], ["VSV", "ORGANISM", 313, 316], ["KZ52", "PROTEIN", 13, 17], ["HIV-1", "SPECIES", 303, 308], ["EBOV GP pseudotyped VSV", "SPECIES", 45, 68], ["KZ52", "SPECIES", 231, 235], ["HIV-1", "SPECIES", 303, 308], ["VSV", "SPECIES", 313, 316], ["pseudotyped virus input", "TREATMENT", 125, 148], ["an EVD survivor", "TEST", 180, 195], ["KZ52", "TREATMENT", 231, 235], ["pseudotyped VSV", "OBSERVATION", 53, 68]]], ["Decreasing quantities of pseudotyped HIV-1 led to more variable and unreliable results, and the KZ52 IC50 of pseudotyped virus neutralisation decreased with decreasing amounts of EBOV GP pseudotyped VSV input.", [["pseudotyped HIV-1", "ORGANISM", 25, 42], ["pseudotyped virus", "ORGANISM", 109, 126], ["EBOV", "ORGANISM", 179, 183], ["VSV", "ORGANISM", 199, 202], ["HIV-1", "SPECIES", 37, 42], ["HIV-1", "SPECIES", 37, 42], ["EBOV", "SPECIES", 179, 183], ["VSV", "SPECIES", 199, 202], ["pseudotyped HIV", "PROBLEM", 25, 40], ["the KZ52 IC50", "TREATMENT", 92, 105], ["pseudotyped virus neutralisation", "TREATMENT", 109, 141], ["EBOV GP pseudotyped VSV input", "TREATMENT", 179, 208], ["pseudotyped HIV", "OBSERVATION", 25, 40]]], ["The variability in neutralisation observed between different amounts of pseudotyped virus input highlights the importance of including standards or reference material with a known activity or potency when comparing neutralising activity, allowing calibration of results39.DiscussionBoth pseudotyped virus systems were able to measure neutralising antibodies in plasma from EVD convalescent patients, and results correlated positively with a live EBOV neutralisation assay.", [["plasma", "ANATOMY", 361, 367], ["pseudotyped virus", "ORGANISM", 72, 89], ["pseudotyped virus", "ORGANISM", 287, 304], ["plasma", "ORGANISM_SUBSTANCE", 361, 367], ["patients", "ORGANISM", 390, 398], ["EBOV", "ORGANISM", 446, 450], ["neutralising antibodies", "PROTEIN", 334, 357], ["patients", "SPECIES", 390, 398], ["EBOV", "SPECIES", 446, 450], ["The variability in neutralisation", "PROBLEM", 0, 33], ["pseudotyped virus input", "TREATMENT", 72, 95], ["pseudotyped virus systems", "PROBLEM", 287, 312], ["neutralising antibodies", "TEST", 334, 357], ["a live EBOV neutralisation assay", "TEST", 439, 471], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["neutralisation", "OBSERVATION", 19, 33], ["pseudotyped virus", "OBSERVATION", 72, 89]]], ["However, the discriminatory power of the HIV-1-based assay with regards to differing antibody titres appeared to be low.", [["HIV-1", "ORGANISM", 41, 46], ["HIV-1", "SPECIES", 41, 46], ["HIV-1", "SPECIES", 41, 46], ["the HIV", "TEST", 37, 44], ["based assay", "TEST", 47, 58], ["differing antibody titres", "TEST", 75, 100], ["low", "OBSERVATION_MODIFIER", 116, 119]]], ["Some of the samples tested, which showed neutralising activity against live EBOV, did not display neutralisation against the pseudotyped virus and vice versa, therefore raising questions on the sensitivity and specificity of the pseudotyped HIV-1 assay.DiscussionIn the current study, human embryonic kidney (293T/17) cells were used for the pseudotyped HIV-1 neutralisation assays, whereas African green monkey kidney (Vero) cells were used in the VSV-based assay and also the live EBOV assay.", [["samples", "ANATOMY", 12, 19], ["embryonic kidney", "ANATOMY", 291, 307], ["293T/17) cells", "ANATOMY", 309, 323], ["kidney", "ANATOMY", 412, 418], ["Vero) cells", "ANATOMY", 420, 431], ["EBOV", "ORGANISM", 76, 80], ["pseudotyped virus", "ORGANISM", 125, 142], ["pseudotyped", "ORGANISM", 229, 240], ["HIV-1", "ORGANISM", 241, 246], ["human", "ORGANISM", 285, 290], ["embryonic kidney", "CELL", 291, 307], ["293T/17) cells", "CELL", 309, 323], ["pseudotyped", "ORGANISM", 342, 353], ["HIV-1", "ORGANISM", 354, 359], ["green monkey kidney", "ORGANISM", 399, 418], ["Vero) cells", "CELL", 420, 431], ["VSV", "ORGANISM", 449, 452], ["EBOV", "ORGANISM", 483, 487], ["human embryonic kidney (293T/17) cells", "CELL_LINE", 285, 323], ["African green monkey kidney (Vero) cells", "CELL_LINE", 391, 431], ["HIV-1", "SPECIES", 241, 246], ["human", "SPECIES", 285, 290], ["HIV-1", "SPECIES", 354, 359], ["green monkey", "SPECIES", 399, 411], ["EBOV", "SPECIES", 76, 80], ["pseudotyped virus", "SPECIES", 125, 142], ["HIV-1", "SPECIES", 241, 246], ["human", "SPECIES", 285, 290], ["HIV-1", "SPECIES", 354, 359], ["African green monkey", "SPECIES", 391, 411], ["Vero", "SPECIES", 420, 424], ["VSV", "SPECIES", 449, 452], ["EBOV", "SPECIES", 483, 487], ["the samples", "TEST", 8, 19], ["neutralising activity against live EBOV", "PROBLEM", 41, 80], ["neutralisation", "PROBLEM", 98, 112], ["the pseudotyped virus", "PROBLEM", 121, 142], ["the sensitivity", "TEST", 190, 205], ["the pseudotyped HIV", "TEST", 225, 244], ["the current study", "TEST", 266, 283], ["human embryonic kidney (293T/17) cells", "TREATMENT", 285, 323], ["the pseudotyped HIV", "TEST", 338, 357], ["neutralisation assays", "TEST", 360, 381], ["kidney", "ANATOMY", 301, 307], ["kidney", "ANATOMY", 412, 418]]], ["Therefore, this could account for some of the differences in results observed between the two assays and for the better performance of the VSV-based assay in relation to live EBOV neutralisation.", [["VSV", "ORGANISM", 139, 142], ["EBOV", "ORGANISM", 175, 179], ["VSV", "SPECIES", 139, 142], ["EBOV", "SPECIES", 175, 179], ["the two assays", "TEST", 86, 100], ["the VSV", "TREATMENT", 135, 142]]], ["Also, the HIV-1- and VSV-based pseudotyped virus systems assessed in the current study utilise different transfection methods, which could have implications on the composition of the pseudotyped viruses, density and/or glycosylation of the viral envelope protein on the surface, and consequently neutralisation results.", [["surface", "ANATOMY", 270, 277], ["HIV-1", "ORGANISM", 10, 15], ["VSV", "ORGANISM", 21, 24], ["pseudotyped virus", "ORGANISM", 31, 48], ["pseudotyped", "ORGANISM", 183, 194], ["surface", "CELLULAR_COMPONENT", 270, 277], ["viral envelope protein", "PROTEIN", 240, 262], ["HIV-1", "SPECIES", 10, 15], ["HIV-1", "SPECIES", 10, 15], ["VSV", "SPECIES", 21, 24], ["the HIV", "TEST", 6, 13], ["VSV", "PROBLEM", 21, 24], ["pseudotyped virus systems", "PROBLEM", 31, 56], ["the current study", "TEST", 69, 86], ["different transfection methods", "TREATMENT", 95, 125], ["the pseudotyped viruses", "PROBLEM", 179, 202], ["the viral envelope protein", "PROBLEM", 236, 262], ["pseudotyped virus", "OBSERVATION", 31, 48], ["pseudotyped viruses", "OBSERVATION", 183, 202], ["viral envelope protein", "OBSERVATION", 240, 262]]], ["This highlights the importance of assessing experimental conditions and methodology when developing and optimising pseudotyped virus neutralisation assays.", [["pseudotyped", "ORGANISM", 115, 126], ["optimising pseudotyped virus neutralisation assays", "PROBLEM", 104, 154]]], ["A limitation to this study was that the level of EBOV GP incorporation per pseudotyped virus type could not be assessed.", [["EBOV", "ORGANISM", 49, 53], ["GP", "GENE_OR_GENE_PRODUCT", 54, 56], ["pseudotyped", "ORGANISM", 75, 86], ["EBOV", "SPECIES", 49, 53], ["this study", "TEST", 16, 26], ["EBOV GP incorporation", "TREATMENT", 49, 70], ["pseudotyped virus type", "PROBLEM", 75, 97], ["pseudotyped virus", "OBSERVATION", 75, 92]]], ["Also, for the VSV-based pseudotyped virus system, traces of VSV-G from the rVSV-\u0394G-Luc-VSV-G virus could be recycled into newly pseudotyped virions40.", [["VSV", "ORGANISM", 14, 17], ["pseudotyped virus", "ORGANISM", 24, 41], ["VSV-G", "ORGANISM", 60, 65], ["rVSV-\u0394G-Luc-VSV-G virus", "ORGANISM", 75, 98], ["pseudotyped", "ORGANISM", 128, 139], ["VSV-G virus", "SPECIES", 87, 98], ["VSV", "SPECIES", 14, 17], ["pseudotyped virus", "SPECIES", 24, 41], ["VSV", "SPECIES", 60, 63], ["VSV-G virus", "SPECIES", 87, 98], ["the VSV", "TEST", 10, 17], ["pseudotyped virus system", "PROBLEM", 24, 48], ["VSV", "TEST", 60, 63], ["the rVSV", "TEST", 71, 79], ["\u0394G", "TEST", 80, 82], ["VSV", "PROBLEM", 87, 90], ["G virus", "PROBLEM", 91, 98], ["newly pseudotyped virions", "PROBLEM", 122, 147], ["pseudotyped virions", "OBSERVATION", 128, 147]]], ["Therefore, the use of anti-VSV-G hybridoma cell culture supernatant could give rise to pseudotyped virions covered by anti-VSV-G antibodies, but are still infectious due to Ebola GP.", [["cell", "ANATOMY", 43, 47], ["supernatant", "ANATOMY", 56, 67], ["virions", "ANATOMY", 99, 106], ["Ebola", "DISEASE", 173, 178], ["anti-VSV-G hybridoma cell", "CELL", 22, 47], ["pseudotyped", "ORGANISM", 87, 98], ["anti-VSV-G antibodies", "GENE_OR_GENE_PRODUCT", 118, 139], ["Ebola GP", "ORGANISM", 173, 181], ["anti-VSV-G hybridoma cell culture supernatant", "CELL_LINE", 22, 67], ["anti-VSV-G antibodies", "PROTEIN", 118, 139], ["anti-VSV", "TREATMENT", 22, 30], ["G hybridoma cell culture supernatant", "TREATMENT", 31, 67], ["pseudotyped virions", "PROBLEM", 87, 106], ["anti-VSV-G antibodies", "TEST", 118, 139], ["still infectious", "PROBLEM", 149, 165], ["Ebola GP", "PROBLEM", 173, 181], ["infectious", "OBSERVATION", 155, 165]]], ["This could potentially induce plasma specific reactivity of virions due to bound anti-VSV-G antibodies more than EBOV GP specific reactivity.DiscussionThere are several differences between EBOV GP pseudotyped and live EBOV neutralisation assays that could affect their results8.", [["plasma", "ANATOMY", 30, 36], ["virions", "ANATOMY", 60, 67], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["anti-VSV-G antibodies", "GENE_OR_GENE_PRODUCT", 81, 102], ["EBOV", "ORGANISM", 113, 117], ["EBOV", "ORGANISM", 189, 193], ["pseudotyped", "ORGANISM", 197, 208], ["EBOV", "ORGANISM", 218, 222], ["anti-VSV", "PROTEIN", 81, 89], ["G antibodies", "PROTEIN", 90, 102], ["EBOV", "SPECIES", 113, 117], ["EBOV", "SPECIES", 189, 193], ["EBOV", "SPECIES", 218, 222], ["plasma specific reactivity of virions", "PROBLEM", 30, 67], ["bound anti-VSV", "PROBLEM", 75, 89], ["G antibodies", "TEST", 90, 102], ["EBOV GP pseudotyped", "TREATMENT", 189, 208], ["EBOV neutralisation assays", "TEST", 218, 244]]], ["Due to their non-replicating nature, such pseudotype systems do not recapitulate all steps in the viral life cycle that may potentially be targeted by neutralising antibodies41.", [["neutralising antibodies41", "PROTEIN", 151, 176], ["such pseudotype systems", "PROBLEM", 37, 60], ["neutralising antibodies", "TEST", 151, 174], ["may potentially be", "UNCERTAINTY", 120, 138]]], ["In addition, the round, spherical shape of EBOV GP pseudotyped HIV-1 or bullet shape of EBOV GP pseudotyped VSV compared to the filamentous shape of authentic EBOV could affect their susceptibility to neutralisation.", [["EBOV GP pseudotyped HIV-1", "ORGANISM", 43, 68], ["EBOV", "ORGANISM", 88, 92], ["GP pseudotyped VSV", "ORGANISM", 93, 111], ["EBOV", "ORGANISM", 159, 163], ["pseudotyped", "SPECIES", 51, 62], ["HIV-1", "SPECIES", 63, 68], ["pseudotyped", "SPECIES", 96, 107], ["HIV-1", "SPECIES", 63, 68], ["EBOV GP pseudotyped VSV", "SPECIES", 88, 111], ["EBOV", "SPECIES", 159, 163], ["EBOV GP pseudotyped HIV", "PROBLEM", 43, 66], ["bullet shape", "PROBLEM", 72, 84], ["EBOV GP pseudotyped VSV", "PROBLEM", 88, 111], ["round", "OBSERVATION_MODIFIER", 17, 22], ["spherical", "OBSERVATION_MODIFIER", 24, 33], ["shape", "OBSERVATION_MODIFIER", 34, 39], ["EBOV", "OBSERVATION_MODIFIER", 43, 47], ["GP pseudotyped", "OBSERVATION", 48, 62], ["bullet", "OBSERVATION_MODIFIER", 72, 78], ["shape", "OBSERVATION_MODIFIER", 79, 84], ["EBOV", "OBSERVATION_MODIFIER", 88, 92], ["GP pseudotyped VSV", "OBSERVATION", 93, 111], ["filamentous shape", "OBSERVATION_MODIFIER", 128, 145], ["authentic EBOV", "OBSERVATION", 149, 163], ["neutralisation", "OBSERVATION_MODIFIER", 201, 215]]], ["Also, the density of GP on the surface of the pseudotyped virus may not be the same as that found on live EBOV and may result in the loss or masking of quaternary epitopes11,42.", [["surface", "ANATOMY", 31, 38], ["GP", "GENE_OR_GENE_PRODUCT", 21, 23], ["surface", "CELLULAR_COMPONENT", 31, 38], ["pseudotyped", "ORGANISM", 46, 57], ["EBOV", "ORGANISM", 106, 110], ["GP", "PROTEIN", 21, 23], ["quaternary epitopes11,42", "PROTEIN", 152, 176], ["EBOV", "SPECIES", 106, 110], ["the pseudotyped virus", "PROBLEM", 42, 63], ["the loss or masking of quaternary epitopes", "PROBLEM", 129, 171], ["density", "OBSERVATION_MODIFIER", 10, 17], ["GP", "OBSERVATION_MODIFIER", 21, 23], ["pseudotyped virus", "OBSERVATION", 46, 63], ["may not be", "UNCERTAINTY", 64, 74]]], ["Furthermore, GP maturation and assembly in live EBOV could be different in the generation of an EBOV pseudotyped virus and may result in different targets and/or conformational epitopes when using whole live EBOV as opposed to EBOV GP alone in a pseudotyped virus.", [["GP", "GENE_OR_GENE_PRODUCT", 13, 15], ["EBOV", "ORGANISM", 48, 52], ["EBOV pseudotyped virus", "ORGANISM", 96, 118], ["EBOV", "ORGANISM", 208, 212], ["EBOV", "ORGANISM", 227, 231], ["GP", "ORGANISM", 232, 234], ["pseudotyped virus", "ORGANISM", 246, 263], ["conformational epitopes", "PROTEIN", 162, 185], ["EBOV GP", "PROTEIN", 227, 234], ["EBOV", "SPECIES", 48, 52], ["EBOV pseudotyped virus", "SPECIES", 96, 118], ["EBOV", "SPECIES", 208, 212], ["EBOV", "SPECIES", 227, 231], ["pseudotyped virus", "SPECIES", 246, 263], ["an EBOV pseudotyped virus", "PROBLEM", 93, 118], ["conformational epitopes", "PROBLEM", 162, 185], ["whole live EBOV", "TREATMENT", 197, 212], ["EBOV GP", "PROBLEM", 227, 234], ["a pseudotyped virus", "PROBLEM", 244, 263]]], ["The presence of shed GP or secreted GP (sGP) in the live EBOV assay compared to absence in the EBOV GP pseudotyped virus assays could also have an effect on neutralisation.", [["GP", "GENE_OR_GENE_PRODUCT", 21, 23], ["GP", "GENE_OR_GENE_PRODUCT", 36, 38], ["EBOV", "ORGANISM", 57, 61], ["EBOV", "ORGANISM", 95, 99], ["GP pseudotyped virus", "ORGANISM", 100, 120], ["shed GP", "PROTEIN", 16, 23], ["secreted GP", "PROTEIN", 27, 38], ["EBOV", "SPECIES", 57, 61], ["EBOV GP pseudotyped virus", "SPECIES", 95, 120], ["the live EBOV assay", "TEST", 48, 67], ["the EBOV GP pseudotyped virus assays", "PROBLEM", 91, 127], ["GP", "OBSERVATION_MODIFIER", 21, 23], ["neutralisation", "OBSERVATION", 157, 171]]], ["In the live EBOV assay, shed GP and sGP could reduce neutralisation of circulating virus by cross-reactive antibodies to surface GP.", [["surface", "ANATOMY", 121, 128], ["sGP", "CHEMICAL", 36, 39], ["EBOV", "ORGANISM", 12, 16], ["GP", "GENE_OR_GENE_PRODUCT", 29, 31], ["sGP", "GENE_OR_GENE_PRODUCT", 36, 39], ["antibodies to surface GP", "GENE_OR_GENE_PRODUCT", 107, 131], ["GP", "PROTEIN", 29, 31], ["sGP", "PROTEIN", 36, 39], ["cross-reactive antibodies", "PROTEIN", 92, 117], ["surface GP", "PROTEIN", 121, 131], ["EBOV", "SPECIES", 12, 16], ["the live EBOV assay", "TEST", 3, 22], ["neutralisation of circulating virus", "PROBLEM", 53, 88]]], ["However, in the current study, weaker relative neutralisation was observed in the HIV-1 based pseudotyped virus assay.", [["HIV-1", "ORGANISM", 82, 87], ["pseudotyped", "ORGANISM", 94, 105], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 82, 87], ["pseudotyped virus", "SPECIES", 94, 111], ["the current study", "TEST", 12, 29], ["weaker relative neutralisation", "PROBLEM", 31, 61], ["the HIV", "TEST", 78, 85], ["pseudotyped virus assay", "PROBLEM", 94, 117], ["neutralisation", "OBSERVATION", 47, 61]]], ["Therefore, it is possible that cell debris or free GP generated during EBOV GP pseudotyped HIV-1 production by polyethylenimine (PEI) transfection could be interfering with neutralisation.", [["cell", "ANATOMY", 31, 35], ["polyethylenimine", "CHEMICAL", 111, 127], ["PEI", "CHEMICAL", 129, 132], ["polyethylenimine", "CHEMICAL", 111, 127], ["PEI", "CHEMICAL", 129, 132], ["cell", "CELL", 31, 35], ["EBOV GP pseudotyped HIV-1", "ORGANISM", 71, 96], ["polyethylenimine", "SIMPLE_CHEMICAL", 111, 127], ["PEI", "SIMPLE_CHEMICAL", 129, 132], ["HIV-1", "SPECIES", 91, 96], ["EBOV", "SPECIES", 71, 75], ["HIV-1", "SPECIES", 91, 96], ["cell debris", "PROBLEM", 31, 42], ["free GP", "PROBLEM", 46, 53], ["EBOV GP pseudotyped HIV", "PROBLEM", 71, 94], ["polyethylenimine (PEI) transfection", "TREATMENT", 111, 146], ["neutralisation", "PROBLEM", 173, 187], ["cell debris", "OBSERVATION", 31, 42], ["free", "OBSERVATION_MODIFIER", 46, 50]]], ["Finally, detection of infected cells via measurement of luminescence in the EBOV GP pseudotyped virus neutralisation assay compared to plaque formation in the live EBOV neutralisation assay could affect neutralisation readout.DiscussionEBOV GP pseudotyped virus neutralisation assays have value for vaccine evaluation and assessment of convalescent blood products and mAbs for use as immunotherapeutics.", [["cells", "ANATOMY", 31, 36], ["plaque", "ANATOMY", 135, 141], ["blood", "ANATOMY", 349, 354], ["cells", "CELL", 31, 36], ["EBOV", "ORGANISM", 76, 80], ["GP pseudotyped virus", "ORGANISM", 81, 101], ["plaque", "PATHOLOGICAL_FORMATION", 135, 141], ["EBOV", "ORGANISM", 164, 168], ["GP pseudotyped virus", "ORGANISM", 241, 261], ["convalescent", "ORGANISM", 336, 348], ["blood", "ORGANISM_SUBSTANCE", 349, 354], ["mAbs", "GENE_OR_GENE_PRODUCT", 368, 372], ["infected cells", "CELL_TYPE", 22, 36], ["convalescent blood products", "PROTEIN", 336, 363], ["mAbs", "PROTEIN", 368, 372], ["EBOV GP pseudotyped virus", "SPECIES", 76, 101], ["EBOV", "SPECIES", 164, 168], ["infected cells", "PROBLEM", 22, 36], ["luminescence", "PROBLEM", 56, 68], ["the EBOV GP pseudotyped virus neutralisation assay", "TREATMENT", 72, 122], ["plaque formation", "PROBLEM", 135, 151], ["EBOV neutralisation assay", "TEST", 164, 189], ["DiscussionEBOV GP pseudotyped virus neutralisation assays", "TEST", 226, 283], ["vaccine evaluation", "TEST", 299, 317], ["assessment", "TEST", 322, 332], ["convalescent blood products", "TREATMENT", 336, 363], ["immunotherapeutics", "TREATMENT", 384, 402], ["infected cells", "OBSERVATION", 22, 36]]], ["However, pseudotyped virus assays may not always accurately determine neutralisation when compared with neutralisation against live virus.", [["pseudotyped virus", "ORGANISM", 9, 26], ["live virus", "ORGANISM", 127, 137], ["pseudotyped virus", "SPECIES", 9, 26], ["pseudotyped virus assays", "TEST", 9, 33], ["live virus", "PROBLEM", 127, 137]]], ["In this study, both EBOV GP pseudotyped HIV-1 and VSV assays were able to detect neutralisation of plasma from EVD survivors and correlated positively with live EBOV neutralisation.", [["plasma", "ANATOMY", 99, 105], ["EBOV", "ORGANISM", 20, 24], ["GP pseudotyped", "ORGANISM", 25, 39], ["HIV-1", "ORGANISM", 40, 45], ["VSV", "ORGANISM", 50, 53], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["EBOV", "ORGANISM", 161, 165], ["pseudotyped", "SPECIES", 28, 39], ["HIV-1", "SPECIES", 40, 45], ["EBOV", "SPECIES", 20, 24], ["HIV-1", "SPECIES", 40, 45], ["VSV", "SPECIES", 50, 53], ["EBOV", "SPECIES", 161, 165], ["this study", "TEST", 3, 13], ["both EBOV GP pseudotyped HIV", "TEST", 15, 43], ["VSV assays", "TEST", 50, 60], ["EVD survivors", "TREATMENT", 111, 124]]], ["However, the VSV-based assay performed better than the HIV-1-based assay in relation to specificity, sensitivity, and correlation with the live EBOV neutralisation assay.", [["VSV", "ORGANISM", 13, 16], ["HIV-1", "ORGANISM", 55, 60], ["EBOV", "ORGANISM", 144, 148], ["HIV-1", "SPECIES", 55, 60], ["VSV", "SPECIES", 13, 16], ["HIV-1", "SPECIES", 55, 60], ["EBOV", "SPECIES", 144, 148], ["the VSV-based assay", "TEST", 9, 28], ["the HIV", "TEST", 51, 58], ["sensitivity", "TEST", 101, 112], ["the live EBOV neutralisation assay", "TEST", 135, 169]]], ["This research has highlighted the importance of optimising pseudotyped virus neutralisation assays in context of the particular viral GP being studied, especially when evaluating vaccine responses and therapeutics, and could provide a better understanding of the correlates of protection against EBOV.Plasmids and cells ::: MethodsThe HIV-1 gag-pol plasmid p8.9143, the firefly luciferase reporter construct pCSFLW44 and a pCAGGS EBOV (Mayinga) GP (GenBank accession number NC_002549) expression construct were kind gifts from Edward Wright[University of Sussex, Brighton, United Kingdom (UK)].Plasmids and cells ::: MethodsHuman embryonic kidney (HEK) 293T clone 17 cells (293T/17; American Type Culture Collection (ATCC), Teddington, UK, CRL-11268) were used for all transfections and as a target cell line for titration and pseudotyped HIV-1 neutralisation assays.", [["cells", "ANATOMY", 314, 319], ["cells", "ANATOMY", 607, 612], ["embryonic kidney (HEK) 293T clone 17 cells", "ANATOMY", 630, 672], ["293T", "ANATOMY", 674, 678], ["cell line", "ANATOMY", 799, 808], ["EBOV", "DISEASE", 296, 300], ["CRL-11268", "CHEMICAL", 740, 749], ["pseudotyped virus", "ORGANISM", 59, 76], ["EBOV", "ORGANISM", 296, 300], ["cells", "CELL", 314, 319], ["HIV-1", "ORGANISM", 335, 340], ["gag", "ORGANISM", 341, 344], ["luciferase", "GENE_OR_GENE_PRODUCT", 378, 388], ["pCSFLW44", "GENE_OR_GENE_PRODUCT", 408, 416], ["pCAGGS EBOV", "ORGANISM", 423, 434], ["cells", "CELL", 607, 612], ["MethodsHuman embryonic kidney", "CELL", 617, 646], ["HEK) 293T clone 17 cells", "CELL", 648, 672], ["293T/17", "CELL", 674, 681], ["ATCC", "CELL", 717, 721], ["CRL-11268", "CELL", 740, 749], ["cell line", "CELL", 799, 808], ["pseudotyped HIV-1", "ORGANISM", 827, 844], ["HIV-1 gag-pol plasmid p8.9143", "DNA", 335, 364], ["firefly luciferase reporter construct pCSFLW44", "DNA", 370, 416], ["pCAGGS EBOV (Mayinga) GP", "DNA", 423, 447], ["MethodsHuman embryonic kidney (HEK) 293T clone 17 cells", "CELL_LINE", 617, 672], ["293T/17", "CELL_LINE", 674, 681], ["target cell line", "CELL_LINE", 792, 808], ["HIV-1 gag", "SPECIES", 335, 344], ["HIV-1", "SPECIES", 839, 844], ["EBOV", "SPECIES", 296, 300], ["HIV-1", "SPECIES", 335, 340], ["HIV-1", "SPECIES", 839, 844], ["optimising pseudotyped virus neutralisation assays", "PROBLEM", 48, 98], ["EBOV", "PROBLEM", 296, 300], ["Methods", "TEST", 324, 331], ["The HIV", "TEST", 331, 338], ["gag", "TEST", 341, 344], ["pol plasmid", "TEST", 345, 356], ["American Type Culture Collection", "TEST", 683, 715], ["CRL", "TEST", 740, 743], ["all transfections", "TREATMENT", 765, 782], ["a target cell line", "TREATMENT", 790, 808], ["pseudotyped HIV", "TEST", 827, 842], ["neutralisation assays", "TEST", 845, 866], ["kidney", "ANATOMY", 640, 646]]], ["Vero E6[Vero 76, clone E6, Vero E6 (European Culture of Authenticated Cell Cultures (ECACC), Salisbury, UK, 85020206) and Huh-7 (Arvind Patel, University of Glasgow, UK) cells were used as target cell lines.", [["Cell Cultures", "ANATOMY", 70, 83], ["Glasgow, UK) cells", "ANATOMY", 157, 175], ["cell lines", "ANATOMY", 196, 206], ["Vero E6", "ORGANISM", 0, 7], ["Vero 76", "CELL", 8, 15], ["clone E6", "ORGANISM", 17, 25], ["Vero E6", "ORGANISM", 27, 34], ["Authenticated Cell Cultures", "CELL", 56, 83], ["ECACC", "CELL", 85, 90], ["Huh-7", "CELL", 122, 127], ["Glasgow, UK) cells", "CELL", 157, 175], ["cell lines", "CELL", 196, 206], ["E6", "PROTEIN", 5, 7], ["clone E6", "CELL_LINE", 17, 25], ["Vero E6", "PROTEIN", 27, 34], ["target cell lines", "CELL_LINE", 189, 206], ["Vero E6", "SPECIES", 0, 7], ["Vero E6", "TEST", 0, 7], ["Vero", "TEST", 8, 12], ["clone E6", "TEST", 17, 25], ["Vero E6", "TEST", 27, 34], ["European Culture", "TEST", 36, 52], ["Authenticated Cell Cultures", "TEST", 56, 83], ["Huh", "TEST", 122, 125], ["cell lines", "OBSERVATION", 196, 206]]], ["All cell lines were cultured at 5% CO2 in Dulbecco\u2019s Modified Eagle Medium (DMEM), high glucose, with l-glutamine (Gibco, Paisley, UK) supplemented with 10% fetal bovine serum (FBS), heat inactivated (Sigma-Aldrich, Gillingham, UK).", [["cell lines", "ANATOMY", 4, 14], ["fetal bovine serum", "ANATOMY", 157, 175], ["FBS", "ANATOMY", 177, 180], ["CO2", "CHEMICAL", 35, 38], ["glucose", "CHEMICAL", 88, 95], ["l-glutamine", "CHEMICAL", 102, 113], ["CO2", "CHEMICAL", 35, 38], ["glucose", "CHEMICAL", 88, 95], ["l-glutamine", "CHEMICAL", 102, 113], ["cell lines", "CELL", 4, 14], ["CO2", "SIMPLE_CHEMICAL", 35, 38], ["glucose", "SIMPLE_CHEMICAL", 88, 95], ["l-glutamine", "SIMPLE_CHEMICAL", 102, 113], ["bovine", "ORGANISM", 163, 169], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["FBS", "ORGANISM_SUBSTANCE", 177, 180], ["UK", "GENE_OR_GENE_PRODUCT", 228, 230], ["cell lines", "CELL_LINE", 4, 14], ["bovine", "SPECIES", 163, 169], ["All cell lines", "TREATMENT", 0, 14], ["high glucose", "PROBLEM", 83, 95], ["l-glutamine", "TREATMENT", 102, 113], ["10% fetal bovine serum (FBS", "TREATMENT", 153, 180], ["cell lines", "OBSERVATION", 4, 14]]], ["HeLa cells (ECACC 93021013) were also used as a target cell line and were cultured in Minimum Essential Media (MEM) + GlutaMAX (Life Technologies, Paisley, UK) supplemented with 10% FBS and 1 \u00d7 MEM Non-Essential Amino Acids (NEAA) solution (Life Technologies).Human samples and purified human antibody ::: MethodsPlasma samples from EVD survivors of the 2013\u20132016 EBOV outbreak recruited 3 to 14 months post-infection from two regions of Guinea (Gu\u00e9ck\u00e9dou and Coyah) and from negative control blood donors in the UK and Guinea, who were not knowingly exposed to persons with EVD and did not attend high risk events such as funerals, were heat inactivated at 56 \u00b0C for 30 min.", [["HeLa cells", "ANATOMY", 0, 10], ["ECACC 93021013", "ANATOMY", 12, 26], ["cell line", "ANATOMY", 55, 64], ["samples", "ANATOMY", 266, 273], ["samples", "ANATOMY", 320, 327], ["blood", "ANATOMY", 493, 498], ["ECACC 93021013", "CHEMICAL", 12, 26], ["Amino Acids", "CHEMICAL", 212, 223], ["NEAA", "CHEMICAL", 225, 229], ["infection", "DISEASE", 408, 417], ["Amino Acids", "CHEMICAL", 212, 223], ["NEAA", "CHEMICAL", 225, 229], ["HeLa cells", "CELL", 0, 10], ["ECACC 93021013", "CELL", 12, 26], ["cell line", "CELL", 55, 64], ["FBS", "ORGANISM_SUBSTANCE", 182, 185], ["Amino Acids", "SIMPLE_CHEMICAL", 212, 223], ["NEAA", "SIMPLE_CHEMICAL", 225, 229], ["Human", "ORGANISM", 260, 265], ["human", "ORGANISM", 287, 292], ["MethodsPlasma samples", "CANCER", 306, 327], ["blood", "ORGANISM_SUBSTANCE", 493, 498], ["persons", "ORGANISM", 562, 569], ["HeLa cells", "CELL_LINE", 0, 10], ["ECACC 93021013", "CELL_LINE", 12, 26], ["target cell line", "CELL_LINE", 48, 64], ["purified human antibody", "PROTEIN", 278, 301], ["Human", "SPECIES", 260, 265], ["human", "SPECIES", 287, 292], ["persons", "SPECIES", 562, 569], ["Human", "SPECIES", 260, 265], ["human", "SPECIES", 287, 292], ["a target cell line", "TREATMENT", 46, 64], ["Essential Media (MEM)", "TREATMENT", 94, 115], ["GlutaMAX (Life Technologies", "TREATMENT", 118, 145], ["10% FBS", "TREATMENT", 178, 185], ["1 \u00d7 MEM Non-Essential Amino Acids (NEAA) solution (Life Technologies", "TREATMENT", 190, 258], ["Human samples", "TEST", 260, 273], ["purified human antibody", "TEST", 278, 301], ["MethodsPlasma samples", "TEST", 306, 327], ["EVD survivors", "TREATMENT", 333, 346], ["infection", "PROBLEM", 408, 417], ["Guinea", "PROBLEM", 438, 444], ["EVD", "TREATMENT", 575, 578], ["high risk events", "PROBLEM", 598, 614], ["cell line", "OBSERVATION", 55, 64], ["infection", "OBSERVATION", 408, 417]]], ["The samples were obtained from a pre-existing biobank, for which live EBOV neutralisation45 data were available (Thomas Strecker, Philipps University Marburg, Germany) in link-anonymised format.", [["samples", "ANATOMY", 4, 11], ["EBOV", "ORGANISM", 70, 74], ["EBOV", "SPECIES", 70, 74], ["The samples", "TEST", 0, 11]]], ["All experiments involving live EBOV were performed in a CL4 facility at Philipps University Marburg, Germany.", [["EBOV", "ORGANISM", 31, 35], ["EBOV", "SPECIES", 31, 35]]], ["All experimental protocols used in this study were approved by the Guinean National Ethics Committee for Research and Health [Comit\u00e9 National d'Ethique pour la Recherche en Sant\u00e9 (CNERS)].", [["All experimental protocols", "TREATMENT", 0, 26], ["National d'Ethique pour la Recherche en Sant\u00e9 (CNERS)", "TREATMENT", 133, 186]]], ["All methods were carried out in accordance with the relevant guidelines and regulations under ethical approval No. 33/CNERS/15.", [["All methods", "TREATMENT", 0, 11]]], ["Informed consent was obtained from all participants.Human samples and purified human antibody ::: MethodsProtein A purified human anti-EBOV GP mAb KZ52 (IBT Bioservices Rockville, Maryland (MD), USA) was also tested in the EBOV GP pseudotyped virus neutralisation assays.Production of pseudotyped viruses ::: MethodsThe generation of HIV-1 pseudotyped viruses was performed as detailed previously44,46,47.", [["samples", "ANATOMY", 58, 65], ["MethodsProtein", "CHEMICAL", 98, 112], ["MethodsProtein", "CHEMICAL", 98, 112], ["Human", "ORGANISM", 52, 57], ["human", "ORGANISM", 79, 84], ["MethodsProtein", "GENE_OR_GENE_PRODUCT", 98, 112], ["human", "ORGANISM", 124, 129], ["EBOV", "ORGANISM", 223, 227], ["pseudotyped", "ORGANISM", 231, 242], ["pseudotyped", "ORGANISM", 285, 296], ["HIV-1", "ORGANISM", 334, 339], ["pseudotyped", "ORGANISM", 340, 351], ["purified human antibody", "PROTEIN", 70, 93], ["MethodsProtein", "PROTEIN", 98, 112], ["purified human anti-EBOV GP mAb KZ52", "PROTEIN", 115, 151], ["participants", "SPECIES", 39, 51], ["Human", "SPECIES", 52, 57], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 124, 129], ["HIV-1 pseudotyped", "SPECIES", 334, 351], ["Human", "SPECIES", 52, 57], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 124, 129], ["EBOV GP pseudotyped virus", "SPECIES", 223, 248], ["HIV-1 pseudotyped viruses", "SPECIES", 334, 359], ["Human samples", "TEST", 52, 65], ["purified human antibody", "TEST", 70, 93], ["MethodsProtein", "TREATMENT", 98, 112], ["A purified human anti-EBOV GP mAb", "TREATMENT", 113, 146], ["Methods", "TREATMENT", 309, 316], ["HIV-1 pseudotyped viruses", "PROBLEM", 334, 359], ["pseudotyped viruses", "OBSERVATION", 285, 304]]], ["Twenty-four hours prior to transfection, approximately 8 \u00d7 105 293T/17 cells were seeded into sterile, 6-well cell culture plates (Corning, Ewloe, UK) and incubated at 37 \u00b0C, 5% CO2 and 95% humidity until 60\u201380% confluence.", [["293T/17 cells", "ANATOMY", 63, 76], ["cell", "ANATOMY", 110, 114], ["CO2", "CHEMICAL", 178, 181], ["CO2", "CHEMICAL", 178, 181], ["293T/17 cells", "CELL", 63, 76], ["cell", "CELL", 110, 114], ["CO2", "SIMPLE_CHEMICAL", 178, 181], ["17 cells", "CELL_LINE", 68, 76], ["transfection", "TEST", 27, 39], ["CO2", "TEST", 178, 181]]], ["The HIV gag-pol plasmid, p8.91, and the firefly luciferase reporter construct, pCSFLW, were transfected simultaneously with the EBOV (Mayinga) GP expression vector at a ratio of 0.6:0.9:0.6 \u00b5g (core:reporter:envelope) using 10 \u00b5l of 1 \u00b5g/ml polyethylenimine (PEI) (Sigma-Aldrich) per 1 \u00b5g DNA in Opti-MEM medium (Gibco).", [["polyethylenimine", "CHEMICAL", 241, 257], ["PEI", "CHEMICAL", 259, 262], ["polyethylenimine", "CHEMICAL", 241, 257], ["PEI", "CHEMICAL", 259, 262], ["HIV", "ORGANISM", 4, 7], ["gag", "GENE_OR_GENE_PRODUCT", 8, 11], ["luciferase", "GENE_OR_GENE_PRODUCT", 48, 58], ["pCSFLW", "GENE_OR_GENE_PRODUCT", 79, 85], ["EBOV", "ORGANISM", 128, 132], ["polyethylenimine", "SIMPLE_CHEMICAL", 241, 257], ["PEI", "SIMPLE_CHEMICAL", 259, 262], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 265, 278], ["DNA", "CELLULAR_COMPONENT", 289, 292], ["HIV gag-pol plasmid", "DNA", 4, 23], ["p8.91", "DNA", 25, 30], ["firefly luciferase reporter construct", "DNA", 40, 77], ["pCSFLW", "DNA", 79, 85], ["EBOV (Mayinga) GP expression vector", "DNA", 128, 163], ["HIV", "SPECIES", 4, 7], ["HIV", "SPECIES", 4, 7], ["EBOV", "SPECIES", 128, 132], ["The HIV gag", "TEST", 0, 11], ["pol plasmid", "TEST", 12, 23], ["the firefly luciferase reporter construct", "TEST", 36, 77], ["a ratio", "TEST", 167, 174], ["polyethylenimine (PEI", "TREATMENT", 241, 262], ["Sigma-Aldrich)", "TREATMENT", 265, 279]]], ["Following overnight transfection, the cells were incubated with fresh medium and incubated at 37 \u00b0C, 5% CO2.", [["cells", "ANATOMY", 38, 43], ["CO2", "CHEMICAL", 104, 107], ["CO2", "CHEMICAL", 104, 107], ["cells", "CELL", 38, 43], ["CO2", "SIMPLE_CHEMICAL", 104, 107]]], ["Pseudotyped virus supernatants were harvested at 48 and 72 h post-transfection, passed through a 0.45 \u00b5m pore filter (Millex, Millipore, Watford, UK) and stored at \u2212 80 \u00b0C.Production of pseudotyped viruses ::: MethodsEBOV GP pseudotyped VSVs were prepared using recombinant VSV, in which the VSV-G gene had been deleted (rVSV-\u0394G) and replaced with a luciferase reporter gene (rVSV-\u0394G-Luc) by a method similar to that described previously48.", [["supernatants", "ANATOMY", 18, 30], ["pseudotyped", "ORGANISM", 186, 197], ["pseudotyped", "ORGANISM", 225, 236], ["VSVs", "GENE_OR_GENE_PRODUCT", 237, 241], ["VSV", "ORGANISM", 274, 277], ["VSV-G", "GENE_OR_GENE_PRODUCT", 292, 297], ["luciferase", "GENE_OR_GENE_PRODUCT", 350, 360], ["rVSV-\u0394G-Luc", "GENE_OR_GENE_PRODUCT", 376, 387], ["VSV-G gene", "DNA", 292, 302], ["rVSV", "DNA", 321, 325], ["\u0394G", "DNA", 326, 328], ["luciferase reporter gene", "DNA", 350, 374], ["rVSV", "DNA", 376, 380], ["\u0394G", "DNA", 381, 383], ["Luc", "DNA", 384, 387], ["pseudotyped", "SPECIES", 225, 236], ["VSV", "SPECIES", 274, 277], ["Pseudotyped virus supernatants", "PROBLEM", 0, 30], ["a 0.45 \u00b5m pore filter", "TREATMENT", 95, 116], ["MethodsEBOV GP pseudotyped VSVs", "TREATMENT", 210, 241], ["recombinant VSV", "TREATMENT", 262, 277], ["rVSV", "TEST", 376, 380], ["pseudotyped viruses", "OBSERVATION", 186, 205]]], ["Twenty-four hours prior to transfection, approximately 2.4 \u00d7 106 293T/17 cells were seeded into sterile, 100 mm cell culture dishes (Corning) and incubated at 37 \u00b0C, 5% CO2 and 95% humidity until 60\u201380% confluence.", [["293T/17 cells", "ANATOMY", 65, 78], ["cell", "ANATOMY", 112, 116], ["CO2", "CHEMICAL", 169, 172], ["CO2", "CHEMICAL", 169, 172], ["293T/17 cells", "CELL", 65, 78], ["CO2", "SIMPLE_CHEMICAL", 169, 172], ["transfection", "TEST", 27, 39], ["CO2", "TEST", 169, 172]]], ["The cells were transfected with the EBOV GP expression vectors using TransIT-LT1 Transfection Reagent (Mirus Bio, Madison, Wisconsin (WI), USA) as per the manufacturer\u2019s instructions.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["EBOV", "ORGANISM", 36, 40], ["GP", "GENE_OR_GENE_PRODUCT", 41, 43], ["EBOV GP expression vectors", "DNA", 36, 62], ["EBOV", "SPECIES", 36, 40], ["the EBOV GP expression vectors", "TREATMENT", 32, 62], ["TransIT", "TEST", 69, 76]]], ["Following overnight transfection, the medium was removed and the cells were infected with rVSV-\u0394G-Luc that was pseudotyped with the VSV glycoprotein (rVSV-\u0394G-Luc-VSV-G) (Masayuki Saijo, National Institute of Infectious Diseases, Tokyo, Japan) at a multiplicity of infection (MOI) of 5 in Opti-MEM medium and incubated at 37 \u00b0C, 5% CO2.", [["cells", "ANATOMY", 65, 70], ["Infectious Diseases", "DISEASE", 208, 227], ["infection", "DISEASE", 264, 273], ["CO2", "CHEMICAL", 331, 334], ["CO2", "CHEMICAL", 331, 334], ["cells", "CELL", 65, 70], ["rVSV", "GENE_OR_GENE_PRODUCT", 90, 94], ["\u0394G", "GENE_OR_GENE_PRODUCT", 95, 97], ["Luc", "GENE_OR_GENE_PRODUCT", 98, 101], ["pseudotyped", "ORGANISM", 111, 122], ["VSV", "ORGANISM", 132, 135], ["rVSV", "ORGANISM", 150, 154], ["CO2", "SIMPLE_CHEMICAL", 331, 334], ["rVSV", "PROTEIN", 90, 94], ["\u0394G", "DNA", 95, 97], ["Luc", "DNA", 98, 101], ["VSV glycoprotein", "PROTEIN", 132, 148], ["rVSV", "PROTEIN", 150, 154], ["\u0394G", "PROTEIN", 155, 157], ["Luc", "PROTEIN", 158, 161], ["VSV", "PROTEIN", 162, 165], ["VSV", "SPECIES", 132, 135], ["the cells", "PROBLEM", 61, 70], ["rVSV", "TEST", 90, 94], ["pseudotyped", "PROBLEM", 111, 122], ["the VSV glycoprotein", "TEST", 128, 148], ["rVSV", "TEST", 150, 154], ["\u0394G", "TEST", 155, 157], ["infection", "PROBLEM", 264, 273], ["infection", "OBSERVATION", 264, 273]]], ["After 2 h, the inoculum was removed, cells were washed twice with Dulbecco\u2019s phosphate buffered saline (DPBS) (Gibco) and fresh medium was added.", [["cells", "ANATOMY", 37, 42], ["phosphate", "CHEMICAL", 77, 86], ["phosphate", "CHEMICAL", 77, 86], ["cells", "CELL", 37, 42], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 77, 102], ["the inoculum", "TREATMENT", 11, 23], ["cells", "TREATMENT", 37, 42], ["Dulbecco\u2019s phosphate buffered saline (DPBS", "TREATMENT", 66, 108], ["fresh medium", "TREATMENT", 122, 134]]], ["Pseudotyped virus supernatants were harvested at 18\u201324 h post-infection, clarified twice by centrifugation at 200xg for 5 min at 10 \u00b0C and stored at \u2212 80 \u00b0C. Prior to use, the pseudotyped viruses were incubated with anti-VSV-G hybridoma cell culture supernatant (Masayuki Saijo, National Institute of Infectious Diseases, Tokyo, Japan) at a 1:125 dilution for 1 h at 37 \u00b0C to reduce background infection mediated by residual virus possessing VSV-G, which can be carried over during preparation48.Production of pseudotyped viruses ::: MethodsAll experiments involving pseudotyped viruses were performed in a CL2 facility at Public Health England (PHE), Porton Down, UK.Pseudotyped virus titration and neutralisation assays ::: MethodsTitration and neutralisation assays were performed in 96-well solid white flat bottom polystyrene TC-treated microplates (Corning) and were based upon previously described protocols44,46,48.Pseudotyped virus titration and neutralisation assays ::: MethodsFor pseudotyped HIV-1 titration assays, five-fold serial dilutions of pseudotyped virus at a starting dilution of 1:5 were prepared in quadruplicate in Opti-MEM medium at a final volume of 100 \u00b5l/well.", [["supernatants", "ANATOMY", 18, 30], ["cell", "ANATOMY", 237, 241], ["supernatant", "ANATOMY", 250, 261], ["infection", "DISEASE", 62, 71], ["Infectious Diseases", "DISEASE", 301, 320], ["infection", "DISEASE", 394, 403], ["polystyrene TC", "CHEMICAL", 819, 833], ["polystyrene", "CHEMICAL", 819, 830], ["pseudotyped", "ORGANISM", 176, 187], ["anti-VSV-G hybridoma cell", "CELL", 216, 241], ["VSV", "ORGANISM", 442, 445], ["-G", "GENE_OR_GENE_PRODUCT", 445, 447], ["pseudotyped", "ORGANISM", 510, 521], ["pseudotyped", "ORGANISM", 567, 578], ["polystyrene TC", "SIMPLE_CHEMICAL", 819, 833], ["pseudotyped", "ORGANISM", 992, 1003], ["HIV-1", "ORGANISM", 1004, 1009], ["pseudotyped", "ORGANISM", 1058, 1069], ["HIV-1", "SPECIES", 1004, 1009], ["anti-VSV", "SPECIES", 216, 224], ["VSV", "SPECIES", 442, 445], ["HIV-1", "SPECIES", 1004, 1009], ["pseudotyped virus", "SPECIES", 1058, 1075], ["Pseudotyped virus supernatants", "PROBLEM", 0, 30], ["infection", "PROBLEM", 62, 71], ["the pseudotyped viruses", "PROBLEM", 172, 195], ["anti-VSV", "TEST", 216, 224], ["G hybridoma cell culture", "TEST", 225, 249], ["background infection", "PROBLEM", 383, 403], ["residual virus", "PROBLEM", 416, 430], ["Methods", "TREATMENT", 534, 541], ["pseudotyped viruses", "PROBLEM", 567, 586], ["Pseudotyped virus titration", "TREATMENT", 668, 695], ["neutralisation assays", "TEST", 700, 721], ["MethodsTitration", "TEST", 726, 742], ["neutralisation assays", "TEST", 747, 768], ["Pseudotyped virus titration", "TREATMENT", 923, 950], ["neutralisation assays", "TEST", 955, 976], ["Methods", "TEST", 981, 988], ["pseudotyped HIV", "TEST", 992, 1007], ["titration assays", "TEST", 1010, 1026], ["pseudotyped virus", "PROBLEM", 1058, 1075], ["a starting dilution", "TREATMENT", 1079, 1098], ["infection", "OBSERVATION", 62, 71], ["pseudotyped viruses", "OBSERVATION", 176, 195], ["hybridoma cell", "OBSERVATION", 227, 241], ["infection", "OBSERVATION", 394, 403], ["pseudotyped viruses", "OBSERVATION", 510, 529], ["pseudotyped viruses", "OBSERVATION", 567, 586]]], ["100 \u00b5l of approximately 2 \u00d7 104 293T/17, Huh-7 or Vero E6 cells, or 1 \u00d7 104 HeLa cells were then added to each well and incubated at 37 \u00b0C, 5% CO2 for 48 h.", [["293T/17", "ANATOMY", 32, 39], ["Huh-7", "ANATOMY", 41, 46], ["Vero E6 cells", "ANATOMY", 50, 63], ["HeLa cells", "ANATOMY", 76, 86], ["CO2", "CHEMICAL", 143, 146], ["CO2", "CHEMICAL", 143, 146], ["Huh-7", "CELL", 41, 46], ["Vero E6 cells", "CELL", 50, 63], ["HeLa cells", "CELL", 76, 86], ["CO2", "SIMPLE_CHEMICAL", 143, 146], ["Huh-7", "CELL_LINE", 41, 46], ["Vero E6 cells", "CELL_LINE", 50, 63], ["1 \u00d7 104 HeLa cells", "CELL_LINE", 68, 86], ["Vero E6", "SPECIES", 50, 57], ["Huh", "TEST", 41, 44], ["Vero E6 cells", "TEST", 50, 63], ["HeLa cells", "TEST", 76, 86]]], ["The medium was removed and 50 \u00b5l of a 50:50 mix of Bright-Glo luciferase assay reagent (Promega, Southampton, UK):fresh medium was added to each well and incubated for at least 2 min at room temperature to allow complete cell lysis.", [["cell", "ANATOMY", 221, 225], ["luciferase", "GENE_OR_GENE_PRODUCT", 62, 72], ["cell", "CELL", 221, 225], ["Bright-Glo luciferase assay reagent", "TREATMENT", 51, 86], ["fresh medium", "TREATMENT", 114, 126], ["complete cell lysis", "TREATMENT", 212, 231], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["cell lysis", "OBSERVATION", 221, 231]]], ["Luminescence was measured using a Glomax-Multi + detection system luminometer (Promega) and relative luminescence units per ml (RLU/ml) were determined.", [["Luminescence", "TEST", 0, 12], ["a Glomax", "TREATMENT", 32, 40], ["Multi + detection system luminometer", "TREATMENT", 41, 77]]], ["The negative cut-off was set at 2.5 times the average RLUs of the cells only control wells.", [["cells", "ANATOMY", 66, 71], ["cells", "CELL", 66, 71], ["negative", "OBSERVATION_MODIFIER", 4, 12], ["cut", "OBSERVATION_MODIFIER", 13, 16]]], ["50% tissue culture infectious dose (TCID50)/ml values were determined using the Reed-Muench method49.Pseudotyped virus titration and neutralisation assays ::: MethodsFor the pseudotyped HIV-1 neutralisation assay, two or threefold serial dilutions of plasma samples at a starting dilution of 1:5 or 1:10, respectively, were prepared in duplicate in Opti-MEM medium at a final volume of 50 \u00b5l/well and incubated with 50 \u00b5l of a standardised RLU per well of pseudotyped virus (as calculated from the titration assay), prepared in Opti-MEM medium, for 1 h at 37 \u00b0C. 100 \u00b5l of approximately 2 \u00d7 105 293T/17 cells were then added to each well and incubated for 48 h at 37 \u00b0C, 5% CO2, prior to taking a chemiluminescent readout as described above.", [["tissue culture", "ANATOMY", 4, 18], ["plasma samples", "ANATOMY", 251, 265], ["293T/17 cells", "ANATOMY", 595, 608], ["CO2", "CHEMICAL", 674, 677], ["CO2", "CHEMICAL", 674, 677], ["tissue", "TISSUE", 4, 10], ["pseudotyped", "ORGANISM", 174, 185], ["HIV-1", "ORGANISM", 186, 191], ["plasma samples", "ORGANISM_SUBSTANCE", 251, 265], ["pseudotyped", "ORGANISM", 456, 467], ["293T/17 cells", "CELL", 595, 608], ["CO2", "SIMPLE_CHEMICAL", 674, 677], ["Reed-Muench method49", "DNA", 80, 100], ["pseudotyped", "SPECIES", 174, 185], ["HIV-1", "SPECIES", 186, 191], ["HIV-1", "SPECIES", 186, 191], ["pseudotyped virus", "SPECIES", 456, 473], ["tissue culture", "TEST", 4, 18], ["ml values", "TEST", 44, 53], ["the Reed-Muench method49", "TREATMENT", 76, 100], ["Pseudotyped virus titration", "TREATMENT", 101, 128], ["neutralisation assays", "TEST", 133, 154], ["Methods", "TREATMENT", 159, 166], ["the pseudotyped HIV", "TEST", 170, 189], ["neutralisation assay", "TEST", 192, 212], ["plasma samples", "TEST", 251, 265], ["a standardised RLU", "TREATMENT", 425, 443], ["pseudotyped virus", "TREATMENT", 456, 473], ["the titration assay", "TEST", 494, 513], ["a chemiluminescent readout", "TEST", 695, 721]]], ["Infectivity was calculated using the formula: Percentage (%) infectivity = [(RLU with sample)/(RLU without sample)] \u00d7 100.Pseudotyped virus titration and neutralisation assays ::: MethodsFor pseudotyped VSV titration assays, 24 h prior, approximately 2.5 \u00d7 104 293T/17 or 1 \u00d7 104 Huh-7, HeLa cells or Vero E6 cells were seeded in 96-well microplates and incubated at 37 \u00b0C, 5% CO2 and 95% humidity.", [["Huh-7", "ANATOMY", 280, 285], ["HeLa cells", "ANATOMY", 287, 297], ["Vero E6 cells", "ANATOMY", 301, 314], ["CO2", "CHEMICAL", 377, 380], ["CO2", "CHEMICAL", 377, 380], ["pseudotyped", "ORGANISM", 191, 202], ["VSV", "ORGANISM", 203, 206], ["Huh-7", "CELL", 280, 285], ["HeLa cells", "CELL", 287, 297], ["Vero E6 cells", "CELL", 301, 314], ["CO2", "SIMPLE_CHEMICAL", 377, 380], ["HeLa cells", "CELL_LINE", 287, 297], ["Vero E6 cells", "CELL_LINE", 301, 314], ["VSV", "SPECIES", 203, 206], ["Vero E6", "SPECIES", 301, 308], ["Percentage", "TEST", 46, 56], ["sample", "TEST", 86, 92], ["Pseudotyped virus titration", "TREATMENT", 122, 149], ["neutralisation assays", "TEST", 154, 175], ["pseudotyped VSV titration assays", "TEST", 191, 223], ["Huh", "TEST", 280, 283], ["HeLa cells", "TEST", 287, 297], ["Vero E6 cells", "TEST", 301, 314], ["CO2", "TEST", 377, 380]]], ["The medium was removed and two-fold serial dilutions of pseudotyped virus in Opti-MEM medium, starting with neat pseudotyped virus were added to each well in quadruplicate at a final volume of 100 \u00b5l/well.", [["pseudotyped", "ORGANISM", 56, 67], ["pseudotyped", "ORGANISM", 113, 124], ["two-fold serial dilutions", "TREATMENT", 27, 52], ["pseudotyped virus in Opti-MEM medium", "TREATMENT", 56, 92], ["neat pseudotyped virus", "TREATMENT", 108, 130], ["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["After 24 h, a chemiluminescent readout was taken and TCID50/ml values were determined as described above.Pseudotyped virus titration and neutralisation assays ::: MethodsTwenty-four hours prior to pseudotyped VSV neutralisation, approximately 1 \u00d7 104 Vero E6 cells were seeded and incubated as for titration above.", [["cells", "ANATOMY", 259, 264], ["pseudotyped", "ORGANISM", 197, 208], ["VSV", "ORGANISM", 209, 212], ["E6", "ORGANISM", 256, 258], ["cells", "CELL", 259, 264], ["Vero E6 cells", "CELL_LINE", 251, 264], ["VSV", "SPECIES", 209, 212], ["a chemiluminescent readout", "TEST", 12, 38], ["TCID50/ml values", "TEST", 53, 69], ["Pseudotyped virus titration", "TREATMENT", 105, 132], ["neutralisation assays", "TEST", 137, 158], ["pseudotyped VSV neutralisation", "TREATMENT", 197, 227], ["Vero E6 cells", "TREATMENT", 251, 264]]], ["Twofold serial dilutions of plasma samples at a starting dilution of 1:10 were prepared in duplicate in Opti-MEM medium at a final volume of 120 \u00b5l/well in 96-well microplates, and incubated with 120 \u00b5l of a standardised RLU per well of pseudotyped virus (as calculated from the titration assay), prepared in Opti-MEM medium, for 1 h at 37 \u00b0C. The medium was removed from the cells, 50 \u00b5l of the plasma-pseudotyped virus mixtures were added to each well in quadruplicate at incubated at 37 \u00b0C, 5% CO2.", [["plasma samples", "ANATOMY", 28, 42], ["cells", "ANATOMY", 376, 381], ["plasma", "ANATOMY", 396, 402], ["CO2", "CHEMICAL", 497, 500], ["CO2", "CHEMICAL", 497, 500], ["plasma samples", "ORGANISM_SUBSTANCE", 28, 42], ["pseudotyped", "ORGANISM", 237, 248], ["cells", "CELL", 376, 381], ["plasma", "ORGANISM_SUBSTANCE", 396, 402], ["CO2", "SIMPLE_CHEMICAL", 497, 500], ["pseudotyped virus", "SPECIES", 237, 254], ["plasma samples", "TEST", 28, 42], ["a starting dilution", "TREATMENT", 46, 65], ["a standardised RLU", "TREATMENT", 206, 224], ["pseudotyped virus", "PROBLEM", 237, 254], ["the titration assay", "TEST", 275, 294], ["the plasma-pseudotyped virus mixtures", "TREATMENT", 392, 429], ["medium", "OBSERVATION_MODIFIER", 348, 354]]], ["After 1 h, 50 \u00b5l of fresh medium was added to each well.", [["fresh medium", "TREATMENT", 20, 32]]], ["Luminescence was measured after 24 h and infectivity was calculated as described above.Statistical analysis ::: MethodsPseudotyped virus neutralisation assay raw data were normalised as percentage (%) infection relative to mean values for pseudotyped virus only controls (equivalent to 100% infection), then IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear regression fit with settings for log (inhibitor) vs. normalised response curves using GraphPad Prism v5 (San Diego, California (CA), USA).Statistical analysis ::: MethodsStatistical comparison between two unpaired groups was performed using the Mann\u2013Whitney test (GraphPad Prism v5).", [["infection", "DISEASE", 201, 210], ["infection", "DISEASE", 291, 300], ["pseudotyped", "ORGANISM", 316, 327], ["infectivity", "PROBLEM", 41, 52], ["Statistical analysis", "TEST", 87, 107], ["MethodsPseudotyped virus neutralisation assay", "TEST", 112, 157], ["percentage (%) infection", "PROBLEM", 186, 210], ["mean values", "TEST", 223, 234], ["pseudotyped virus", "PROBLEM", 239, 256], ["pseudotyped virus neutralisation", "TREATMENT", 316, 348], ["log (inhibitor", "TREATMENT", 419, 433], ["normalised response curves", "TEST", 439, 465], ["the Mann\u2013Whitney test", "TEST", 627, 648]]], ["Correlation between two variables was quantified using Spearman nonparametric correlation (GraphPad Prism v5).", [["Spearman nonparametric correlation", "TEST", 55, 89]]]], "e67a3d69e75c26be4e832ce5c07e0e923c2b69ee": [["INTRODUCTIONIn November, 2002, the first cases of a severe respiratory disease emerged in the Guangdong province of China, and by March, 2003 , this translated into a worldwide outbreak of severe acute respiratory syndrome (SARS).", [["respiratory", "ANATOMY", 59, 70], ["respiratory disease", "DISEASE", 59, 78], ["acute respiratory syndrome", "DISEASE", 196, 222], ["SARS", "DISEASE", 224, 228], ["a severe respiratory disease", "PROBLEM", 50, 78], ["severe acute respiratory syndrome", "PROBLEM", 189, 222], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["respiratory disease", "OBSERVATION", 59, 78], ["severe", "OBSERVATION_MODIFIER", 189, 195], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["respiratory syndrome", "OBSERVATION", 202, 222]]], ["The ensuing search for the cause of the disease led to identification of a novel coronavirus Ksiazek et al., 2003 ].", [["the disease", "PROBLEM", 36, 47], ["disease", "OBSERVATION", 40, 47]]], ["This was closely followed by genomic characterization of the virus [Marra et al., 2003; Rota et al., 2003] , and subsequent confirmation that the new SARS-associated coronavirus (SARS-CoV: order Nidovirales, family Coronaviridae, genus Coronavirus) fulfils Koch's postulates for SARS disease .INTRODUCTIONSeveral diagnostic assays were developed in response to the outbreak to determine the most sensitive and accurate method for early detection of SARS.", [["SARS", "DISEASE", 150, 154], ["SARS disease", "DISEASE", 279, 291], ["SARS", "DISEASE", 449, 453], ["coronavirus", "ORGANISM", 166, 177], ["SARS-CoV", "ORGANISM", 179, 187], ["coronavirus", "SPECIES", 166, 177], ["SARS-CoV", "SPECIES", 179, 187], ["the new SARS", "PROBLEM", 142, 154], ["coronavirus", "PROBLEM", 166, 177], ["Nidovirales", "TREATMENT", 195, 206], ["Coronaviridae", "TREATMENT", 215, 228], ["SARS disease", "PROBLEM", 279, 291], ["diagnostic assays", "TEST", 313, 330], ["SARS", "PROBLEM", 449, 453], ["coronavirus", "OBSERVATION", 166, 177]]], ["Culture detection of live SARS-CoV requires biosafety level three facilities and expertise, which severely limits the number of facilities or institutions in which it can be performed.", [["SARS", "DISEASE", 26, 30], ["SARS-CoV", "ORGANISM", 26, 34], ["SARS-CoV", "SPECIES", 26, 34], ["Culture detection", "TEST", 0, 17], ["live SARS", "TEST", 21, 30]]], ["In addition, cell culture isolation of SARS-CoV is not as sensitive as detection by real-time RT-PCR [Emery et al., 2004] .", [["cell", "ANATOMY", 13, 17], ["SARS", "DISEASE", 39, 43], ["cell", "CELL", 13, 17], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS-CoV", "SPECIES", 39, 47], ["cell culture", "TEST", 13, 25], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47]]], ["Conversely, serological methods have been shown to be sensitive for confirmation of infection but detection of antibodies occurs late in the course of illness, which limits their efficacy for early detection and disease control .", [["infection", "DISEASE", 84, 93], ["illness", "DISEASE", 151, 158], ["antibodies", "PROTEIN", 111, 121], ["serological methods", "TEST", 12, 31], ["infection", "PROBLEM", 84, 93], ["antibodies", "PROBLEM", 111, 121], ["illness", "PROBLEM", 151, 158], ["disease control", "TREATMENT", 212, 227], ["infection", "OBSERVATION", 84, 93]]], ["The focus of early diagnosis has therefore centered on the development of molecular-based assays including conventional as well as real-time reverse transcription-polymerase chain reaction (RT-PCR) methods.", [["polymerase chain reaction", "PROBLEM", 163, 188], ["RT-PCR) methods", "TREATMENT", 190, 205], ["early", "OBSERVATION_MODIFIER", 13, 18]]], ["It has been suggested that these provide the greatest sensitivity for testing within the first 2 weeks of infection [Wu et al., 2004] .", [["infection", "DISEASE", 106, 115], ["testing", "TEST", 70, 77], ["infection", "PROBLEM", 106, 115]]], ["Studies have found that realtime RT-PCR is more sensitive [Emery et al., 2004; Jiang et al., 2004; Poon et al., 2004] , and is less likely to produce cross contamination of samples compared to end-point RT-PCR.", [["samples", "ANATOMY", 173, 180], ["Studies", "TEST", 0, 7], ["realtime RT-PCR", "TEST", 24, 39], ["cross contamination of samples", "PROBLEM", 150, 180], ["less likely", "UNCERTAINTY", 127, 138]]], ["Nested PCR assays have also been described Yam et al., 2003; Jiang et al., 2004] but they carry an inherently high risk of sample cross contamination.INTRODUCTIONGiven the very low viral load at disease onset , maximum assay sensitivity is crucial for early SARS-CoV detection.", [["SARS-CoV", "SPECIES", 258, 266], ["Nested PCR assays", "TEST", 0, 17], ["sample cross contamination", "PROBLEM", 123, 149], ["the very low viral load at disease onset", "PROBLEM", 168, 208], ["maximum assay sensitivity", "TEST", 211, 236], ["early SARS", "PROBLEM", 252, 262], ["CoV detection", "TEST", 263, 276]]], ["Nucleic acid sequence-based amplification (NASBA) has been developed specifically to detect RNA and is more sensitive than RT-PCR for the detection of some RNA viruses [Lanciotti and Kerst, 2001; Ginocchio et al., 2003] .", [["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid sequence", "TEST", 0, 21], ["NASBA", "TEST", 43, 48], ["RNA", "PROBLEM", 92, 95], ["RT-PCR", "TEST", 123, 129], ["the detection", "TEST", 134, 147], ["some RNA viruses", "PROBLEM", 151, 167], ["RNA viruses", "OBSERVATION", 156, 167]]], ["We therefore developed a real-time NASBA SARS-CoV assay and evaluated it in comparison with the real-time RT-PCR assays developed at the Centers for Disease Control (CDC) Emery et al., 2004] .SARS-CoV RNAHigh titer whole genome material (Urbani strain) was kindly provided by Dean Erdman, CDC, Atlanta, GA in Trizol.", [["SARS", "DISEASE", 192, 196], ["GA", "CHEMICAL", 303, 305], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 192, 200], ["SARS-CoV", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 192, 200], ["CoV assay", "TEST", 46, 55], ["PCR assays", "TEST", 109, 119], ["SARS", "TEST", 192, 196], ["Urbani strain", "TREATMENT", 238, 251], ["Trizol", "TREATMENT", 309, 315]]], ["Ten microlitre aliquots were transferred to 0.9 ml NucliSens Lysis Buffer (bioM\u00e9rieux, Durham, NC) and stored at \u00c0808C prior to extraction.", [["Ten microlitre aliquots", "TREATMENT", 0, 23], ["NC", "TREATMENT", 95, 97], ["extraction", "TREATMENT", 128, 138]]], ["The 200 nt in vitro transcribed SARS-CoV RNA fragment was kindly provided by Christian Drosten, Bernhard-Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany , reconstituted at an estimated 10 8 copies/ml, and aliquots stored at \u00c0808C.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["200 nt in vitro transcribed SARS-CoV RNA fragment", "DNA", 4, 53], ["SARS-CoV", "SPECIES", 32, 40], ["CoV RNA fragment", "PROBLEM", 37, 53], ["Tropical Medicine", "TREATMENT", 125, 142]]], ["Hong Kong and Frankfurt isolates of SARS-CoV were kindly provided by Mathias Niedrig as part of a European Quality Assurance (EQA) study.", [["SARS", "DISEASE", 36, 40], ["SARS-CoV", "ORGANISM", 36, 44], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40]]], ["Three Vietnamese SARS-CoV isolates were kindly provided by Dean Erdman as extracted nucleic acid material.", [["SARS", "DISEASE", 17, 21], ["nucleic acid", "CHEMICAL", 84, 96], ["CoV", "ORGANISM", 22, 25], ["SARS-CoV", "SPECIES", 17, 25], ["nucleic acid material", "PROBLEM", 84, 105]]], ["229E and OC43 human respiratory coronaviruses were obtained from the American Type Culture Collection (Manassas, VA).RNA PreparationSamples in 0.9 ml of lysis buffer (bioM\u00e9rieux) were extracted on a NucliSens Extractor (bioM\u00e9rieux) according to the manufacturer's instructions, yielding an approximate eluate volume of 50 ml, and 5 ml of total nucleic acid was used per amplification reaction.Real-Time NASBAMultiple upstream and downstream primers targeting the SARS-CoV (Urbani strain AY278741) polymerase gene (Pol), the nucleocapsid (N), 5 0 -Leader (5 0 -L), and 3 0 -non-coding (3 0 -NCR) regions, along with corresponding beacons, 5 0 -6-FAM labeled and quenched by 3 0 -Dabcyl, were designed for real-time detection of SARS-CoV RNA (Table I) .", [["respiratory coronaviruses", "DISEASE", 20, 45], ["nucleic acid", "CHEMICAL", 344, 356], ["3 0 -Dabcyl", "CHEMICAL", 673, 684], ["OC43", "ORGANISM", 9, 13], ["human", "ORGANISM", 14, 19], ["coronaviruses", "ORGANISM", 32, 45], ["nucleic acid", "SIMPLE_CHEMICAL", 344, 356], ["SARS-CoV", "ORGANISM", 463, 471], ["Urbani strain AY278741) polymerase", "GENE_OR_GENE_PRODUCT", 473, 507], ["Pol", "GENE_OR_GENE_PRODUCT", 514, 517], ["-6-FAM", "SIMPLE_CHEMICAL", 642, 648], ["3 0 -Dabcyl", "SIMPLE_CHEMICAL", 673, 684], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 727, 735], ["Real-Time NASBAMultiple upstream", "DNA", 393, 425], ["SARS-CoV (Urbani strain AY278741) polymerase gene", "DNA", 463, 512], ["Pol", "DNA", 514, 517], ["3 0 -non-coding (3 0 -NCR) regions", "DNA", 568, 602], ["5 0 -6", "DNA", 638, 644], ["SARS-CoV RNA", "RNA", 727, 739], ["human", "SPECIES", 14, 19], ["human respiratory coronaviruses", "SPECIES", 14, 45], ["SARS-CoV", "SPECIES", 463, 471], ["SARS-CoV", "SPECIES", 727, 735], ["OC43 human respiratory coronaviruses", "PROBLEM", 9, 45], ["RNA PreparationSamples", "TREATMENT", 117, 139], ["lysis buffer (bioM\u00e9rieux", "TREATMENT", 153, 177], ["a NucliSens Extractor (bioM\u00e9rieux)", "TREATMENT", 197, 231], ["an approximate eluate volume", "TREATMENT", 287, 315], ["total nucleic acid", "TREATMENT", 338, 356], ["downstream primers", "TEST", 430, 448], ["the SARS", "TEST", 459, 467], ["CoV (Urbani strain", "TEST", 468, 486], ["SARS", "PROBLEM", 727, 731], ["respiratory coronaviruses", "OBSERVATION", 20, 45]]], ["Different combinations and concentrations of the primers were tested to optimize the assay using NucliSens Basic Kit reagents (bioM\u00e9rieux) according to the manufacturer's instructions.", [["the primers", "TREATMENT", 45, 56], ["the assay", "TEST", 81, 90], ["NucliSens Basic Kit reagents", "TREATMENT", 97, 125]]], ["Briefly, a reagent sphere was dissolved in diluent to which KCl (80 mM final concentration) and water were added.", [["KCl", "CHEMICAL", 60, 63], ["KCl", "CHEMICAL", 60, 63], ["KCl", "SIMPLE_CHEMICAL", 60, 63], ["water", "SIMPLE_CHEMICAL", 96, 101], ["a reagent sphere", "TREATMENT", 9, 25], ["KCl", "TREATMENT", 60, 63], ["water", "TREATMENT", 96, 101]]], ["Five microlitres of nucleic acid was added to 10 ml of this reagent mix and incubated at 658C for 2 min then 418C for 2 min.", [["nucleic acid", "CHEMICAL", 20, 32], ["nucleic acid", "SIMPLE_CHEMICAL", 20, 32], ["nucleic acid", "TREATMENT", 20, 32], ["this reagent mix", "TREATMENT", 55, 71]]], ["Five microlitres of reconstituted enzymes was then added, and samples were transferred to the NucliSens EasyQ Analyzer (bioM\u00e9rieux).", [["samples", "ANATOMY", 62, 69], ["reconstituted enzymes", "PROTEIN", 20, 41]]], ["The isothermal real-time NASBA reaction continued at 418C for 90 min, and fluorescence was measured every 45 sec.Real-Time NASBAprimers contain a T7 RNA polymerase promoter sequence in lower case, and the stem sequence for the molecular beacons is also shown in lower case.CDC Real-Time RT-PCRReal-time RT-PCR was performed with a first generation primer/probe set (Qiagen, Germantown, MD), for which sequences were obtained from the CDC, targeting the SARS-CoV polymerase gene (see Table II ).", [["418C", "CHEMICAL", 53, 57], ["SARS-CoV polymerase", "GENE_OR_GENE_PRODUCT", 453, 472], ["Real-Time NASBAprimers", "DNA", 113, 135], ["T7 RNA polymerase promoter sequence", "DNA", 146, 181], ["stem sequence", "DNA", 205, 218], ["SARS-CoV polymerase gene", "DNA", 453, 477], ["SARS-CoV", "SPECIES", 453, 461], ["The isothermal", "TEST", 0, 14], ["NASBA reaction", "TEST", 25, 39], ["fluorescence", "TEST", 74, 86], ["a T7 RNA polymerase promoter sequence", "TREATMENT", 144, 181], ["the molecular beacons", "PROBLEM", 223, 244], ["RT-PCR", "TEST", 303, 309], ["a first generation primer", "TREATMENT", 329, 354], ["the CDC", "TEST", 430, 437], ["the SARS", "TEST", 449, 457]]], ["In accordance with the protocol, 5 ml sample was added to a mix containing a final concentration of 1 \u00c2 RT-PCR reaction mix (Invitrogen, Carlsbad, CA), 5 mM MgSO 4 , 250 nM forward and reverse primers, 200 nM 5 0 -FAM labeled Taqman probe quenched with 3 0 -TAMRA, and 0.5 U SS-RT/Taq (Invitrogen, Carlsbad, CA).", [["sample", "ANATOMY", 38, 44], ["MgSO", "CHEMICAL", 157, 161], ["5 0 -FAM", "CHEMICAL", 209, 217], ["3 0 -TAMRA", "CHEMICAL", 253, 263], ["FAM", "SIMPLE_CHEMICAL", 214, 217], ["RT-PCR reaction mix", "TREATMENT", 104, 123], ["Invitrogen", "TEST", 125, 135], ["RT/Taq (Invitrogen", "TREATMENT", 278, 296]]], ["An initial primer and probe titration was performed to confirm primer/probe concentrations (results not shown).", [["An initial primer and probe titration", "TREATMENT", 0, 37], ["primer/probe concentrations", "TEST", 63, 90]]], ["Cycling conditions were as follows: (508C, 30 min; 948C, 5 min) \u00c2 1 followed by (958C, 15 sec; 608C, 1 min) \u00c2 40, and reactions were carried out on an ABI Prism 7000 (Applied Biosystems, Foster City, CA).", [["an ABI Prism", "TEST", 148, 160]]], ["A second generation multi-target assay (kindly provided by Dean Erdman, CDC, Atlanta) including N-target primer/probe sets [see Table II ; Emery et al., 2004] was carried out as directed (CDC) with Taqman One-Step RT-PCR Master Mix Reagents (Applied Biosystems, Foster City, CA) under the following conditions: (488C, 30 min; 958C, 10 min) \u00c2 1 followed by (958C, 15 sec; 608C, 1 min) \u00c2 45.RESULTSMolecular testing for SARS-CoV was developed using real-time NASBA and was compared to a real-time RT-PCR assay developed by the CDC.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 418, 426], ["N-target primer", "DNA", 96, 111], ["SARS-CoV", "SPECIES", 418, 426], ["Taqman One-Step RT", "TREATMENT", 198, 216], ["RESULTSMolecular testing", "TEST", 389, 413], ["SARS", "PROBLEM", 418, 422], ["CoV", "PROBLEM", 423, 426], ["a real-time RT-PCR assay", "TEST", 483, 507]]], ["The first generation Pol 1 NASBA primer set was tested on whole genome Urbani strain and BNITM SARS-CoV transcript as well as the 229E and OC43 human respiratory coronaviruses to determine assay specificity.", [["Pol 1", "GENE_OR_GENE_PRODUCT", 21, 26], ["BNITM SARS-CoV", "ORGANISM", 89, 103], ["OC43", "ORGANISM", 139, 143], ["human", "ORGANISM", 144, 149], ["Pol 1 NASBA primer set", "DNA", 21, 43], ["BNITM SARS-CoV transcript", "RNA", 89, 114], ["human", "SPECIES", 144, 149], ["BNITM SARS-CoV", "SPECIES", 89, 103], ["human respiratory coronaviruses", "SPECIES", 144, 175], ["The first generation Pol", "TREATMENT", 0, 24], ["whole genome Urbani strain", "TREATMENT", 58, 84], ["OC43 human respiratory coronaviruses", "TEST", 139, 175], ["assay specificity", "TEST", 189, 206]]], ["Data in Figure 1 demonstrate that the NASBA-based test is specific, and does not cross-react with the non-SARS 229E and OC43 coronavirus materials, whereas both Urbani and BNITM control RNAs are positive.", [["OC43 coronavirus", "ORGANISM", 120, 136], ["Urbani and BNITM control RNAs", "RNA", 161, 190], ["OC43 coronavirus", "SPECIES", 120, 136], ["the NASBA", "TEST", 34, 43], ["OC43 coronavirus materials", "PROBLEM", 120, 146], ["Urbani", "TEST", 161, 167]]], ["Whole blood and bronchoalveolar lavage (BAL) samples from a suspected SARS case that presented at the University of Pittsburgh Medical Center in May, 2003 were also screened by this assay (Fig. 1) .", [["Whole blood", "ANATOMY", 0, 11], ["bronchoalveolar lavage (BAL) samples", "ANATOMY", 16, 52], ["SARS", "DISEASE", 70, 74], ["Whole blood", "ORGANISM_SUBSTANCE", 0, 11], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 16, 38], ["BAL) samples", "CANCER", 40, 52], ["Whole blood", "TEST", 0, 11], ["bronchoalveolar lavage", "TEST", 16, 38], ["bronchoalveolar lavage", "OBSERVATION", 16, 38]]], ["The patient was negative for SARS-CoV by NASBA testing and subsequently shown to be negative for serum antibodies by the CDC (data not shown).RESULTSBecause of the potential mutation rate of SARS-CoV and possible corresponding difficulties in viral detection, several primer/beacon sets were designed to target a number of different regions in the genome.", [["serum", "ANATOMY", 97, 102], ["SARS", "DISEASE", 191, 195], ["patient", "ORGANISM", 4, 11], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 191, 199], ["genome", "CELLULAR_COMPONENT", 348, 354], ["serum antibodies", "PROTEIN", 97, 113], ["patient", "SPECIES", 4, 11], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 191, 199], ["SARS", "PROBLEM", 29, 33], ["NASBA testing", "TEST", 41, 54], ["serum antibodies", "TEST", 97, 113], ["the CDC", "TEST", 117, 124], ["SARS", "PROBLEM", 191, 195], ["CoV", "PROBLEM", 196, 199], ["corresponding difficulties in viral detection", "PROBLEM", 213, 258], ["several primer/beacon sets", "PROBLEM", 260, 286], ["genome", "ANATOMY", 348, 354]]], ["These sets were optimized by evaluating different combinations for each target, and optimized primer/beacon combinations were then tested on a 10-fold dilution series of cultured SARS-CoV RNA (derived from the Frankfurt SARS index case) (Fig. 2) .", [["CoV", "ORGANISM", 184, 187], ["cultured SARS-CoV RNA", "RNA", 170, 191], ["SARS-CoV", "SPECIES", 179, 187], ["optimized primer/beacon combinations", "TREATMENT", 84, 120], ["a 10-fold dilution series", "TREATMENT", 141, 166], ["cultured SARS", "TEST", 170, 183], ["CoV RNA", "PROBLEM", 184, 191]]], ["Initial analysis indicated the Pol 1 and N2 primer sets gave the greatest sensitivity followed by the Pol 2 set as defined by detection of these targets at the highest dilution of SARS-CoV RNA.", [["Pol 1", "GENE_OR_GENE_PRODUCT", 31, 36], ["Pol 2", "GENE_OR_GENE_PRODUCT", 102, 107], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 180, 188], ["Pol 1 and N2 primer sets", "DNA", 31, 55], ["Pol 2 set", "DNA", 102, 111], ["SARS-CoV RNA", "RNA", 180, 192], ["SARS-CoV", "SPECIES", 180, 188], ["Initial analysis", "TEST", 0, 16], ["the Pol", "TREATMENT", 27, 34], ["N2 primer sets", "TEST", 41, 55], ["SARS", "PROBLEM", 180, 184], ["CoV RNA", "PROBLEM", 185, 192], ["CoV RNA", "OBSERVATION", 185, 192]]], ["None of the primer sets demonstrated cross-reactivity with other clinically relevant viruses [Zhang et al., 2004] .", [["the primer sets", "TEST", 8, 23], ["other clinically relevant viruses", "PROBLEM", 59, 92]]], ["Differences in signal amplitude between the various targets are a function of the individual kinetics of a given primer/probe set interaction with its target and do not relate to sensitivity since the assay is not quantitative.", [["a given primer/probe set interaction", "TREATMENT", 105, 141], ["the assay", "TEST", 197, 206], ["amplitude", "OBSERVATION_MODIFIER", 22, 31]]], ["In order to establish a negative cut-off for the assay, nine SARS-CoV negative respiratory samples were tested, and a fluorescence value greater than the average of the negative controls plus four standard deviations was defined as positive for the assay.RESULTSIn the absence of access to abundant positive clinical samples and given the inherent differences between transcript and genomic RNA, we tested the performance of the different NASBA primer/beacon sets with several SARS-CoV isolates.", [["respiratory samples", "ANATOMY", 79, 98], ["samples", "ANATOMY", 317, 324], ["SARS-CoV", "ORGANISM", 61, 69], ["SARS-CoV", "ORGANISM", 477, 485], ["genomic RNA", "RNA", 383, 394], ["NASBA primer", "DNA", 439, 451], ["SARS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 477, 485], ["the assay", "TEST", 45, 54], ["nine SARS", "TEST", 56, 65], ["a fluorescence value", "TEST", 116, 136], ["the assay", "TEST", 245, 254], ["abundant positive clinical samples", "PROBLEM", 290, 324], ["the inherent differences between transcript and genomic RNA", "PROBLEM", 335, 394], ["the different NASBA primer", "TREATMENT", 425, 451], ["CoV isolates", "TREATMENT", 482, 494], ["genomic RNA", "OBSERVATION", 383, 394]]], ["Coronaviruses synthesize eight subgenomic 5 0 and 3 0 coterminal RNAs containing the leader sequence at the 5 0 terminus and the N gene at the 3 0 terminus.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["subgenomic 5 0 and 3 0 coterminal RNAs", "RNA", 31, 69], ["leader sequence", "DNA", 85, 100], ["5 0 terminus", "DNA", 108, 120], ["N gene", "DNA", 129, 135], ["3 0 terminus", "DNA", 143, 155], ["Coronaviruses synthesize eight subgenomic", "PROBLEM", 0, 41], ["the leader sequence", "TEST", 81, 100], ["eight", "OBSERVATION_MODIFIER", 25, 30], ["subgenomic", "OBSERVATION_MODIFIER", 31, 41]]], ["For this reason it was anticipated that an assay targeting the N gene might be more sensitive than those targeting other regions of the viral genome, due to the predicted abundance of N RNA transcripts in SARS-CoV infected cells.", [["cells", "ANATOMY", 223, 228], ["SARS-CoV infected", "DISEASE", 205, 222], ["SARS-CoV", "ORGANISM", 205, 213], ["cells", "CELL", 223, 228], ["N gene", "DNA", 63, 69], ["viral genome", "DNA", 136, 148], ["N RNA transcripts", "RNA", 184, 201], ["SARS-CoV infected cells", "CELL_TYPE", 205, 228], ["SARS-CoV", "SPECIES", 205, 213], ["an assay", "TEST", 40, 48], ["the viral genome", "PROBLEM", 132, 148], ["N RNA transcripts", "PROBLEM", 184, 201], ["SARS", "PROBLEM", 205, 209], ["CoV infected cells", "PROBLEM", 210, 228], ["viral genome", "OBSERVATION", 136, 148], ["infected cells", "OBSERVATION", 214, 228]]], ["Indeed, the N primer/beacon sets outperformed the Pol 2 set and could consistently detect SARS-CoV at a 10 \u00c06 and frequently at a 10 \u00c07 dilution of whole genome Urbani strain RNA (Table III) .", [["Pol 2", "GENE_OR_GENE_PRODUCT", 50, 55], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 90, 98], ["N primer", "DNA", 12, 20], ["Pol 2 set", "DNA", 50, 59], ["SARS-CoV", "SPECIES", 90, 98], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["whole genome Urbani strain RNA", "TREATMENT", 148, 178], ["SARS", "OBSERVATION", 90, 94]]], ["However, interestingly, the Pol 1 primer/probe set was equally as sensitive as either of the N target sets.RESULTSThe different target sets were also used to detect SARS-CoV in known copy number and high titer isolates from Frankfurt and Hong Kong, respectively.", [["Pol 1", "GENE_OR_GENE_PRODUCT", 28, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["Pol 1 primer", "DNA", 28, 40], ["N target sets", "DNA", 93, 106], ["SARS-CoV", "SPECIES", 165, 173], ["the Pol 1 primer/probe set", "TEST", 24, 50], ["SARS", "PROBLEM", 165, 169], ["CoV", "PROBLEM", 170, 173], ["high titer isolates", "PROBLEM", 199, 218]]], ["Similar results were obtained for the Urbani strain (data not shown).", [["the Urbani strain", "PROBLEM", 34, 51]]], ["The Pol and N sets showed highest sensitivity compared to the 5 0 -L and 3 0 -NCR targets, for detection of the Frankfurt SARS-CoV (Table IV) , and these Pol and N sets were therefore further characterized in the remaining studies.", [["SARS", "DISEASE", 122, 126], ["Pol", "GENE_OR_GENE_PRODUCT", 4, 7], ["Pol", "GENE_OR_GENE_PRODUCT", 154, 157], ["Pol", "PROTEIN", 4, 7], ["5 0 -L and 3 0 -NCR targets", "DNA", 62, 89], ["Pol", "PROTEIN", 154, 157], ["Frankfurt SARS-CoV", "SPECIES", 112, 130], ["The Pol and N sets", "TEST", 0, 18], ["highest sensitivity", "PROBLEM", 26, 45], ["the Frankfurt SARS", "TEST", 108, 126], ["CoV (Table IV)", "TREATMENT", 127, 141], ["these Pol and N sets", "TREATMENT", 148, 168], ["the remaining studies", "TEST", 209, 230]]], ["In order to verify the ability of the assay to detect N and Pol targets in different strains of SARS-CoV, a dilution series of Vietnamese isolates from early and late in the epidemic were also tested.", [["SARS", "DISEASE", 96, 100], ["Pol", "GENE_OR_GENE_PRODUCT", 60, 63], ["SARS-CoV", "ORGANISM", 96, 104], ["SARS-CoV", "SPECIES", 96, 104], ["the assay", "TEST", 34, 43], ["SARS", "PROBLEM", 96, 100], ["a dilution series", "TEST", 106, 123], ["Vietnamese isolates", "TREATMENT", 127, 146]]], ["All assays on both of these targets were able to detect all strains ( Table V) .RESULTSThe sensitivity of the multi-target real-time NASBA assay for SARS-CoV was directly compared to the three target real-time RT-PCR Taqman assay by testing the same freshly prepared dilution series of SARS-CoV RNA in parallel.", [["SARS", "DISEASE", 286, 290], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 286, 294], ["SARS-CoV RNA", "RNA", 286, 298], ["SARS-CoV", "SPECIES", 149, 157], ["SARS-CoV", "SPECIES", 286, 294], ["All assays", "TEST", 0, 10], ["NASBA assay", "TEST", 133, 144], ["SARS", "PROBLEM", 149, 153], ["CoV", "PROBLEM", 154, 157], ["SARS", "PROBLEM", 286, 290]]], ["While the two multi-target assays appear to have comparable sensitivity overall, there are some interesting differences.", [["the two multi-target assays", "TEST", 6, 33], ["some", "OBSERVATION_MODIFIER", 91, 95], ["interesting", "OBSERVATION_MODIFIER", 96, 107], ["differences", "OBSERVATION_MODIFIER", 108, 119]]], ["The N targets consistently demonstrate higher sensitivity over the Pol target for RT-PCR, while in the NASBA assay, the N targets are mores sensitive than the Pol 2 but not the Pol 1.", [["Pol", "GENE_OR_GENE_PRODUCT", 67, 70], ["Pol 2", "GENE_OR_GENE_PRODUCT", 159, 164], ["Pol 1", "GENE_OR_GENE_PRODUCT", 177, 182], ["Pol target", "DNA", 67, 77], ["Pol 2", "PROTEIN", 159, 164], ["Pol 1", "PROTEIN", 177, 182], ["higher sensitivity", "PROBLEM", 39, 57], ["RT-PCR", "TEST", 82, 88], ["the NASBA assay", "TEST", 99, 114], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["Additionally, the Taqman SARS2 (N) and NASBA N1 targets appear to be equivalent, while the Taqman SARS3 (N) target was at least an order of magnitude more sensitive compared to all the targets (Table III) .", [["SARS2", "GENE_OR_GENE_PRODUCT", 25, 30], ["SARS3 (N)", "GENE_OR_GENE_PRODUCT", 98, 107], ["Taqman SARS2 (N) and NASBA N1 targets", "DNA", 18, 55], ["Taqman SARS3 (N) target", "DNA", 91, 114], ["the Taqman SARS2", "TEST", 14, 30], ["NASBA N1 targets", "TEST", 39, 55], ["the Taqman SARS3", "TEST", 87, 103]]], ["Furthermore, the NASBA Pol 1 target was more sensitive than the Taqman SARS 1 (Pol) target by two orders of magnitude.", [["Pol 1", "GENE_OR_GENE_PRODUCT", 23, 28], ["Pol", "GENE_OR_GENE_PRODUCT", 79, 82], ["NASBA Pol 1 target", "DNA", 17, 35], ["Taqman SARS 1 (Pol) target", "DNA", 64, 90], ["the NASBA Pol", "TEST", 13, 26], ["the Taqman SARS", "TEST", 60, 75]]], ["Given that two targets are required to establish positivity by either test it appears that both assays are comparable in sensitivity.DISCUSSIONA multi-target real-time NASBA application for the detection of SARS-CoV has been developed and shown to be comparable in sensitivity and specificity to a Taqman RT-PCR test [Emery et al., 2004] .", [["SARS", "DISEASE", 207, 211], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 207, 215], ["SARS-CoV", "SPECIES", 207, 215], ["the detection", "TEST", 190, 203], ["SARS", "PROBLEM", 207, 211], ["CoV", "PROBLEM", 212, 215], ["a Taqman RT-PCR test", "TEST", 296, 316]]], ["The NASBA SARS-CoV assay consistently detected at least four different targets in six different isolates, demonstrating sensitivity across different times and geographical locations of the disease outbreak.", [["SARS-CoV", "SPECIES", 10, 18], ["The NASBA SARS", "TEST", 0, 14], ["CoV assay", "TEST", 15, 24], ["the disease outbreak", "PROBLEM", 185, 205], ["disease", "OBSERVATION", 189, 196]]], ["The N and Pol targets show greatest sensitivity for real-time NASBA detection of SARS-CoV in the materials tested and this is concordant with results obtained for similar targets in the CDC Taqman test [Emery et al., 2004] .", [["SARS", "DISEASE", 81, 85], ["Pol", "GENE_OR_GENE_PRODUCT", 10, 13], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 81, 89], ["N and Pol targets", "DNA", 4, 21], ["SARS-CoV", "SPECIES", 81, 89], ["SARS", "PROBLEM", 81, 85]]], ["Similar to the N region, the 5 0 -leader sequence is present in all the subgenomic RNA populations.", [["N region", "DNA", 15, 23], ["5 0 -leader sequence", "DNA", 29, 49], ["subgenomic RNA populations", "OBSERVATION", 72, 98]]], ["It was therefore anticipated that this target might also provide increased sensitivity for SARS-CoV detection.", [["SARS", "DISEASE", 91, 95], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "PROBLEM", 91, 95], ["CoV detection", "TEST", 96, 109]]], ["This sequence, however, is too short for efficient design of NASBA primer sets, necessitating placement of the downstream primer outside the leader region.", [["NASBA primer sets", "DNA", 61, 78], ["downstream primer", "DNA", 111, 128], ["leader region", "DNA", 141, 154], ["This sequence", "TEST", 0, 13], ["NASBA primer sets", "TREATMENT", 61, 78], ["placement", "TREATMENT", 94, 103], ["the downstream primer", "TREATMENT", 107, 128]]], ["Consequently, the 5 0 -L NASBA assay detects only genomic RNA, and exhibits lower sensitivity than assays targeting the N region.DISCUSSIONFor clinical testing, it is important to determine the RNA population in patient samples, since this could differ from that found in cultured virus material and subsequently affect the choice for the most sensitive SARS-CoV target.", [["samples", "ANATOMY", 220, 227], ["patient", "ORGANISM", 212, 219], ["genomic RNA", "RNA", 50, 61], ["N region", "DNA", 120, 128], ["patient", "SPECIES", 212, 219], ["SARS-CoV", "SPECIES", 354, 362], ["L NASBA assay", "TEST", 23, 36], ["genomic RNA", "PROBLEM", 50, 61], ["lower sensitivity", "PROBLEM", 76, 93], ["clinical testing", "TEST", 143, 159], ["cultured virus material", "PROBLEM", 272, 295], ["genomic RNA", "OBSERVATION", 50, 61], ["lower sensitivity", "OBSERVATION_MODIFIER", 76, 93]]], ["In a recent study, the abundance of N and Pol RNA transcripts in virus cultures were found to converge after 4 days in culture [Drosten et al., 2004] .", [["Pol", "GENE_OR_GENE_PRODUCT", 42, 45], ["N and Pol RNA transcripts", "RNA", 36, 61], ["a recent study", "TEST", 3, 17], ["N and Pol RNA transcripts", "TREATMENT", 36, 61], ["virus cultures", "TEST", 65, 79], ["culture", "TEST", 119, 126]]], ["Additionally, detection of N gene transcripts did not provide greater sensitivity over those of the Pol gene in clinical specimens from 29 confirmed SARS patients.", [["specimens", "ANATOMY", 121, 130], ["SARS", "DISEASE", 149, 153], ["Pol", "GENE_OR_GENE_PRODUCT", 100, 103], ["patients", "ORGANISM", 154, 162], ["N gene transcripts", "RNA", 27, 45], ["Pol gene", "DNA", 100, 108], ["patients", "SPECIES", 154, 162], ["N gene transcripts", "PROBLEM", 27, 45], ["clinical specimens", "TEST", 112, 130]]], ["However, specimens were collected at a median of 12 days after onset of symptoms; further studies are needed to determine if the N gene may provide greater sensitivity for specimens collected in the earlier days of disease onset.DISCUSSIONRapid and accurate detection of the SARS-CoV was a major concern during the SARS outbreak.", [["specimens", "ANATOMY", 9, 18], ["specimens", "ANATOMY", 172, 181], ["SARS", "DISEASE", 275, 279], ["SARS", "DISEASE", 315, 319], ["specimens", "CANCER", 9, 18], ["SARS-CoV", "ORGANISM", 275, 283], ["N gene", "DNA", 129, 135], ["SARS-CoV", "SPECIES", 275, 283], ["specimens", "TEST", 9, 18], ["symptoms", "PROBLEM", 72, 80], ["further studies", "TEST", 82, 97], ["specimens", "TEST", 172, 181], ["disease onset", "PROBLEM", 215, 228], ["the SARS", "PROBLEM", 271, 279], ["CoV", "PROBLEM", 280, 283], ["the SARS outbreak", "PROBLEM", 311, 328]]], ["That concern continues following occurrences of laboratory-acquired infections and the ongoing possibility of the re-emergence of SARS in the community.", [["infections", "DISEASE", 68, 78], ["SARS", "DISEASE", 130, 134], ["laboratory-acquired infections", "PROBLEM", 48, 78], ["SARS", "PROBLEM", 130, 134], ["infections", "OBSERVATION", 68, 78]]], ["SARS-CoV is similar to the more common respiratory influenza viruses in that it is a zoonosis, has dual tropism for respiratory andDISCUSSIONData shown are representative of multiple replicate experiments.", [["SARS", "DISEASE", 0, 4], ["respiratory influenza viruses", "DISEASE", 39, 68], ["zoonosis", "DISEASE", 85, 93], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["the more common respiratory influenza viruses", "PROBLEM", 23, 68], ["CoV", "OBSERVATION", 5, 8], ["influenza viruses", "OBSERVATION", 51, 68]]], ["The results were recorded as positive (\u00fe) or negative (\u00c0) for each duplicate value obtained as defined by the value being above (positive) or below (negative) the cut-off for NASBA (as described in Results) or crossing the signal threshold for RT-PCR.", [["each duplicate value", "TEST", 62, 82], ["NASBA", "TEST", 175, 180], ["RT-PCR", "TEST", 244, 250]]], ["In the case of a discrepancy between duplicates, the result was recorded as (\u00c0), i.e., the endpoint was determined by the value at which both duplicates were consistently positive.DISCUSSIONData shown are representative of multiple replicate experiments.DISCUSSIONgastrointestinal tissues, and efficient mechanisms for generating genetic variation.", [[".DISCUSSIONgastrointestinal tissues", "ANATOMY", 253, 288], [".DISCUSSIONgastrointestinal tissues", "TISSUE", 253, 288], ["a discrepancy between duplicates", "PROBLEM", 15, 47], ["positive", "OBSERVATION", 171, 179]]], ["While 16 recurring SARS-CoV mutations were identified by Ruan et al. [2003] , these probably arose as a result of passaging through Vero cells in culture, and it has been suggested that the virus is in fact fairly genetically stable when passing through humans [Brown and Tetro, 2003 ].", [["Vero cells", "ANATOMY", 132, 142], ["Vero cells", "CELL", 132, 142], ["humans", "ORGANISM", 254, 260], ["Vero cells", "CELL_LINE", 132, 142], ["humans", "SPECIES", 254, 260], ["SARS-CoV", "SPECIES", 19, 27], ["humans", "SPECIES", 254, 260], ["CoV mutations", "PROBLEM", 24, 37], ["passaging through Vero cells", "PROBLEM", 114, 142], ["culture", "TEST", 146, 153], ["the virus", "PROBLEM", 186, 195], ["virus", "OBSERVATION", 190, 195]]], ["However, it should not be overlooked that the viral replicase is error prone, and therefore capable of causing rapid, unpredictable genetic changes [Rest and Mindell, 2003 ].DISCUSSIONIn direct contrast to influenza viruses where viral titer is highest at onset of the disease, viral load in SARS is initially low and does not typically peak until day 10 of disease ].", [["influenza viruses", "DISEASE", 206, 223], ["SARS", "DISEASE", 292, 296], ["influenza viruses", "ORGANISM", 206, 223], ["the viral replicase", "PROBLEM", 42, 61], ["rapid, unpredictable genetic changes", "PROBLEM", 111, 147], ["influenza viruses", "PROBLEM", 206, 223], ["viral titer", "PROBLEM", 230, 241], ["the disease", "PROBLEM", 265, 276], ["viral load in SARS", "PROBLEM", 278, 296], ["disease", "PROBLEM", 358, 365], ["disease", "OBSERVATION", 269, 276]]], ["This presents a challenge for early detection and highlights the need for extremely sensitive assays to aid in the early diagnosis of disease; particularly important given the wide variation in clinical presentation and difficulties faced with diagnosing based on symptoms.", [["early detection", "TEST", 30, 45], ["extremely sensitive assays", "PROBLEM", 74, 100], ["disease", "PROBLEM", 134, 141], ["symptoms", "PROBLEM", 264, 272], ["disease", "OBSERVATION", 134, 141]]], ["To date, at least three types of diagnostic laboratory tests are available but all have their limitations [World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory Syndrome Diagnosis, 2003; Chen et al., 2004] .", [["Acute Respiratory Syndrome", "DISEASE", 178, 204], ["diagnostic laboratory tests", "TEST", 33, 60], ["Severe Acute Respiratory Syndrome", "PROBLEM", 171, 204], ["Severe", "OBSERVATION_MODIFIER", 171, 177], ["Acute", "OBSERVATION_MODIFIER", 178, 183], ["Respiratory Syndrome", "OBSERVATION", 184, 204]]], ["ELISA tests can only reliably detect antigen after a week post onset of symptoms depending on the specimen [Lau et al., 2004] , making detection of cases difficult at the time they are most infectious.", [["specimen", "ANATOMY", 98, 106], ["ELISA tests", "TEST", 0, 11], ["symptoms", "PROBLEM", 72, 80], ["the specimen", "TEST", 94, 106], ["infectious", "OBSERVATION", 190, 200]]], ["Likewise, an indirect immunofluorescence assay is only able to detect antibodies reliably after day 10 [World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory Syndrome Diagnosis, 2003].", [["Acute Respiratory Syndrome", "DISEASE", 175, 201], ["antibodies", "PROTEIN", 70, 80], ["an indirect immunofluorescence assay", "TEST", 10, 46], ["Severe Acute Respiratory Syndrome", "PROBLEM", 168, 201], ["Severe", "OBSERVATION_MODIFIER", 168, 174], ["Acute", "OBSERVATION_MODIFIER", 175, 180], ["Respiratory Syndrome", "OBSERVATION", 181, 201]]], ["Any culturebased detection requires specialized biosafety level three facilities, which are beyond the scope of most diagnostic laboratories.", [["Any culturebased detection", "TEST", 0, 26]]], ["A number of RT-PCR tests have been developed and some have been simultaneously evaluated [Yam et al., 2003; Bressler and Nolte, 2004; Mahony et al., 2004] , but detection of SARS-CoV RNA by real-time NASBA has not been previously reported in the literature.DISCUSSIONThe advantage of the real-time NASBA assay platform is that the reaction is isothermal, allowing testing of a range of common respiratory viruses such as influenza virus or human metapneumovirus to be performed simultaneously on the same plate.", [["SARS", "DISEASE", 174, 178], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["influenza virus", "ORGANISM", 421, 436], ["human", "ORGANISM", 440, 445], ["metapneumovirus", "ORGANISM", 446, 461], ["SARS-CoV RNA", "RNA", 174, 186], ["influenza virus", "SPECIES", 421, 436], ["human", "SPECIES", 440, 445], ["metapneumovirus", "SPECIES", 446, 461], ["SARS-CoV", "SPECIES", 174, 182], ["influenza virus", "SPECIES", 421, 436], ["human metapneumovirus", "SPECIES", 440, 461], ["RT-PCR tests", "TEST", 12, 24], ["SARS", "PROBLEM", 174, 178], ["CoV RNA", "TEST", 179, 186], ["NASBA", "TEST", 200, 205], ["the reaction", "PROBLEM", 327, 339], ["common respiratory viruses", "PROBLEM", 386, 412], ["influenza virus", "PROBLEM", 421, 436], ["human metapneumovirus", "PROBLEM", 440, 461], ["respiratory viruses", "OBSERVATION", 393, 412]]], ["The assay incubation time is also almost an hour shorter than that for RT-PCR tests, allowing for a faster diagnostic turnaround time.", [["The assay incubation", "TEST", 0, 20], ["RT-PCR tests", "TEST", 71, 83]]], ["Finally, as is the case for all SARS-CoV molecular assays, more extensive studies are needed to explore the importance of specimen type and timing of collection, in order to achieve maximum reliability for SARS-CoV NASBA diagnostic testing.", [["SARS-CoV", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 206, 214], ["all SARS", "PROBLEM", 28, 36], ["CoV molecular assays", "TEST", 37, 57], ["extensive studies", "TEST", 64, 81], ["SARS", "PROBLEM", 206, 210], ["CoV NASBA diagnostic testing", "TEST", 211, 239]]]], "23d083670f409a442e250e13709048ba569fd31a": [["IntroductionThe current outbreak of a novel coronavirus 2019_nCoV (now named SARS-CoV-2) that started in December 2019 in the city of Wuhan, Hubei, China, once again demonstrates the risk of emerging zoonotic viral infections in general, and that of coronavirus species in particular.", [["coronavirus 2019_nCoV", "DISEASE", 44, 65], ["zoonotic viral infections", "DISEASE", 200, 225], ["coronavirus 2019_nCoV", "ORGANISM", 44, 65], ["SARS-CoV-2", "ORGANISM", 77, 87], ["coronavirus species", "ORGANISM", 250, 269], ["coronavirus", "SPECIES", 44, 55], ["coronavirus 2019_nCoV", "SPECIES", 44, 65], ["a novel coronavirus", "TREATMENT", 36, 55], ["emerging zoonotic viral infections", "PROBLEM", 191, 225], ["coronavirus species", "PROBLEM", 250, 269], ["coronavirus species", "OBSERVATION", 250, 269]]], ["After only 2 months, the epidemic of COVID-19 is already larger than the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) outbreak, which during 2002/2003 lasted 8 months and infected 8096 people, with a mortality rate of 9\u00c15%.", [["COVID-19", "CHEMICAL", 37, 45], ["acute respiratory syndrome (SARS) coronavirus (SARS-CoV)", "DISEASE", 80, 136], ["SARS-CoV", "ORGANISM", 127, 135], ["people", "ORGANISM", 204, 210], ["people", "SPECIES", 204, 210], ["SARS) coronavirus", "SPECIES", 108, 125], ["SARS-CoV", "SPECIES", 127, 135], ["COVID", "TEST", 37, 42], ["the severe acute respiratory syndrome", "PROBLEM", 69, 106], ["SARS) coronavirus (SARS-CoV) outbreak", "PROBLEM", 108, 145], ["a mortality rate", "TEST", 217, 233], ["larger", "OBSERVATION_MODIFIER", 57, 63], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106]]], ["It is a larger threat than the multiple smaller outbreaks of Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV), a zoonotic coronavirus that was discovered in 2012 (Bermingham et al. 2012) .IntroductionCoronaviruses that are closely related to SARS-CoV are typically found in bats (Li et al. 2005) .", [["Middle East Respiratory Syndrome (MERS) coronavirus", "DISEASE", 61, 112], ["zoonotic coronavirus", "DISEASE", 127, 147], ["SARS", "DISEASE", 256, 260], ["Middle East Respiratory Syndrome (MERS) coronavirus", "ORGANISM", 61, 112], ["MERS-CoV", "ORGANISM", 114, 122], ["coronavirus", "ORGANISM", 136, 147], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 214, 227], ["SARS-CoV", "ORGANISM", 256, 264], ["Coronaviruses", "PROTEIN", 214, 227], ["Middle East Respiratory Syndrome (MERS) coronavirus", "SPECIES", 61, 112], ["MERS-CoV", "SPECIES", 114, 122], ["zoonotic coronavirus", "SPECIES", 127, 147], ["SARS-CoV", "SPECIES", 256, 264], ["a larger threat", "PROBLEM", 6, 21], ["Middle East Respiratory Syndrome", "PROBLEM", 61, 93], ["coronavirus", "PROBLEM", 101, 112], ["a zoonotic coronavirus", "PROBLEM", 125, 147], ["IntroductionCoronaviruses", "PROBLEM", 202, 227], ["larger", "OBSERVATION_MODIFIER", 8, 14], ["threat", "OBSERVATION_MODIFIER", 15, 21], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["smaller", "OBSERVATION_MODIFIER", 40, 47], ["outbreaks", "OBSERVATION_MODIFIER", 48, 57], ["Middle", "ANATOMY_MODIFIER", 61, 67], ["East", "OBSERVATION_MODIFIER", 68, 72], ["Respiratory Syndrome", "OBSERVATION", 73, 93]]], ["There is evidence that SARS-CoV originated in bats in China and reached humans most probably after jumping to an intermediate host, the civet (Paguma larvata) (reviewed by Wang and Eaton 2007) .", [["SARS", "DISEASE", 23, 27], ["SARS-CoV", "ORGANISM", 23, 31], ["bats", "ORGANISM", 46, 50], ["humans", "ORGANISM", 72, 78], ["Paguma larvata", "ORGANISM", 143, 157], ["humans", "SPECIES", 72, 78], ["Paguma larvata", "SPECIES", 143, 157], ["SARS-CoV", "SPECIES", 23, 31], ["humans", "SPECIES", 72, 78], ["Paguma larvata", "SPECIES", 143, 157], ["SARS", "PROBLEM", 23, 27], ["CoV", "PROBLEM", 28, 31], ["SARS", "OBSERVATION", 23, 27], ["CoV", "OBSERVATION_MODIFIER", 28, 31]]], ["Similarly, MERS-CoV is endemic in dromedary camels in the Middle East, from which it can be transmitted to humans, but it may also have originated in bats (Cui et al. 2019) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 11, 19], ["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["MERS-CoV", "SPECIES", 11, 19], ["humans", "SPECIES", 107, 113], ["CoV", "OBSERVATION_MODIFIER", 16, 19], ["endemic", "OBSERVATION_MODIFIER", 23, 30], ["dromedary camels", "OBSERVATION", 34, 50], ["Middle", "ANATOMY_MODIFIER", 58, 64], ["East", "ANATOMY_MODIFIER", 65, 69]]], ["The MERS epidemic is ongoing, and as of December 2019, 2468 cases have been reported (Baharoon and Memish 2019) and the mortality rate has been as high as 42% (Mohd et al. 2016) .", [["the mortality rate", "TEST", 116, 134]]], ["At the other end of the virulence spectrum are coronavirus species that cause common colds in humans with relatively mild symptoms (reviewed by Su et al. 2016) .IntroductionSome coronaviruses are strictly host-specific, while others can be found in a range of hosts (Drexler et al. 2014) .", [["colds", "DISEASE", 85, 90], ["coronavirus", "ORGANISM", 47, 58], ["humans", "ORGANISM", 94, 100], ["coronaviruses", "ORGANISM", 178, 191], ["humans", "SPECIES", 94, 100], ["humans", "SPECIES", 94, 100], ["coronavirus species", "PROBLEM", 47, 66], ["common colds in humans", "PROBLEM", 78, 100], ["relatively mild symptoms", "PROBLEM", 106, 130], ["Some coronaviruses", "PROBLEM", 173, 191], ["coronavirus species", "OBSERVATION", 47, 66], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["coronaviruses", "OBSERVATION", 178, 191]]], ["The genome sequences of 2019_nCoV that is responsible for the current outbreak suggest that it too may have originated from bats, though it may have undergone a host jump to another mammal that was sold on a liveanimal market in Wuhan, where the outbreak presumably had started (Zhang et al. 2020) .", [["2019_nCoV", "GENE_OR_GENE_PRODUCT", 24, 33], ["2019_nCoV", "DNA", 24, 33], ["The genome sequences", "TEST", 0, 20]]], ["While this manuscript was under review, it was published that this animal might have been a pangolin (Manis javanica; Liu et al. 2019) .", [["Manis javanica", "ORGANISM", 102, 116], ["Manis javanica", "SPECIES", 102, 116], ["Manis javanica", "SPECIES", 102, 116]]], ["Alternatively, though less likely, a highly infectious patient zero may have been present at the market, as we now know that the virus can spread via human-to-human contacts (Riou and Althaus 2020) and individuals infected with a coronavirus can be 'super-spreaders', as was demonstrated for MERS (Cho et al. 2016; Kang et al. 2017) .IntroductionCoronaviruses are divided into three genera: Alphacoronavirus, Betacoronavirus and Gammacoronavirus.", [["coronavirus", "DISEASE", 230, 241], ["patient", "ORGANISM", 55, 62], ["human", "ORGANISM", 150, 155], ["human", "ORGANISM", 159, 164], ["coronavirus", "ORGANISM", 230, 241], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 346, 359], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 391, 407], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 409, 424], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 429, 445], ["patient", "SPECIES", 55, 62], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 159, 164], ["coronavirus", "SPECIES", 230, 241], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 159, 164], ["a highly infectious patient zero", "PROBLEM", 35, 67], ["the virus", "PROBLEM", 125, 134], ["a coronavirus", "PROBLEM", 228, 241], ["IntroductionCoronaviruses", "TREATMENT", 334, 359], ["Alphacoronavirus", "TREATMENT", 391, 407], ["Betacoronavirus", "TREATMENT", 409, 424], ["Gammacoronavirus", "TREATMENT", 429, 445], ["less likely", "UNCERTAINTY", 22, 33], ["highly", "OBSERVATION_MODIFIER", 37, 43], ["infectious", "OBSERVATION", 44, 54]]], ["SARS, MERS and 2019_nCoV are members of Betacoronavirus, which is divided into the subgenera Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus and Sarbecovirus.", [["SARS", "DISEASE", 0, 4], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 40, 55], ["SARS", "PROBLEM", 0, 4], ["Betacoronavirus", "TREATMENT", 40, 55], ["the subgenera Embecovirus", "TEST", 79, 104], ["Hibecovirus", "PROBLEM", 106, 117], ["Merbecovirus", "PROBLEM", 119, 131], ["Nobecovirus", "PROBLEM", 133, 144], ["Sarbecovirus", "TREATMENT", 149, 161]]], ["All coronaviruses have a genome consisting of a positive-sense single-strand RNA molecule.", [["coronaviruses", "ORGANISM", 4, 17], ["positive-sense single-strand RNA molecule", "RNA", 48, 89], ["All coronaviruses", "PROBLEM", 0, 17], ["coronaviruses", "OBSERVATION", 4, 17]]], ["A long polycystronic messenger is produced from this that codes for a number of proteins, some of which are posttranslationally cleaved to produce smaller proteins (Cui et al. 2019) .", [["A long polycystronic messenger", "PROBLEM", 0, 30]]], ["Approximately two-thirds of the genome codes for a large open reading frame, often called 'orf 1ab' that undergoes a frame shift during translation, and whose product is processed into a number of smaller proteins, while a variable number of smaller open reading frames are located downstream of orf 1ab.IntroductionA number of highly similar genome sequences of 2019_nCoV have now been released in the public domain, and these are currently being analysed by multiple groups in an attempt to understand the biology of the virus, although it is still a challenge to predict virulence from viral genome sequences.", [["1ab", "GENE_OR_GENE_PRODUCT", 300, 303], ["2019_nCoV", "GENE_OR_GENE_PRODUCT", 363, 372], ["open reading frame", "DNA", 57, 75], ["open reading frames", "DNA", 250, 269], ["orf 1ab", "DNA", 296, 303], ["2019_nCoV", "DNA", 363, 372], ["viral genome sequences", "DNA", 589, 611], ["the virus", "PROBLEM", 519, 528], ["large", "OBSERVATION_MODIFIER", 51, 56], ["open", "OBSERVATION", 57, 61]]], ["The fact that Coronaviruses are extremely diverse complicates such analyses.IntroductionIn order to be better prepared during a future zoonotic coronavirus outbreak, we attempted to identify a DNA target that would be able to detect all known members of Betacoronavirus, and further to identify commonality between members of the subgenera.", [["zoonotic coronavirus", "DISEASE", 135, 155], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 14, 27], ["coronavirus", "ORGANISM", 144, 155], ["DNA", "CELLULAR_COMPONENT", 193, 196], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 254, 269], ["zoonotic coronavirus", "SPECIES", 135, 155], ["Coronaviruses", "PROBLEM", 14, 27], ["a future zoonotic coronavirus outbreak", "PROBLEM", 126, 164], ["a DNA target", "PROBLEM", 191, 203], ["Coronaviruses", "OBSERVATION", 14, 27]]], ["The analysis identified that a relatively short fragment of the noncoding upstream flank of the genome is sufficient for phylogenetic analysis.", [["noncoding upstream flank", "DNA", 64, 88], ["The analysis", "TEST", 0, 12], ["a relatively short fragment", "PROBLEM", 29, 56], ["phylogenetic analysis", "TEST", 121, 142], ["relatively", "OBSERVATION_MODIFIER", 31, 41], ["short", "OBSERVATION_MODIFIER", 42, 47], ["fragment", "OBSERVATION_MODIFIER", 48, 56], ["noncoding", "OBSERVATION_MODIFIER", 64, 73], ["upstream", "OBSERVATION_MODIFIER", 74, 82], ["flank", "OBSERVATION_MODIFIER", 83, 88], ["genome", "ANATOMY", 96, 102]]], ["Moreover, the types of bats that have commercial value in China were considered as potential sources for zoonotic coronaviruses.Results and discussionIn a pilot experiment, all coding regions of four virus species representing three subgenera (MERS-CoV for Merbecovirus, human coronavirus OC43 for Embecovirus and SARS-CoV and 2019_nCoV for Sarbecovirus) were compared by multiple alignment of nucleotide sequences.", [["zoonotic coronaviruses", "DISEASE", 105, 127], ["nucleotide", "CHEMICAL", 394, 404], ["nucleotide", "CHEMICAL", 394, 404], ["bats", "ORGANISM", 23, 27], ["coronaviruses", "ORGANISM", 114, 127], ["MERS-CoV", "ORGANISM", 244, 252], ["Merbecovirus", "ORGANISM", 257, 269], ["human", "ORGANISM", 271, 276], ["coronavirus OC43", "ORGANISM", 277, 293], ["SARS-CoV", "ORGANISM", 314, 322], ["Merbecovirus", "PROTEIN", 257, 269], ["human", "SPECIES", 271, 276], ["coronavirus", "SPECIES", 277, 288], ["MERS-CoV", "SPECIES", 244, 252], ["human coronavirus", "SPECIES", 271, 288], ["SARS-CoV", "SPECIES", 314, 322], ["zoonotic coronaviruses", "PROBLEM", 105, 127], ["four virus species", "PROBLEM", 195, 213], ["Merbecovirus", "PROBLEM", 257, 269], ["human coronavirus OC43", "PROBLEM", 271, 293], ["Embecovirus", "TEST", 298, 309], ["SARS", "PROBLEM", 314, 318], ["CoV", "TEST", 319, 322], ["Sarbecovirus", "TEST", 341, 353], ["nucleotide sequences", "TEST", 394, 414], ["four virus", "OBSERVATION", 195, 205]]], ["This did not identify any region that was sufficiently conserved to potentially design an RNA-two-primer amplification detection target for all betacoronavirus genera, which we had set as our initial goal to identify.", [["an RNA", "TEST", 87, 93], ["all betacoronavirus genera", "TREATMENT", 140, 166]]], ["It is clear that addition of the genomes of more virus species would only decrease conservation further.Results and discussionThis lack of homologous DNA sequences was a bit surprising, as Lu et al. (2020) recently published a phylogenetic tree based on 50 genome sequences (including 10 2019_nCoV isolates) with high bootstrap values, which can only be obtained with sufficient degrees of conservation between members of the data set.", [["DNA", "CELLULAR_COMPONENT", 150, 153], ["homologous DNA sequences", "DNA", 139, 163], ["50 genome sequences", "DNA", 254, 273], ["more virus species", "PROBLEM", 44, 62], ["homologous DNA sequences", "PROBLEM", 139, 163], ["high bootstrap values", "PROBLEM", 313, 334], ["clear", "OBSERVATION", 6, 11]]], ["Their analysis was based on complete genomes (presumably, nucleotide sequences), whereas in our pilot analysis only protein-coding nucleotide sequences were compared.", [["nucleotide", "CHEMICAL", 58, 68], ["protein-coding nucleotide sequences", "DNA", 116, 151], ["Their analysis", "TEST", 0, 14], ["nucleotide sequences", "TEST", 58, 78], ["our pilot analysis", "TEST", 92, 110], ["protein", "TEST", 116, 123], ["coding nucleotide sequences", "TEST", 124, 151]]], ["This initiated an analysis to identify how much of the phylogenetic signal and conservation was actually present in noncoding regions of the viral genomes.", [["noncoding regions", "DNA", 116, 133], ["viral genomes", "DNA", 141, 154], ["an analysis", "TEST", 15, 26], ["the phylogenetic signal", "PROBLEM", 51, 74], ["the viral genomes", "PROBLEM", 137, 154], ["viral genomes", "OBSERVATION", 141, 154]]], ["In case of coronavirus these are mostly restricted to the 5'-and 3-'end flanks, as all open reading frames are tightly packed.", [["coronavirus", "ORGANISM", 11, 22], ["3-'end flanks", "CELLULAR_COMPONENT", 65, 78], ["5'-and 3-'end flanks", "DNA", 58, 78], ["open reading frames", "DNA", 87, 106], ["coronavirus", "PROBLEM", 11, 22], ["coronavirus", "OBSERVATION", 11, 22], ["flanks", "ANATOMY", 72, 78], ["tightly", "OBSERVATION_MODIFIER", 111, 118], ["packed", "OBSERVATION_MODIFIER", 119, 125]]], ["Therefore, a more extensive comparison was performed, this time with either the 5'-or the 3'-end noncoding flanks, obtained from 31 whole genome sequences covering all subspecies of Betacoronavirus (Table 1) .", [["flanks", "ANATOMY", 107, 113], ["flanks", "PATHOLOGICAL_FORMATION", 107, 113], ["5'-or the 3'-end noncoding flanks", "DNA", 80, 113], ["31 whole genome sequences", "DNA", 129, 154], ["flanks", "ANATOMY", 107, 113]]], ["This selection included the most variable genomes identified by Lu and colleagues, complemented with other members of the subgenera, while genomes with high similarity to another genome were discarded to remove redundancy.", [["This selection", "TREATMENT", 0, 14]]], ["The phylogenetic trees obtained with these two noncoding regions are shown in Fig. 1 .", [["noncoding regions", "DNA", 47, 64], ["phylogenetic trees", "OBSERVATION", 4, 22]]], ["Both fragments could separate the four subspecies, and an unclassified bat isolate from Cameroon could be identified as a member of the Nobecovirus.", [["fragments", "ANATOMY", 5, 14], ["bat", "ORGANISM", 71, 74], ["Both fragments", "PROBLEM", 0, 14], ["an unclassified bat isolate", "PROBLEM", 55, 82], ["fragments", "OBSERVATION", 5, 14], ["four", "OBSERVATION_MODIFIER", 34, 38], ["subspecies", "OBSERVATION_MODIFIER", 39, 49], ["unclassified", "OBSERVATION_MODIFIER", 58, 70], ["bat isolate", "OBSERVATION", 71, 82]]], ["Another unclassified virus isolated from a Nigerian bat showed high similarity with the only other fully sequenced member of Hibecovirus, at least for its 5'-flank (Fig. 1a) .Results and discussionAssigning a betacoronavirus to a subgenus does not implicate information about its virulence, host specificity or geographical origin.", [["Hibecovirus", "GENE_OR_GENE_PRODUCT", 125, 136], ["5'-flank", "DNA", 155, 163], ["Another unclassified virus", "PROBLEM", 0, 26], ["a Nigerian bat", "TEST", 41, 55], ["virus", "OBSERVATION", 21, 26], ["flank", "ANATOMY", 158, 163]]], ["However, the two analysed fragments were relatively strongly conserved within a subgenus, as illustrated by multiple alignments shown in Supporting Information.", [["the two analysed fragments", "PROBLEM", 9, 35], ["fragments", "OBSERVATION", 26, 35]]], ["Since only two, highly similar, genome sequences of Hibecovirus members were available for analysis, their comparison was not included.", [["Hibecovirus", "ORGANISM", 52, 63], ["genome sequences", "DNA", 32, 48], ["analysis", "TEST", 91, 99]]], ["The identified conserved regions could provide potential targets for PCR or rt-PCR, allowing for rapid classification of novel coronaviruses, in particular for the Sarbecovirus group.Results and discussionAlthough any section of the viral genome that is conserved within but not between subspecies would result in correct classification, the conservation of such regions within coding sequences of Sarbecovirus members was generally weaker than we observed for the noncoding flanks.", [["coronaviruses", "DISEASE", 127, 140], ["coronaviruses", "ORGANISM", 127, 140], ["flanks", "ORGANISM_SUBDIVISION", 475, 481], ["viral genome", "DNA", 233, 245], ["noncoding flanks", "DNA", 465, 481], ["PCR", "TEST", 69, 72], ["rt-PCR", "TEST", 76, 82], ["novel coronaviruses", "PROBLEM", 121, 140], ["the Sarbecovirus group", "TREATMENT", 160, 182], ["the viral genome", "PROBLEM", 229, 245], ["such regions", "PROBLEM", 358, 370], ["the noncoding flanks", "PROBLEM", 461, 481], ["coronaviruses", "OBSERVATION", 127, 140], ["viral genome", "OBSERVATION", 233, 245]]], ["Using coding sequences of this same small345selection of seven Sarbecovirus members, the maximum conservation at nucleotide level for gene 1a/b was 85% within a sliding window of 60 bases, compared to 93% for the downstream and 90% for the upstream flank.", [["flank", "ANATOMY", 249, 254], ["nucleotide", "CHEMICAL", 113, 123], ["flank", "ORGANISM_SUBDIVISION", 249, 254], ["gene 1a", "DNA", 134, 141], ["upstream flank", "DNA", 240, 254], ["nucleotide level", "TEST", 113, 129], ["bases", "ANATOMY_MODIFIER", 182, 187], ["flank", "ANATOMY", 249, 254]]], ["The longest stretch of conserved nucleotides was 22 in the upstream flank, 33 in the downstream flank and only 20 nucleotides in orf 1ab (results not shown).", [["flank", "ANATOMY", 68, 73], ["flank", "ANATOMY", 96, 101], ["nucleotides", "CHEMICAL", 33, 44], ["nucleotides", "CHEMICAL", 114, 125], ["flank", "ORGANISM_SUBDIVISION", 68, 73], ["flank", "ORGANISM_SUBDIVISION", 96, 101], ["upstream flank", "DNA", 59, 73], ["downstream flank", "DNA", 85, 101], ["orf 1ab", "TEST", 129, 136], ["flank", "ANATOMY", 68, 73], ["flank", "ANATOMY", 96, 101]]], ["Only the gene coding for envelope protein E was as strongly conserved as the noncoding flanks (maximum conservation 95% over a window of 60 bases, with a longest conserved stretch of 32 nucleotides) for the seven genomes analysed here.", [["envelope protein E", "GENE_OR_GENE_PRODUCT", 25, 43], ["flanks", "PATHOLOGICAL_FORMATION", 87, 93], ["envelope protein E", "PROTEIN", 25, 43], ["noncoding flanks", "DNA", 77, 93], ["envelope protein E", "PROBLEM", 25, 43], ["a longest conserved stretch of 32 nucleotides", "TREATMENT", 152, 197], ["flanks", "OBSERVATION_MODIFIER", 87, 93]]], ["As conservation of coding sequences decreases with third-base variation, it is likely that this degree of conservation in gene E would decrease as more genomes would be included in the comparison.", [["coding sequences", "DNA", 19, 35], ["gene E", "DNA", 122, 128], ["coding sequences", "TEST", 19, 35]]], ["Thus, restricting analyses to only comparing coding regions may reduce the chance a proposed detection target might be able to detect a novel Sarbecovirus species.", [["coding regions", "DNA", 45, 59], ["a novel Sarbecovirus species", "PROBLEM", 134, 162]]], ["Instead, we recommend inclusion of the noncoding genome regions in such attempts.345Although it was not our aim to develop improved detection methods (for which we would have to experimentally test any proposed target region), our findings can be a starting point for such studies.", [["noncoding genome regions", "DNA", 39, 63], ["the noncoding genome regions", "TREATMENT", 35, 63], ["such studies", "TEST", 268, 280]]], ["It has been proposed, though not yet proven, that 2019_nCoV naturally propagates in bats, but the bat species in which the population mainly resides was unknown at the time of writing.", [["2019_nCoV", "CHEMICAL", 50, 59], ["2019_nCoV", "PROTEIN", 50, 59], ["the bat species", "PROBLEM", 94, 109]]], ["It is also possible that the virus had infected another mammal that was traded at the market and served as the source of the infection.", [["infection", "DISEASE", 125, 134], ["the virus", "PROBLEM", 25, 34], ["the infection", "PROBLEM", 121, 134], ["also possible", "UNCERTAINTY", 6, 19], ["virus", "OBSERVATION", 29, 34], ["infected", "OBSERVATION", 39, 47], ["infection", "OBSERVATION", 125, 134]]], ["Such a case has been proposed for Malayan pangolins (Liu et al. 2019 ), a meat delicacy that was most likely sold in the exotic meat market.", [["meat", "ANATOMY", 74, 78], ["meat", "ANATOMY", 128, 132], ["meat", "ORGANISM", 74, 78], ["meat", "ORGANISM_SUBDIVISION", 128, 132], ["a meat delicacy", "PROBLEM", 72, 87], ["most likely", "UNCERTAINTY", 97, 108], ["exotic meat market", "OBSERVATION", 121, 139]]], ["Such cross-infection could also have occurred during handling, storage or selling prior to animals reaching the food market.", [["Such cross-infection", "PROBLEM", 0, 20], ["cross-infection", "OBSERVATION", 5, 20]]], ["The case for pangolins being the actual source of 2019_nCoV has not yet been proven, but was referred from sequence similarities (Liu et al. 2019) .", [["2019_nCoV", "CHEMICAL", 50, 59], ["pangolins", "GENE_OR_GENE_PRODUCT", 13, 22], ["2019_nCoV", "GENE_OR_GENE_PRODUCT", 50, 59], ["2019_nCoV", "PROTEIN", 50, 59], ["pangolins", "PROBLEM", 13, 22]]], ["Even in this scenario there must have been a reason why an infected bat came in the vicinity of a pangolin that ended up in the market, for which only bat species with local commercial value come into question.345Of an extensive list of bat species that historically have been used in TCM (Riccucci 2012) , five were found to carry coronaviruses, as reported in a surveillance study (Tang et al. 2006) : Pipistrellus abramus, Murina leucogaster, Rhinolophus ferrumequinum, Scotophilus kuhlii and Scotomanes ornatus.", [["pangolin", "CHEMICAL", 98, 106], ["bat", "ORGANISM", 68, 71], ["pangolin", "GENE_OR_GENE_PRODUCT", 98, 106], ["bat", "ORGANISM", 237, 240], ["coronaviruses", "ORGANISM", 332, 345], ["Pipistrellus abramus", "ORGANISM", 404, 424], ["Murina leucogaster", "ORGANISM", 426, 444], ["Rhinolophus ferrumequinum", "ORGANISM", 446, 471], ["Scotophilus kuhlii", "ORGANISM", 473, 491], ["Scotomanes ornatus", "ORGANISM", 496, 514], ["Pipistrellus abramus", "SPECIES", 404, 424], ["Murina leucogaster", "SPECIES", 426, 444], ["Rhinolophus ferrumequinum", "SPECIES", 446, 471], ["Scotophilus kuhlii", "SPECIES", 473, 491], ["Scotomanes ornatus", "SPECIES", 496, 514], ["Pipistrellus abramus", "SPECIES", 404, 424], ["Murina leucogaster", "SPECIES", 426, 444], ["Rhinolophus ferrumequinum", "SPECIES", 446, 471], ["Scotophilus kuhlii", "SPECIES", 473, 491], ["Scotomanes ornatus", "SPECIES", 496, 514], ["an infected bat", "PROBLEM", 56, 71], ["bat species", "PROBLEM", 237, 248], ["coronaviruses", "PROBLEM", 332, 345], ["a surveillance study", "TEST", 362, 382], ["Pipistrellus", "TEST", 404, 416], ["Murina", "TEST", 426, 432], ["infected", "OBSERVATION", 59, 67], ["extensive", "OBSERVATION_MODIFIER", 219, 228]]], ["Of these bat species, the first three can be found in the province of Hubei (source: www. iucnredlist.org); the habitat of S. ornatus reaches to the south of the province but does not cover the Wuhan area, while S. kuhlii is not endemic in this region.", [["S. ornatus", "ORGANISM", 123, 133], ["S. kuhlii", "ORGANISM", 212, 221], ["S. ornatus", "SPECIES", 123, 133], ["S. kuhlii", "SPECIES", 212, 221], ["S. ornatus", "SPECIES", 123, 133], ["S. kuhlii", "SPECIES", 212, 221], ["these bat species", "PROBLEM", 3, 20], ["bat species", "OBSERVATION", 9, 20], ["not", "UNCERTAINTY", 225, 228], ["endemic", "OBSERVATION", 229, 236]]], ["A number of whole genome Sarbecovirus sequences isolated from these bats and other bat species were selected and their 5'-flank was compared to that of 2019_nCoV (Fig. 2) .", [["flank", "ORGANISM_SUBDIVISION", 122, 127], ["whole genome Sarbecovirus sequences", "DNA", 12, 47], ["5'-flank", "DNA", 119, 127], ["2019_nCoV", "DNA", 152, 161], ["whole genome Sarbecovirus sequences", "TEST", 12, 47], ["other bat species", "PROBLEM", 77, 94], ["flank", "ANATOMY", 122, 127]]], ["This produced the highest identity to the same isolate that Lu and coworkers had identified (Lu et al. 2020) , demonstrating that an analysis of 253 nucleotides directly upstream of the start codon of the polycystronic messenger suffices to identify genetic relationships between Sarbecovirus species.345The bat CoV to which 2019_nCoV has the highest similarity was isolated from Rhinolophus sinicus (MG772933, described in Hu et al. 2018) , which might indicate that this species may also have been the original source of Figure 2 Phylogenetic tree of the 253 5'-end noncoding sequences of Sarbecovirus species from bats.", [["2019_nCoV", "CHEMICAL", 325, 334], ["nucleotides", "CHEMICAL", 149, 160], ["bat CoV", "ORGANISM", 308, 315], ["2019_nCoV", "GENE_OR_GENE_PRODUCT", 325, 334], ["Rhinolophus sinicus", "ORGANISM", 380, 399], ["Sarbecovirus species", "ORGANISM", 591, 611], ["start codon", "DNA", 186, 197], ["2019_nCoV", "DNA", 325, 334], ["253 5'-end noncoding sequences", "DNA", 557, 587], ["Rhinolophus sinicus", "SPECIES", 380, 399], ["bat CoV", "SPECIES", 308, 315], ["Rhinolophus sinicus", "SPECIES", 380, 399], ["an analysis", "TEST", 130, 141], ["the polycystronic messenger suffices", "TREATMENT", 201, 237], ["Sarbecovirus species", "PROBLEM", 280, 300], ["The bat CoV", "TEST", 304, 315], ["Sarbecovirus species", "PROBLEM", 591, 611]]], ["A Merbecovirus was included as an outlier.", [["A Merbecovirus", "TREATMENT", 0, 14]]], ["The asterisks indicate highly similar CoV sequences obtained from different bat species.3452019_nCoV.", [["3452019_nCoV", "CHEMICAL", 88, 100], ["CoV", "ORGANISM", 38, 41], ["CoV sequences", "DNA", 38, 51], ["highly similar CoV sequences", "PROBLEM", 23, 51]]], ["However, the database is highly biased towards particular bat species that were specifically sampled in search of the source of SARS.", [["SARS", "DISEASE", 128, 132], ["bat", "ORGANISM", 58, 61], ["the database", "TEST", 9, 21], ["particular bat species", "PROBLEM", 47, 69], ["SARS", "PROBLEM", 128, 132]]], ["Highly similar coronaviruses can be detected in different bat species (as identified by asterisks in Fig. 2) , so that even a high similarity match to a bat isolate may not always identify the correct bat species that was the cause of a given zoonotic outbreak.", [["coronaviruses", "ORGANISM", 15, 28], ["Highly similar coronaviruses", "PROBLEM", 0, 28], ["a bat isolate", "TREATMENT", 151, 164], ["zoonotic outbreak", "PROBLEM", 243, 260], ["coronaviruses", "OBSERVATION", 15, 28]]], ["This caution can be extended to other possible animal hosts that have been or will be claimed as sources of the 2019_nCoV without a proven epidemiological link.345The use of bats in TCM is of great concern, and the use of the Greater horseshoe bat, Rhinolophus ferrumequinum, is of particular interest.", [["TCM", "CHEMICAL", 182, 185], ["bats", "ORGANISM", 174, 178], ["horseshoe bat", "ORGANISM", 234, 247], ["Rhinolophus ferrumequinum", "ORGANISM", 249, 274], ["Rhinolophus ferrumequinum", "SPECIES", 249, 274], ["horseshoe bat", "SPECIES", 234, 247], ["Rhinolophus ferrumequinum", "SPECIES", 249, 274], ["the Greater horseshoe bat", "TREATMENT", 222, 247]]], ["The faeces of this bat (Y e ming sh\u01ce in Chinese, marketed as Vespertilionis, see for instance https://www.bestplant.shop/products/yeming-sha-bat-feces-bat-dung-bat-guano) is used to cure eye conditions, while body parts are dried and added to wine or ground into a powder for oral intake as a means to 'detoxify' the body.", [["eye", "ANATOMY", 187, 190], ["body parts", "ANATOMY", 209, 219], ["oral", "ANATOMY", 276, 280], ["body", "ANATOMY", 317, 321], ["Y e ming sh\u01ce", "CHEMICAL", 24, 36], ["faeces", "ORGANISM_SUBSTANCE", 4, 10], ["bat", "ORGANISM", 19, 22], ["eye", "ORGAN", 187, 190], ["body", "ORGANISM_SUBDIVISION", 209, 213], ["oral", "ORGANISM_SUBDIVISION", 276, 280], ["body", "ORGANISM_SUBDIVISION", 317, 321], ["body", "ANATOMY", 317, 321]]], ["Both practices could be highly risky in case an animal was infected with a coronavirus, particularly the first use, as the virus can be present in faeces and can enter a host via the eye.", [["faeces", "ANATOMY", 147, 153], ["eye", "ANATOMY", 183, 186], ["coronavirus", "DISEASE", 75, 86], ["faeces", "ORGANISM_SUBSTANCE", 147, 153], ["eye", "ORGAN", 183, 186], ["a coronavirus", "PROBLEM", 73, 86], ["the virus", "PROBLEM", 119, 128], ["eye", "ANATOMY", 183, 186]]], ["We speculate that a live or recently deceased infected bat species was handled by traders because of its value in TCM, and that such an infected individual, or the still infective bat or bat products, may have been the route by which the virus entered the exotic meat market in Wuhan.", [["bat", "ORGANISM", 55, 58], ["meat", "ORGANISM_SUBDIVISION", 263, 267], ["infected bat species", "PROBLEM", 46, 66], ["an infected individual", "PROBLEM", 133, 155], ["the still infective bat", "PROBLEM", 160, 183], ["the virus", "PROBLEM", 234, 243], ["infected", "OBSERVATION", 46, 54], ["infected", "OBSERVATION", 136, 144], ["infective", "OBSERVATION", 170, 179]]], ["Alternatively, during the trade chain, a host jump occurred between an infected bat (handled for TCM purposes) and another mammal, that then was the source of infection.", [["infection", "DISEASE", 159, 168], ["a host jump", "PROBLEM", 39, 50], ["an infected bat", "PROBLEM", 68, 83], ["TCM purposes", "TREATMENT", 97, 109], ["infection", "PROBLEM", 159, 168], ["infected", "OBSERVATION", 71, 79], ["infection", "OBSERVATION", 159, 168]]], ["In this respect it is interesting to note that the first known onset of symptoms (on 1 December 2019) were observed in a patient with no known epidemiological links to the Wuhan food market (Huang et al. 2020) .345The possibility that bat-derived materials sold for TCM practices may be involved in this outbreak, has severe implications.", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["symptoms", "PROBLEM", 72, 80], ["TCM practices", "TREATMENT", 266, 279]]], ["We point out there is a serious risk of producing bat-derived materials sold for TCM practices as it involves handling of and trading with wild bats.", [["TCM practices", "TREATMENT", 81, 94]]], ["Even when the selling of live wild animals at food markets would be completely prohibited in China, the trading and handling of bats for traditional medicinal practices would remain a serious risk for future zoonotic coronavirus epidemics.Materials and methodsAll genome sequences used in this study were extracted from GenBank (Table 1) .", [["zoonotic coronavirus epidemics", "DISEASE", 208, 238], ["coronavirus", "ORGANISM", 217, 228], ["genome sequences", "DNA", 264, 280], ["traditional medicinal practices", "TREATMENT", 137, 168], ["future zoonotic coronavirus epidemics", "PROBLEM", 201, 238], ["All genome sequences", "TEST", 260, 280], ["this study", "TEST", 289, 299]]], ["In all cases, the reading frame of gene 1a/b was corrected for slippage.", [["b", "GENE_OR_GENE_PRODUCT", 43, 44], ["reading frame", "DNA", 18, 31], ["gene 1a/b", "DNA", 35, 44], ["slippage", "PROBLEM", 63, 71]]], ["Open reading frames missing from the annotation in some of the genomes were corrected.Materials and methodsMultiple alignments were performed with Muscle at www.ebi.ac.uk.", [["Muscle", "ANATOMY", 147, 153], ["Muscle", "TISSUE", 147, 153], ["Open reading frames", "PROBLEM", 0, 19], ["genomes", "OBSERVATION", 63, 70], ["Muscle", "ANATOMY", 147, 153]]], ["Phylogenetic Maximum Likelihood trees were produced with PhyMLy ver.", [["Maximum", "OBSERVATION_MODIFIER", 13, 20], ["Likelihood trees", "OBSERVATION", 21, 37]]], ["3.0 (Guindon et al. 2010 ) at www.phylogeny.fr with default settings except for skipping Gblock.", [["default settings", "TREATMENT", 52, 68], ["skipping Gblock", "PROBLEM", 80, 95]]]], "PMC7114211": [["IntroductionThe mammalian cell is a highly organised, dynamic structure that compartmentalises its many functions into organelles such as the nucleus, Golgi, and endoplasmic reticulum.", [["cell", "ANATOMY", 26, 30], ["organelles", "ANATOMY", 119, 129], ["nucleus", "ANATOMY", 142, 149], ["Golgi", "ANATOMY", 151, 156], ["endoplasmic reticulum", "ANATOMY", 162, 183], ["mammalian cell", "CELL", 16, 30], ["organelles", "CELLULAR_COMPONENT", 119, 129], ["nucleus", "CELLULAR_COMPONENT", 142, 149], ["Golgi", "CELLULAR_COMPONENT", 151, 156], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 162, 183], ["mammalian cell", "OBSERVATION", 16, 30], ["highly", "OBSERVATION_MODIFIER", 36, 42], ["dynamic structure", "OBSERVATION", 54, 71], ["nucleus", "ANATOMY", 142, 149], ["Golgi", "ANATOMY_MODIFIER", 151, 156], ["endoplasmic reticulum", "OBSERVATION", 162, 183]]], ["The nucleus retains the genetic material for cell maintenance and replication, whereby efficient signal dependent targeting of cellular proteins into or out of the nucleus, mediated by the importin (IMP) superfamily of transporters (see Fig. 2; Section 2) is required for the cell to function.", [["nucleus", "ANATOMY", 4, 11], ["cell", "ANATOMY", 45, 49], ["cellular", "ANATOMY", 127, 135], ["nucleus", "ANATOMY", 164, 171], ["cell", "ANATOMY", 276, 280], ["nucleus", "CELLULAR_COMPONENT", 4, 11], ["cell", "CELL", 45, 49], ["cellular", "CELL", 127, 135], ["nucleus", "CELLULAR_COMPONENT", 164, 171], ["importin", "GENE_OR_GENE_PRODUCT", 189, 197], ["IMP", "GENE_OR_GENE_PRODUCT", 199, 202], ["cell", "CELL", 276, 280], ["cellular proteins", "PROTEIN", 127, 144], ["importin (IMP) superfamily", "PROTEIN", 189, 215], ["cell maintenance", "TREATMENT", 45, 61], ["replication", "TREATMENT", 66, 77], ["cellular proteins", "PROBLEM", 127, 144], ["nucleus", "ANATOMY_MODIFIER", 4, 11], ["cellular proteins", "OBSERVATION", 127, 144], ["nucleus", "ANATOMY", 164, 171]]], ["During infection by various viruses, specific viral-encoded gene products exploit the host cell nucleocytoplasmic trafficking machinery to enter and exit the nucleus as part of the strategy of the virus to evade the host immune response and replicate productively.", [["cell", "ANATOMY", 91, 95], ["nucleus", "ANATOMY", 158, 165], ["infection", "DISEASE", 7, 16], ["cell", "CELL", 91, 95], ["nucleus", "CELLULAR_COMPONENT", 158, 165], ["viral-encoded gene products", "PROTEIN", 46, 73], ["infection", "PROBLEM", 7, 16], ["various viruses", "PROBLEM", 20, 35], ["specific viral-encoded gene products", "TREATMENT", 37, 73], ["the host cell nucleocytoplasmic trafficking machinery", "TREATMENT", 82, 135], ["the virus", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 7, 16], ["host cell", "OBSERVATION", 86, 95], ["nucleus", "ANATOMY", 158, 165]]], ["Many of these viral proteins appear not only to possess targeting signals mediating high affinity interaction with the cellular nuclear transport factors, but also show precise regulation thereof by phosphorylation of these interactions by cellular/virally encoded kinases or other enzymes (see Section 3).IntroductionThis review will focus in detail on viral proteins for which there is evidence of regulated nucleocytoplasmic trafficking in infected cells, including gene products from DNA viruses such as simian virus 40 (SV40) large tumour antigen (T-ag), human cytomegalovirus (HCMV) processivity factor ppUL44, and the human papilloma virus (HPV) E1 protein, as well as the phospho \u201cP\u201d protein from the negative stranded RNA Rabies virus (RV).", [["cellular nuclear", "ANATOMY", 119, 135], ["cellular", "ANATOMY", 240, 248], ["nucleocytoplasmic", "ANATOMY", 410, 427], ["cells", "ANATOMY", 452, 457], ["human papilloma virus", "DISEASE", 625, 646], ["phospho", "CHEMICAL", 680, 687], ["cellular", "CELL", 119, 127], ["cellular", "CELL", 240, 248], ["cells", "CELL", 452, 457], ["DNA", "CELLULAR_COMPONENT", 488, 491], ["simian virus 40", "ORGANISM", 508, 523], ["SV40", "ORGANISM", 525, 529], ["large tumour antigen", "GENE_OR_GENE_PRODUCT", 531, 551], ["T-ag", "GENE_OR_GENE_PRODUCT", 553, 557], ["human cytomegalovirus", "ORGANISM", 560, 581], ["HCMV", "ORGANISM", 583, 587], ["ppUL44", "GENE_OR_GENE_PRODUCT", 609, 615], ["human papilloma virus", "ORGANISM", 625, 646], ["HPV", "ORGANISM", 648, 651], ["E1", "GENE_OR_GENE_PRODUCT", 653, 655], ["phospho \u201cP\u201d", "GENE_OR_GENE_PRODUCT", 680, 691], ["Rabies virus", "ORGANISM", 731, 743], ["viral proteins", "PROTEIN", 14, 28], ["cellular nuclear transport factors", "PROTEIN", 119, 153], ["cellular/virally encoded kinases", "PROTEIN", 240, 272], ["enzymes", "PROTEIN", 282, 289], ["viral proteins", "PROTEIN", 354, 368], ["infected cells", "CELL_TYPE", 443, 457], ["simian virus 40 (SV40) large tumour antigen", "PROTEIN", 508, 551], ["T-ag", "PROTEIN", 553, 557], ["human cytomegalovirus (HCMV) processivity factor", "PROTEIN", 560, 608], ["ppUL44", "PROTEIN", 609, 615], ["human papilloma virus (HPV) E1 protein", "PROTEIN", 625, 663], ["phospho \u201cP\u201d protein", "PROTEIN", 680, 699], ["simian virus", "SPECIES", 508, 520], ["human", "SPECIES", 560, 565], ["human", "SPECIES", 625, 630], ["papilloma virus", "SPECIES", 631, 646], ["Rabies virus", "SPECIES", 731, 743], ["simian virus 40", "SPECIES", 508, 523], ["human cytomegalovirus", "SPECIES", 560, 581], ["HCMV", "SPECIES", 583, 587], ["human papilloma virus", "SPECIES", 625, 646], ["HPV", "SPECIES", 648, 651], ["Rabies virus", "SPECIES", 731, 743], ["these viral proteins", "PROBLEM", 8, 28], ["high affinity interaction", "PROBLEM", 84, 109], ["other enzymes", "TEST", 276, 289], ["viral proteins", "PROBLEM", 354, 368], ["regulated nucleocytoplasmic trafficking in infected cells", "PROBLEM", 400, 457], ["gene products", "TREATMENT", 469, 482], ["DNA viruses", "PROBLEM", 488, 499], ["simian virus", "PROBLEM", 508, 520], ["large tumour antigen", "PROBLEM", 531, 551], ["human cytomegalovirus (HCMV) processivity factor ppUL44", "PROBLEM", 560, 615], ["the human papilloma virus", "PROBLEM", 621, 646], ["HPV) E1 protein", "TEST", 648, 663], ["the phospho \u201c", "TEST", 676, 689], ["protein", "TEST", 692, 699], ["viral proteins", "OBSERVATION", 14, 28], ["high affinity", "OBSERVATION", 84, 97], ["evidence of", "UNCERTAINTY", 388, 399], ["nucleocytoplasmic trafficking", "OBSERVATION", 410, 439], ["infected cells", "OBSERVATION", 443, 457], ["large", "OBSERVATION_MODIFIER", 531, 536], ["tumour", "OBSERVATION", 537, 543], ["cytomegalovirus", "OBSERVATION", 566, 581]]], ["The regulatory mechanisms and evidence for a physiologically important role in the viral infectious cycle will be discussed (Section 4), with the implication being that the regulation of viral protein nuclear import is crucial for many diverse viruses, thereby representing a potential target for the future development of anti-viral agents.Nucleocytoplasmic transportAll transport into and out of the nucleus occurs through the nuclear pore complexes (NPCs), macromolecular structures (> 60 MDa) that span the double lipid bilayer of the nuclear envelope (NE) [1], [2], [3], [4].", [["nuclear", "ANATOMY", 201, 208], ["Nucleocytoplasmic", "ANATOMY", 341, 358], ["nucleus", "ANATOMY", 402, 409], ["nuclear pore complexes", "ANATOMY", 429, 451], ["NPCs", "ANATOMY", 453, 457], ["macromolecular structures", "ANATOMY", 460, 485], ["nuclear envelope", "ANATOMY", 539, 555], ["nuclear", "CELLULAR_COMPONENT", 201, 208], ["nucleus", "CELLULAR_COMPONENT", 402, 409], ["NPCs", "CELLULAR_COMPONENT", 453, 457], ["nuclear", "CELLULAR_COMPONENT", 539, 546], ["[3]", "SIMPLE_CHEMICAL", 571, 574], ["[4]", "SIMPLE_CHEMICAL", 576, 579], ["viral protein", "PROTEIN", 187, 200], ["nuclear pore complexes", "PROTEIN", 429, 451], ["NPCs", "CELL_TYPE", 453, 457], ["NE", "PROTEIN", 557, 559], ["the viral infectious cycle", "PROBLEM", 79, 105], ["viral protein nuclear import", "PROBLEM", 187, 215], ["many diverse viruses", "PROBLEM", 231, 251], ["anti-viral agents", "TREATMENT", 323, 340], ["Nucleocytoplasmic transport", "TEST", 341, 368], ["viruses", "OBSERVATION", 244, 251], ["anti-viral agents", "OBSERVATION", 323, 340], ["nucleus", "ANATOMY", 402, 409]]], ["There are approximately 2000 NPCs per \u201ctypical\u201d vertebrate cell, depending on the stage of the cell cycle and the cell type.", [["NPCs", "ANATOMY", 29, 33], ["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 114, 118], ["NPCs", "CELL", 29, 33], ["cell", "CELL", 59, 63], ["cell", "CELL", 95, 99], ["cell type", "CELL", 114, 123], ["approximately", "OBSERVATION_MODIFIER", 10, 23], ["2000 NPCs", "OBSERVATION_MODIFIER", 24, 33], ["vertebrate cell", "OBSERVATION", 48, 63], ["cell cycle", "OBSERVATION", 95, 105], ["cell type", "OBSERVATION", 114, 123]]], ["NPC structure is typified by 8-fold symmetry, being made up of multiple proteins called nucleoporins (Nups) [5], [6], [7], [8] which occur in multiples of eight [9].", [["NPC", "ANATOMY", 0, 3], ["NPC", "CANCER", 0, 3], ["[6]", "SIMPLE_CHEMICAL", 113, 116], ["[7]", "SIMPLE_CHEMICAL", 118, 121], ["[8]", "SIMPLE_CHEMICAL", 123, 126], ["NPC", "PROTEIN", 0, 3], ["multiple proteins", "PROTEIN", 63, 80], ["nucleoporins", "PROTEIN", 88, 100], ["Nups", "PROTEIN", 102, 106]]], ["With the exception of certain peripheral, asymmetric Nups, most Nups localise on both sides of a symmetry axis in the plane of the NE [2], [9], and can be grouped into several classes based on homology and functional similarity [10], including (i) transmembrane Nups (i.e. POM121 and Gp210 in vertebrates), which anchor the NPC within the NE and are bound by (ii) structural Nups (c.", [["transmembrane", "ANATOMY", 248, 261], ["NPC", "ANATOMY", 324, 327], ["Nups", "GENE_OR_GENE_PRODUCT", 64, 68], ["POM121", "GENE_OR_GENE_PRODUCT", 273, 279], ["NPC", "CANCER", 324, 327], ["Nups", "PROTEIN", 64, 68], ["transmembrane Nups", "PROTEIN", 248, 266], ["POM121", "PROTEIN", 273, 279], ["Gp210", "PROTEIN", 284, 289], ["NPC", "PROTEIN", 324, 327], ["NE", "PROTEIN", 339, 341], ["certain peripheral, asymmetric Nups", "PROBLEM", 22, 57], ["peripheral", "ANATOMY_MODIFIER", 30, 40], ["asymmetric", "OBSERVATION_MODIFIER", 42, 52], ["Nups", "OBSERVATION", 53, 57]]], ["50% of all Nups), which contribute to the overall architecture of the NPC and represent the scaffold linking the transmembrane Nups and (iii) FG-Nups (c.", [["NPC", "ANATOMY", 70, 73], ["transmembrane", "ANATOMY", 113, 126], ["NPC", "DISEASE", 70, 73], ["NPC", "CANCER", 70, 73], ["transmembrane", "CELLULAR_COMPONENT", 113, 126], ["NPC", "PROTEIN", 70, 73], ["transmembrane Nups", "PROTEIN", 113, 131], ["FG", "PROTEIN", 142, 144], ["Nups", "PROTEIN", 145, 149], ["the NPC", "PROBLEM", 66, 73], ["NPC", "ANATOMY", 70, 73]]], ["33% of all Nups/50% of the NPC mass), which are distinguished by the fact that they contain multiple FxFG (single letter amino acid code, where x is any amino acid) or GLFG motifs separated by varying numbers of charged or polar amino acids [2], [11].", [["NPC mass", "ANATOMY", 27, 35], ["FxFG", "CHEMICAL", 101, 105], ["amino acid", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 153, 163], ["amino acids", "CHEMICAL", 229, 240], ["amino acid", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 153, 163], ["amino acids", "CHEMICAL", 229, 240], ["NPC", "CANCER", 27, 30], ["FxFG", "GENE_OR_GENE_PRODUCT", 101, 105], ["amino acid", "AMINO_ACID", 121, 131], ["amino acid", "AMINO_ACID", 153, 163], ["amino acids", "AMINO_ACID", 229, 240], ["FxFG", "PROTEIN", 101, 105], ["single letter amino acid code", "PROTEIN", 107, 136], ["GLFG motifs", "PROTEIN", 168, 179], ["the NPC mass", "PROBLEM", 23, 35], ["multiple FxFG (single letter amino acid code", "TREATMENT", 92, 136], ["any amino acid", "TREATMENT", 149, 163], ["GLFG motifs", "TREATMENT", 168, 179], ["polar amino acids", "TREATMENT", 223, 240], ["NPC", "ANATOMY", 27, 30], ["mass", "OBSERVATION", 31, 35]]], ["Fig. 1shows the distribution of specific FG-Nups within the NPC, highlighting their position throughout the NPC.", [["NPC", "ANATOMY", 60, 63], ["NPC", "ANATOMY", 108, 111], ["NPC", "DISEASE", 108, 111], ["FG-Nups", "GENE_OR_GENE_PRODUCT", 41, 48], ["NPC", "CANCER", 60, 63], ["NPC", "CANCER", 108, 111], ["FG", "PROTEIN", 41, 43], ["Nups", "PROTEIN", 44, 48], ["the NPC", "TREATMENT", 56, 63], ["distribution", "OBSERVATION_MODIFIER", 16, 28], ["NPC", "ANATOMY", 60, 63], ["NPC", "ANATOMY", 108, 111]]], ["A number of studies indicate that FG-Nups are integral to bidirectional active transport through the NPC because of their ability to interact transiently with IMPs [9], [12], [13], [14], [15], [16].Nucleocytoplasmic transportTranslocation through the NPC of proteins > 45 kDa is generally mediated by members of the IMP superfamily of nuclear transporters, which includes 6 \u03b1 and c.", [["NPC", "ANATOMY", 101, 104], ["Nucleocytoplasmic", "ANATOMY", 198, 215], ["NPC", "ANATOMY", 251, 254], ["nuclear", "ANATOMY", 335, 342], ["FG-Nups", "SIMPLE_CHEMICAL", 34, 41], ["NPC", "CANCER", 101, 104], ["[12]", "SIMPLE_CHEMICAL", 169, 173], ["[13], [14], [15], [16]", "SIMPLE_CHEMICAL", 175, 197], ["NPC", "CANCER", 251, 254], ["IMP", "GENE_OR_GENE_PRODUCT", 316, 319], ["nuclear", "CELLULAR_COMPONENT", 335, 342], ["\u03b1", "GENE_OR_GENE_PRODUCT", 374, 375], ["Nups", "PROTEIN", 37, 41], ["NPC", "PROTEIN", 101, 104], ["NPC", "PROTEIN", 251, 254], ["45 kDa", "PROTEIN", 269, 275], ["IMP superfamily", "PROTEIN", 316, 331], ["nuclear transporters", "PROTEIN", 335, 355], ["\u03b1", "PROTEIN", 374, 375], ["studies", "TEST", 12, 19], ["bidirectional active transport", "TREATMENT", 58, 88], ["the NPC", "TREATMENT", 97, 104], ["IMPs", "TEST", 159, 163], ["Nucleocytoplasmic transport", "TEST", 198, 225]]], ["20 \u03b2 forms in humans.", [["\u03b2", "GENE_OR_GENE_PRODUCT", 3, 4], ["humans", "ORGANISM", 14, 20], ["humans", "SPECIES", 14, 20], ["humans", "SPECIES", 14, 20]]], ["IMP\u03b1s are adaptors that function as heterodimers with IMP\u03b21 [1], [17], [18], [19] in nuclear import, whilst IMP\u03b2s can mediate transport in either direction through the NPC, with those mediating nuclear export called exportins (EXPs).", [["nuclear", "ANATOMY", 85, 92], ["NPC", "ANATOMY", 168, 171], ["nuclear", "ANATOMY", 194, 201], ["IMP", "CHEMICAL", 0, 3], ["IMP", "CHEMICAL", 108, 111], ["IMP\u03b1s", "GENE_OR_GENE_PRODUCT", 0, 5], ["IMP\u03b21", "GENE_OR_GENE_PRODUCT", 54, 59], ["[17], [18], [19]", "SIMPLE_CHEMICAL", 65, 81], ["nuclear", "CELLULAR_COMPONENT", 85, 92], ["IMP\u03b2s", "GENE_OR_GENE_PRODUCT", 108, 113], ["NPC", "CANCER", 168, 171], ["nuclear", "CELLULAR_COMPONENT", 194, 201], ["exportins", "GENE_OR_GENE_PRODUCT", 216, 225], ["EXPs", "GENE_OR_GENE_PRODUCT", 227, 231], ["IMP\u03b1s", "PROTEIN", 0, 5], ["heterodimers", "PROTEIN", 36, 48], ["IMP\u03b2s", "PROTEIN", 108, 113], ["NPC", "PROTEIN", 168, 171], ["exportins", "PROTEIN", 216, 225], ["EXPs", "PROTEIN", 227, 231], ["IMP", "TEST", 54, 57], ["NPC", "ANATOMY", 168, 171]]], ["IMPs/EXPs recognise specific sequences, nuclear localisation sequences (NLSs) or nuclear export signals (NESs) respectively within the cargo protein with which they interact, with the monomeric guanine nucleotide binding protein/GTPase Ran a key additional factor (see below) modulating cargo binding [17], [20].Nucleocytoplasmic transportMonopartite basic NLSs, such as that from SV40 T-ag (PKKKRKV132) [21], [22] and HCMV ppUL44 (PNTKKQK431) [23] as well as bipartite NLSs, which comprise two clusters of basic residues such as the HPV E1 NLS (KRK85-/-KKVKRR125) [24], are generally recognised by the IMP\u03b1/IMP\u03b21 heterodimer.", [["nuclear", "ANATOMY", 40, 47], ["nuclear", "ANATOMY", 81, 88], ["Nucleocytoplasmic", "ANATOMY", 312, 329], ["guanine", "CHEMICAL", 194, 201], ["guanine nucleotide", "CHEMICAL", 194, 212], ["IMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["EXPs", "GENE_OR_GENE_PRODUCT", 5, 9], ["NLSs", "CELLULAR_COMPONENT", 72, 76], ["nuclear", "CELLULAR_COMPONENT", 81, 88], ["guanine nucleotide binding protein/GTPase Ran", "GENE_OR_GENE_PRODUCT", 194, 239], ["SV40 T-ag (PKKKRKV132) [21]", "GENE_OR_GENE_PRODUCT", 381, 408], ["HCMV ppUL44 (PNTKKQK431) [23]", "GENE_OR_GENE_PRODUCT", 419, 448], ["KRK85-/-KKVKRR125) [24]", "GENE_OR_GENE_PRODUCT", 546, 569], ["IMP\u03b1", "GENE_OR_GENE_PRODUCT", 603, 607], ["IMP\u03b21", "GENE_OR_GENE_PRODUCT", 608, 613], ["IMPs", "PROTEIN", 0, 4], ["EXPs", "PROTEIN", 5, 9], ["nuclear localisation sequences", "PROTEIN", 40, 70], ["NLSs", "PROTEIN", 72, 76], ["NESs", "PROTEIN", 105, 109], ["cargo protein", "PROTEIN", 135, 148], ["monomeric guanine nucleotide binding protein", "PROTEIN", 184, 228], ["GTPase", "PROTEIN", 229, 235], ["Ran", "PROTEIN", 236, 239], ["Monopartite basic NLSs", "PROTEIN", 339, 361], ["bipartite NLSs", "PROTEIN", 460, 474], ["HPV E1 NLS", "PROTEIN", 534, 544], ["KRK85", "PROTEIN", 546, 551], ["/-KKVKRR125", "PROTEIN", 552, 563], ["IMP\u03b1", "PROTEIN", 603, 607], ["IMP\u03b21 heterodimer", "PROTEIN", 608, 625], ["specific sequences", "TEST", 20, 38], ["nuclear localisation sequences", "TEST", 40, 70], ["Nucleocytoplasmic transport", "TEST", 312, 339], ["Monopartite basic NLSs", "PROBLEM", 339, 361], ["SV40 T", "TEST", 381, 387], ["HCMV ppUL44", "TEST", 419, 430], ["bipartite NLSs", "PROBLEM", 460, 474], ["basic residues", "PROBLEM", 507, 521], ["the HPV E1 NLS", "TEST", 530, 544], ["KRK85", "TEST", 546, 551]]], ["All IMP\u03b2s including IMP\u03b21, in contrast, are able to mediate import or export of their cargoes without the need for IMP\u03b1 or other adaptors, although the NLS/NES sequences have not been defined in many cases.", [["IMP", "CHEMICAL", 4, 7], ["IMP", "CHEMICAL", 115, 118], ["IMP\u03b2s", "GENE_OR_GENE_PRODUCT", 4, 9], ["IMP\u03b21", "GENE_OR_GENE_PRODUCT", 20, 25], ["IMP\u03b1", "GENE_OR_GENE_PRODUCT", 115, 119], ["NLS", "GENE_OR_GENE_PRODUCT", 152, 155], ["NES", "GENE_OR_GENE_PRODUCT", 156, 159], ["IMP\u03b2s", "PROTEIN", 4, 9], ["IMP\u03b21", "PROTEIN", 20, 25], ["IMP\u03b1", "PROTEIN", 115, 119], ["NLS", "PROTEIN", 152, 155], ["NES", "PROTEIN", 156, 159], ["the NLS/NES sequences", "TEST", 148, 169]]], ["NESs recognised by EXP-1 (Crm1) [25], [26], [27] comprise 3\u20134 hydrophobic residues interspersed with 1 to 3 non-hydrophobic residues (L-x2-3-(L,I,M,F,M)-x2-3-L-x-(L,I,V) [17], [20]), the classic example being the NES from HIV-1 Rev (LPPLERLTL83) [28].Nucleocytoplasmic transportAs indicated above, IMP-dependent passage through the NPC is effected by transient interactions of the IMP\u03b2s with FG-Nups; Nup358 is proposed to play a key role in assembly of the IMP\u2013cargo complex [29], [30], with a gradient of increasing affinity postulated to facilitate the passage of IMP\u2013cargo complexes from cytoplasmic to nucleoplasmic side of the NPC (see [31]).", [["Nucleocytoplasmic", "ANATOMY", 251, 268], ["NPC", "ANATOMY", 332, 335], ["cytoplasmic", "ANATOMY", 592, 603], ["nucleoplasmic", "ANATOMY", 607, 620], ["NPC", "ANATOMY", 633, 636], ["IMP", "CHEMICAL", 298, 301], ["IMP", "CHEMICAL", 381, 384], ["Nup358", "CHEMICAL", 401, 407], ["IMP", "CHEMICAL", 298, 301], ["EXP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["Crm1", "GENE_OR_GENE_PRODUCT", 26, 30], ["[26], [27]", "SIMPLE_CHEMICAL", 38, 48], ["M,F,M)-x2-3-L-x-(L,I,V) [17], [20]", "SIMPLE_CHEMICAL", 146, 180], ["IMP", "SIMPLE_CHEMICAL", 298, 301], ["NPC", "CANCER", 332, 335], ["IMP\u03b2s", "GENE_OR_GENE_PRODUCT", 381, 386], ["FG-Nups", "GENE_OR_GENE_PRODUCT", 392, 399], ["Nup358", "GENE_OR_GENE_PRODUCT", 401, 407], ["[30]", "SIMPLE_CHEMICAL", 482, 486], ["IMP\u2013cargo", "GENE_OR_GENE_PRODUCT", 567, 576], ["cytoplasmic", "ORGANISM_SUBSTANCE", 592, 603], ["nucleoplasmic", "ORGANISM_SUBSTANCE", 607, 620], ["NPC", "CANCER", 633, 636], ["NES", "PROTEIN", 213, 216], ["IMP", "PROTEIN", 298, 301], ["NPC", "PROTEIN", 332, 335], ["IMP\u03b2s", "PROTEIN", 381, 386], ["FG", "PROTEIN", 392, 394], ["Nups", "PROTEIN", 395, 399], ["Nup358", "PROTEIN", 401, 407], ["IMP\u2013cargo complex", "PROTEIN", 458, 475], ["IMP\u2013cargo complexes", "PROTEIN", 567, 586], ["NPC", "PROTEIN", 633, 636], ["HIV-1", "SPECIES", 222, 227], ["hydrophobic residues", "TEST", 62, 82], ["L-x2", "TEST", 134, 138], ["HIV", "TEST", 222, 225], ["Nucleocytoplasmic transport", "TEST", 251, 278], ["increasing affinity", "PROBLEM", 507, 526], ["IMP\u2013cargo complexes", "PROBLEM", 567, 586], ["NPC", "ANATOMY", 633, 636]]], ["In the case of nuclear import, release at the nuclear face requires Ran in its activated GTP-bound form to bind to the IMP\u03b2 to dissociate the import complex (Fig. 2left).", [["nuclear", "ANATOMY", 15, 22], ["nuclear face", "ANATOMY", 46, 58], ["GTP", "CHEMICAL", 89, 92], ["GTP", "CHEMICAL", 89, 92], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["nuclear", "CELLULAR_COMPONENT", 46, 53], ["Ran", "GENE_OR_GENE_PRODUCT", 68, 71], ["GTP", "SIMPLE_CHEMICAL", 89, 92], ["IMP\u03b2", "GENE_OR_GENE_PRODUCT", 119, 123], ["Ran", "PROTEIN", 68, 71], ["activated GTP-bound form", "PROTEIN", 79, 103], ["IMP\u03b2", "PROTEIN", 119, 123], ["import complex", "PROTEIN", 142, 156], ["Fig. 2left", "PROTEIN", 158, 168]]], ["Nuclear export is analogous, where the EXP, only when in complex with RanGTP, recognises a NES within a cargo and forms a trimeric export complex (EXP/RanGTP/NES-cargo) that is able to translocate through the NPC through transient interactions with FG-Nups such as Nup98 [32] and the non-FG-Nup Tpr ([33]) on the nuclear side, and Nup214 [34] on the cytoplasmic side (see Fig. 1), where the complex is dissociated via GTP hydrolysis by Ran of GTP to GDP, facilitated by RanGTPase-activating protein (RanGAP) (Fig. 2 right) and Ran binding protein 1 (RanBP1) and/or the RanBP1-like domains of Nup358 [30].Nucleocytoplasmic transportMany viral proteins utilise the host cell nucleocytoplasmic trafficking machinery (Fig. 2) to achieve efficient nuclear import and/or export in order to carry out particular roles in viral replication and pathogenesis, and/or modulate the host cell cycle or innate immune response (see below and Table 1).", [["Nuclear", "ANATOMY", 0, 7], ["NPC", "ANATOMY", 209, 212], ["nuclear", "ANATOMY", 313, 320], ["cytoplasmic", "ANATOMY", 350, 361], ["Nucleocytoplasmic", "ANATOMY", 604, 621], ["cell", "ANATOMY", 668, 672], ["nuclear", "ANATOMY", 743, 750], ["cell", "ANATOMY", 875, 879], ["GTP", "CHEMICAL", 418, 421], ["GTP", "CHEMICAL", 443, 446], ["GDP", "CHEMICAL", 450, 453], ["GTP", "CHEMICAL", 418, 421], ["GTP", "CHEMICAL", 443, 446], ["GDP", "CHEMICAL", 450, 453], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["RanGTP", "GENE_OR_GENE_PRODUCT", 70, 76], ["NES", "GENE_OR_GENE_PRODUCT", 91, 94], ["RanGTP", "GENE_OR_GENE_PRODUCT", 151, 157], ["NES", "GENE_OR_GENE_PRODUCT", 158, 161], ["NPC", "CANCER", 209, 212], ["FG-Nups", "GENE_OR_GENE_PRODUCT", 249, 256], ["Nup98 [32]", "GENE_OR_GENE_PRODUCT", 265, 275], ["non-FG-Nup Tpr", "GENE_OR_GENE_PRODUCT", 284, 298], ["cytoplasmic", "ORGANISM_SUBSTANCE", 350, 361], ["GTP", "SIMPLE_CHEMICAL", 418, 421], ["Ran", "GENE_OR_GENE_PRODUCT", 436, 439], ["GTP", "SIMPLE_CHEMICAL", 443, 446], ["GDP", "SIMPLE_CHEMICAL", 450, 453], ["RanGTPase-activating protein", "GENE_OR_GENE_PRODUCT", 470, 498], ["RanGAP", "GENE_OR_GENE_PRODUCT", 500, 506], ["Ran binding protein 1", "GENE_OR_GENE_PRODUCT", 527, 548], ["RanBP1", "GENE_OR_GENE_PRODUCT", 550, 556], ["RanBP1", "GENE_OR_GENE_PRODUCT", 569, 575], ["cell", "CELL", 668, 672], ["nuclear", "CELLULAR_COMPONENT", 743, 750], ["cell", "CELL", 875, 879], ["EXP", "DNA", 39, 42], ["RanGTP", "PROTEIN", 70, 76], ["NES", "PROTEIN", 91, 94], ["trimeric export complex", "PROTEIN", 122, 145], ["EXP", "PROTEIN", 147, 150], ["RanGTP", "PROTEIN", 151, 157], ["NES", "PROTEIN", 158, 161], ["cargo", "PROTEIN", 162, 167], ["NPC", "PROTEIN", 209, 212], ["FG", "PROTEIN", 249, 251], ["Nups", "PROTEIN", 252, 256], ["Nup98 [32]", "PROTEIN", 265, 275], ["non-FG", "PROTEIN", 284, 290], ["Nup Tpr", "PROTEIN", 291, 298], ["Ran", "PROTEIN", 436, 439], ["GDP", "PROTEIN", 450, 453], ["RanGTPase-activating protein", "PROTEIN", 470, 498], ["RanGAP", "PROTEIN", 500, 506], ["Fig. 2 right", "PROTEIN", 509, 521], ["Ran binding protein 1", "PROTEIN", 527, 548], ["RanBP1", "PROTEIN", 550, 556], ["RanBP1", "PROTEIN", 569, 575], ["Nup358", "PROTEIN", 592, 598], ["viral proteins", "PROTEIN", 636, 650], ["the non-FG", "TEST", 280, 290], ["GTP hydrolysis", "PROBLEM", 418, 432], ["RanGTPase", "TEST", 470, 479], ["RanGAP", "TEST", 500, 506], ["Ran binding protein", "TEST", 527, 546], ["RanBP1", "TEST", 550, 556], ["the RanBP1", "TEST", 565, 575], ["Nucleocytoplasmic transport", "TEST", 604, 631], ["Many viral proteins", "PROBLEM", 631, 650], ["the host cell nucleocytoplasmic trafficking machinery", "TREATMENT", 659, 712], ["viral replication", "PROBLEM", 814, 831], ["pathogenesis", "PROBLEM", 836, 848], ["EXP", "OBSERVATION", 39, 42], ["host cell", "OBSERVATION", 663, 672], ["viral replication", "OBSERVATION", 814, 831], ["host cell", "OBSERVATION", 870, 879]]], ["The next sections examine a number of different viral proteins by way of illustrating the diverse mechanisms regulating viral protein nuclear import/export.The cellular nuclear transport machinery as a viral target ::: Regulation of nuclear transportThe NPC and the Nups that constitute it are thought to be passive in nucleocytoplasmic transport in most situations.", [["sections", "ANATOMY", 9, 17], ["nuclear", "ANATOMY", 134, 141], ["cellular", "ANATOMY", 160, 168], ["nuclear", "ANATOMY", 169, 176], ["nuclear", "ANATOMY", 233, 240], ["NPC", "ANATOMY", 254, 257], ["nuclear", "CELLULAR_COMPONENT", 134, 141], ["cellular", "CELL", 160, 168], ["nuclear", "CELLULAR_COMPONENT", 233, 240], ["NPC", "CANCER", 254, 257], ["viral proteins", "PROTEIN", 48, 62], ["viral protein", "PROTEIN", 120, 133], ["NPC", "PROTEIN", 254, 257], ["Nups", "PROTEIN", 266, 270], ["different viral proteins", "TREATMENT", 38, 62], ["The NPC", "TREATMENT", 250, 257], ["viral protein", "OBSERVATION", 120, 133], ["nuclear transport", "OBSERVATION", 233, 250], ["thought to be", "UNCERTAINTY", 294, 307], ["passive", "OBSERVATION", 308, 315], ["nucleocytoplasmic transport", "OBSERVATION", 319, 346]]], ["However, NPC composition and Nup conformation can have an influence on the transport of IMPs/EXPs as well as cargoes.", [["NPC", "ANATOMY", 9, 12], ["NPC", "CANCER", 9, 12], ["IMPs", "GENE_OR_GENE_PRODUCT", 88, 92], ["EXPs", "GENE_OR_GENE_PRODUCT", 93, 97], ["NPC", "PROTEIN", 9, 12], ["IMPs", "PROTEIN", 88, 92], ["EXPs", "PROTEIN", 93, 97], ["NPC composition", "TREATMENT", 9, 24], ["IMPs/EXPs", "TREATMENT", 88, 97]]], ["Since IMPs/EXPs appear to have different affinities for the FG-Nups (see Section 2), the presence or absence of certain FG-Nups may favour one set of transport factors/cargo over another [13], [14], [15], [16].The cellular nuclear transport machinery as a viral target ::: Regulation of nuclear transportCertain viral proteins are known to act directly or indirectly on the NPC and IMPs/EXPs [49] in order to act to alter host cell functions.", [["cellular", "ANATOMY", 214, 222], ["nuclear", "ANATOMY", 223, 230], ["nuclear", "ANATOMY", 287, 294], ["NPC", "ANATOMY", 374, 377], ["cell", "ANATOMY", 427, 431], ["IMPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["EXPs", "GENE_OR_GENE_PRODUCT", 11, 15], ["FG-Nups", "SIMPLE_CHEMICAL", 120, 127], ["[14]", "SIMPLE_CHEMICAL", 193, 197], ["[15]", "SIMPLE_CHEMICAL", 199, 203], ["[16]", "SIMPLE_CHEMICAL", 205, 209], ["cellular", "CELL", 214, 222], ["nuclear", "CELLULAR_COMPONENT", 287, 294], ["NPC", "CANCER", 374, 377], ["IMPs", "GENE_OR_GENE_PRODUCT", 382, 386], ["EXPs", "GENE_OR_GENE_PRODUCT", 387, 391], ["host cell", "CELL", 422, 431], ["IMPs", "PROTEIN", 6, 10], ["EXPs", "PROTEIN", 11, 15], ["FG-Nups", "PROTEIN", 120, 127], ["transport factors", "PROTEIN", 150, 167], ["viral proteins", "PROTEIN", 312, 326], ["NPC", "PROTEIN", 374, 377], ["IMPs", "PROTEIN", 382, 386], ["EXPs", "PROTEIN", 387, 391], ["different affinities", "PROBLEM", 31, 51], ["Certain viral proteins", "PROBLEM", 304, 326], ["IMPs/EXPs", "TEST", 382, 391], ["nuclear transport", "OBSERVATION", 287, 304], ["host cell functions", "OBSERVATION", 422, 441]]], ["An example with respect to the NPC is the 3C protease from the picornavirus Rhinovirus [50], which is thought to target Nups153, 214 and 358 for specific degradation in order to impair host cell nucleocytoplasmic transport (see Section 2 and Fig. 1), and thereby dampen anti-viral responses [50]; altered NPC structures have also been visualised in cells infected by the closely related poliovirus [51].", [["NPC", "ANATOMY", 31, 34], ["cell", "ANATOMY", 190, 194], ["NPC structures", "ANATOMY", 305, 319], ["cells", "ANATOMY", 349, 354], ["NPC", "CANCER", 31, 34], ["cell", "CELL", 190, 194], ["NPC structures", "MULTI-TISSUE_STRUCTURE", 305, 319], ["cells", "CELL", 349, 354], ["poliovirus", "ORGANISM", 387, 397], ["NPC", "PROTEIN", 31, 34], ["3C protease", "PROTEIN", 42, 53], ["NPC", "PROTEIN", 305, 308], ["the NPC", "PROBLEM", 27, 34], ["the 3C protease", "TREATMENT", 38, 53], ["the picornavirus Rhinovirus", "PROBLEM", 59, 86], ["altered NPC structures", "PROBLEM", 297, 319], ["NPC", "ANATOMY", 31, 34], ["picornavirus Rhinovirus", "OBSERVATION", 63, 86]]], ["2A protease from both Rhinovirus and poliovirus appears to act similarly to 3C in this respect [52], [53], [54], implying that the NPC is a key target of picornaviruses to disrupt host cell transport processes, and lead to \u201chost cell shut down\u201d to enable viral replication to proceed unchecked in the cytoplasm.The cellular nuclear transport machinery as a viral target ::: Regulation of nuclear transportIMPs/EXPs can also be targets of viral proteins.", [["NPC", "ANATOMY", 131, 134], ["cell", "ANATOMY", 185, 189], ["cell", "ANATOMY", 229, 233], ["cytoplasm", "ANATOMY", 301, 310], ["cellular", "ANATOMY", 315, 323], ["nuclear", "ANATOMY", 324, 331], ["nuclear", "ANATOMY", 388, 395], ["2A", "GENE_OR_GENE_PRODUCT", 0, 2], ["Rhinovirus", "GENE_OR_GENE_PRODUCT", 22, 32], ["poliovirus", "ORGANISM", 37, 47], ["NPC", "CANCER", 131, 134], ["cell", "CELL", 185, 189], ["cell", "CELL", 229, 233], ["cytoplasm", "ORGANISM_SUBSTANCE", 301, 310], ["cellular", "CELL", 315, 323], ["nuclear", "CELLULAR_COMPONENT", 388, 395], ["transportIMPs", "GENE_OR_GENE_PRODUCT", 396, 409], ["EXPs", "GENE_OR_GENE_PRODUCT", 410, 414], ["2A protease", "PROTEIN", 0, 11], ["NPC", "PROTEIN", 131, 134], ["nuclear transportIMPs", "PROTEIN", 388, 409], ["EXPs", "PROTEIN", 410, 414], ["viral proteins", "PROTEIN", 438, 452], ["2A protease", "TREATMENT", 0, 11], ["Rhinovirus", "PROBLEM", 22, 32], ["poliovirus", "PROBLEM", 37, 47], ["picornaviruses", "PROBLEM", 154, 168], ["viral replication", "TREATMENT", 255, 272], ["nuclear transportIMPs/EXPs", "TEST", 388, 414], ["viral proteins", "PROBLEM", 438, 452], ["Rhinovirus", "OBSERVATION", 22, 32], ["NPC", "ANATOMY", 131, 134], ["host cell", "OBSERVATION_MODIFIER", 180, 189], ["viral proteins", "OBSERVATION", 438, 452]]], ["Ebola virus VP24, for example, binds to and sequesters IMP\u03b11 [55], [56], [57] in the cytoplasm, whilst IMP\u03b12 is similarly sequestered by severe acute respiratory syndrome (SARS) coronavirus ORF6 [58].", [["cytoplasm", "ANATOMY", 85, 94], ["Ebola", "DISEASE", 0, 5], ["acute respiratory syndrome", "DISEASE", 144, 170], ["SARS", "DISEASE", 172, 176], ["Ebola virus VP24", "ORGANISM", 0, 16], ["IMP\u03b11", "GENE_OR_GENE_PRODUCT", 55, 60], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["IMP\u03b12", "GENE_OR_GENE_PRODUCT", 103, 108], ["VP24", "PROTEIN", 12, 16], ["IMP\u03b12", "PROTEIN", 103, 108], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["severe acute respiratory syndrome (SARS) coronavirus", "SPECIES", 137, 189], ["Ebola virus VP24", "TEST", 0, 16], ["IMP", "TEST", 55, 58], ["severe acute respiratory syndrome", "PROBLEM", 137, 170], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory syndrome", "OBSERVATION", 150, 170]]], ["In both cases, the IMP\u03b1 is prevented from playing its normal role in mediating nuclear import of the STAT (signal transducer and activator of transcription) proteins in response to interferon (IFN), as part of the innate immune response (see [59]).", [["nuclear", "ANATOMY", 79, 86], ["IMP", "CHEMICAL", 19, 22], ["IMP\u03b1", "GENE_OR_GENE_PRODUCT", 19, 23], ["nuclear", "CELLULAR_COMPONENT", 79, 86], ["STAT", "GENE_OR_GENE_PRODUCT", 101, 105], ["signal transducer and activator of transcription) proteins", "GENE_OR_GENE_PRODUCT", 107, 165], ["interferon", "GENE_OR_GENE_PRODUCT", 181, 191], ["IFN", "GENE_OR_GENE_PRODUCT", 193, 196], ["IMP\u03b1", "PROTEIN", 19, 23], ["STAT (signal transducer and activator of transcription) proteins", "PROTEIN", 101, 165], ["interferon", "PROTEIN", 181, 191], ["IFN", "PROTEIN", 193, 196], ["the STAT (signal transducer and activator of transcription) proteins", "TREATMENT", 97, 165], ["interferon (IFN)", "TREATMENT", 181, 197]]], ["Thus, it seems that various cytoplasmically replicating RNA viruses disrupt the cellular nuclear transport machinery in order to subvert the host cell transport processes necessary for the anti-viral response.The cellular nuclear transport machinery as a viral target ::: Regulation of nuclear transportIn the case of DNA viruses that replicate in the nucleus, however, efficient nuclear entry of many viral components is crucial for replication, so that disrupting the host cell nuclear import apparatus would not be a viable strategy to ensure efficient replication.", [["cellular nuclear", "ANATOMY", 80, 96], ["cell", "ANATOMY", 146, 150], ["cellular", "ANATOMY", 213, 221], ["nuclear", "ANATOMY", 222, 229], ["nuclear", "ANATOMY", 286, 293], ["nucleus", "ANATOMY", 352, 359], ["nuclear", "ANATOMY", 380, 387], ["cell nuclear", "ANATOMY", 475, 487], ["cellular", "CELL", 80, 88], ["cell", "CELL", 146, 150], ["cellular", "CELL", 213, 221], ["nuclear", "CELLULAR_COMPONENT", 286, 293], ["DNA", "CELLULAR_COMPONENT", 318, 321], ["nucleus", "CELLULAR_COMPONENT", 352, 359], ["nuclear", "CELLULAR_COMPONENT", 380, 387], ["cell", "CELL", 475, 479], ["various cytoplasmically replicating RNA viruses", "PROBLEM", 20, 67], ["DNA viruses", "PROBLEM", 318, 329], ["many viral components", "PROBLEM", 397, 418], ["a viable strategy", "TREATMENT", 518, 535], ["RNA viruses", "OBSERVATION", 56, 67], ["host cell", "OBSERVATION", 141, 150], ["nuclear transport", "OBSERVATION", 286, 303], ["viruses", "OBSERVATION", 322, 329], ["nucleus", "ANATOMY", 352, 359], ["many", "OBSERVATION_MODIFIER", 397, 401], ["viral", "OBSERVATION", 402, 407]]], ["The next section discusses the ways in which IMPs and cellular kinases can be subverted to enable efficient nuclear transport of gene products from DNA viruses that are required in the nucleus for replication.Specific switches regulating IMP/EXP mediated trafficking ::: Regulation of nuclear transportAs indicated, the most common posttranslational modification known to regulate nuclear transport is phosphorylation.", [["cellular", "ANATOMY", 54, 62], ["nuclear", "ANATOMY", 108, 115], ["nucleus", "ANATOMY", 185, 192], ["nuclear", "ANATOMY", 285, 292], ["nuclear", "ANATOMY", 381, 388], ["IMP", "CHEMICAL", 238, 241], ["IMPs", "CELLULAR_COMPONENT", 45, 49], ["cellular", "CELL", 54, 62], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["nucleus", "CELLULAR_COMPONENT", 185, 192], ["IMP", "GENE_OR_GENE_PRODUCT", 238, 241], ["EXP", "GENE_OR_GENE_PRODUCT", 242, 245], ["nuclear", "CELLULAR_COMPONENT", 285, 292], ["nuclear", "CELLULAR_COMPONENT", 381, 388], ["IMPs", "PROTEIN", 45, 49], ["cellular kinases", "PROTEIN", 54, 70], ["gene products", "PROTEIN", 129, 142], ["IMP", "PROTEIN", 238, 241], ["The next section", "TREATMENT", 0, 16], ["gene products", "TREATMENT", 129, 142], ["DNA viruses", "PROBLEM", 148, 159], ["nucleus", "ANATOMY", 185, 192], ["nuclear transport", "OBSERVATION", 285, 302]]], ["A number of viral proteins are known to require specific phosphorylation in different ways for efficient nuclear accumulation, including T-ag (see Section 4.1), HCMV ppUL44, chicken anaemia virus (CAV) VP3 and many others [23], [37], [38], [49].", [["nuclear", "ANATOMY", 105, 112], ["chicken anaemia", "DISEASE", 174, 189], ["nuclear", "CELLULAR_COMPONENT", 105, 112], ["T-ag", "GENE_OR_GENE_PRODUCT", 137, 141], ["HCMV", "ORGANISM", 161, 165], ["ppUL44", "GENE_OR_GENE_PRODUCT", 166, 172], ["chicken anaemia virus", "ORGANISM", 174, 195], ["VP3", "GENE_OR_GENE_PRODUCT", 202, 205], ["viral proteins", "PROTEIN", 12, 26], ["HCMV ppUL44", "PROTEIN", 161, 172], ["chicken anaemia virus", "SPECIES", 174, 195], ["HCMV", "SPECIES", 161, 165], ["chicken anaemia virus", "SPECIES", 174, 195], ["viral proteins", "PROBLEM", 12, 26], ["specific phosphorylation", "TREATMENT", 48, 72], ["efficient nuclear accumulation", "PROBLEM", 95, 125], ["HCMV ppUL44", "TEST", 161, 172], ["chicken anaemia virus", "PROBLEM", 174, 195], ["VP3", "TEST", 202, 205], ["viral proteins", "OBSERVATION", 12, 26], ["nuclear accumulation", "OBSERVATION", 105, 125], ["anaemia virus", "OBSERVATION", 182, 195]]], ["Phosphorylation can regulate nuclear transport (see Fig. 3) by 1) directly modulating the affinity of an NLS/NES for its IMP/EXP; 2) facilitating masking or unmasking (intramolecular masking) of an NLS/NES within the protein carrying it; or 3) effecting the binding or release of an NLS/NES binding factor that is not an IMP/EXP (intermolecular masking) [4], [38].Specific switches regulating IMP/EXP mediated trafficking ::: Regulation of nuclear transport", [["nuclear", "ANATOMY", 29, 36], ["nuclear", "ANATOMY", 440, 447], ["IMP", "CHEMICAL", 121, 124], ["IMP", "CHEMICAL", 321, 324], ["IMP", "CHEMICAL", 393, 396], ["nuclear", "CELLULAR_COMPONENT", 29, 36], ["IMP", "SIMPLE_CHEMICAL", 321, 324], ["IMP", "GENE_OR_GENE_PRODUCT", 393, 396], ["EXP", "GENE_OR_GENE_PRODUCT", 397, 400], ["nuclear", "CELLULAR_COMPONENT", 440, 447], ["NLS", "PROTEIN", 105, 108], ["NES", "PROTEIN", 109, 112], ["IMP", "PROTEIN", 121, 124], ["NLS", "PROTEIN", 198, 201], ["NES", "PROTEIN", 202, 205], ["NLS", "PROTEIN", 283, 286], ["NES binding factor", "PROTEIN", 287, 305], ["IMP", "PROTEIN", 393, 396], ["an NLS/NES", "TREATMENT", 102, 112], ["its IMP/EXP", "TREATMENT", 117, 128], ["unmasking (intramolecular masking", "TREATMENT", 157, 190], ["an NLS/NES", "PROBLEM", 195, 205], ["the binding", "PROBLEM", 254, 265], ["an NLS/NES binding factor", "PROBLEM", 280, 305], ["nuclear transport", "OBSERVATION", 440, 457]]]]}